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ABSTRACT
The study assessed the evidence for the efficacy of lithium in the acute
treatment and prophylaxis of unipolar depression and as an augmentation drug
in treatment resistant depression. It examined the relationship between
hormonal changes, lithium discontinuation and relapse in bipolar illness.
Finally, it investigated the addition of inositol in the diet of bipolar patients as an
alternative treatment for lithium side effects.
The specific aims were:
1) to assess the efficacy of lithium in unipolar depression by comparing
readmission rates in patients after lithium discontinuation and in patients who
continued to take lithium as a prophylactic agent, and evidence for a lithium
withdrawal syndrome in unipolar patients during the first three months of
discontinuation.
2) to analyze quantitatively the results of lithium trials in the acute treatment and
prophylaxis of unipolar depression in order to estimate the therapeutic value of
lithium by measuring an overall effect size.
3) to investigate the neuroendocrine changes involving thyroxine (T4), thyroid
stimulating hormone (TSH) and Cortisol before and after lithium discontinuation
in bipolar patients and to test whether they are related to the withdrawal
syndrome observed in these patients.
4) to evaluate the effects of adding inositol to the diet of clinically stable bipolar
patients on prophylactic lithium upon thyroxine (T4) and thyroid stimulating
hormone (TSH) concentrations and on other peripheral side-effects of lithium,
comparing the results to those found in a group of normal controls not taking
lithium.
5) to assess the efficacy of lithium augmentation in treatment resistant




1) forty patients who discontinued lithium therapy were compared with 105
patients who continued the drug and served as a control group. The time to
readmission from starting on lithium was compared in a phase while both groups
were still on lithium and in a second phase after discontinuation in one group and
further continuation in the control group. The progressive increase in the
probability of recurrence over a two year follow-up interval was greatest after
discontinuation of lithium. For the patients who eventually discontinued lithium,
the cumulative probability of recurrence in two years was 0.08 on lithium and 0.58
after stopping it. The probability of recurrence was unchanged over the duration of
the study for patients who continued to take lithium. There was no evidence of a
lithium withdrawal syndrome within three months of stopping the drug. No
evidence of a seasonal pattern in readmissions of the patients who discontinued
lithium was found. The results provide evidence for a major benefit from lithium
prophylaxis of unipolar depression under ordinary clinical conditions and no
evidence of a withdrawal syndrome.
2) meta-analysis was used to establish the efficacy of lithium in acute treatment
and prophylaxis of depressive illness from existing published trials. Effects
sizes were measured by the odds ratio and Pearson correlation coefficient.
Some benefit from lithium, compared with other treatments, emerged from trials
of acute treatment. Lithium was superior to placebo in the acute treatment of
bipolar depression. In the controlled studies of lithium prophylaxis, a
substantial effect was revealed when lithium was compared with placebo. For
uncontrolled trials a similar effect size was found, which corresponded to an
improvement in the rate of favourable outcome from 35% for placebo to 70%
with lithium treatment. The comparison of lithium with other antidepressants in
prophylaxis showed no clear advantage for lithium in unipolar illness.
3) thyroid and adrenal functions were assessed in euthymic bipolar patients
stable on prophylactic lithium for at least one year before and after lithium
discontinuation in a randomised double-blind placebo-controlled trial. All
hormonal measurements were within the normal range, but a significant
increase (p<0.001) in serum T4 levels and decrease (p<0.01) in TSH levels
were observed after one month of lithium withdrawal while Cortisol
viii
concentrations showed a non-significant decrease in the same period. This
result suggests that long-term lithium did not induce evident hypothyroidism but
it has lowered thyroid function (T4) to the bottom segment of the normal range
while elevating TSH to the top region of the normal values. Both alterations
were reversible after lithium discontinuation.
4) a pilot trial was designed to add inositol to the diet of bipolar patients being
treated with prophylactic lithium and to that of normal controls for eleven days.
No modification was shown in thyroid (T4) and pituitary (TSH) function in either
group before or after inositol administration. Inositol did not alleviate other
side-effects such as tremor and thirst in the patient group. This result suggests
that short-term dietary inositol is of little use in reducing thyroid and other
adverse effects of lithium prophylaxis.
5) a quantitative analysis was used to examine the efficacy of lithium
augmentation in the acute treatment of depressed patients resistant to a
standard trial of an antidepressant. Effect sizes were measured by the odds
ratio using the Mantel-Haenszel method. Only controlled trials were included
in order to minimise methodological bias. A highly statistically significant effect
for lithium augmentation was found, measured by the pooled odds ratio (0.14)
and its 95% confidence interval (0.05 to 0.44). In other words the odds of
remaining ill are reduced by between 56% and 95% with the use of lithium
treatment. While these results support the case for lithium augmentation in
treatment-resistant depression, there remains considerable uncertainty over the
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Psychopharmacology is certainly one of the most important instruments
in modern psychiatric practice. The prescription of drugs for treatment and
prophylaxis of mental disorders has changed the management of the mentally
ill dramatically in the last 40 years. The introduction of effective drugs in the
treatment of severe mental illness has allowed patients to live in their
communities instead of being isolated in mental institutions. A wide range of
pharmacological products are now available (antidepressants, anticonvulsants,
neuroleptics, tranquillisers, etc) for the different psychiatric syndromes. In the
therapy of affective disorders, lithium was one of the first psychotherapeutic
drugs to be introduced.
The importance of lithium therapy has changed considerably since 1960.
In that year, the textbook The Pharmacological Basis of Therapy by Goodman
and Gilman stated that the lithium ion has "no therapeutic applications". At the
moment, lithium is probably the most widely investigated psychoactive drug
(Prien and Potter, 1990). By the mid-1970's there were approximately 3000
medically-related articles on lithium. This number increased by an average of
1000 a year so that the medical literature related to lithium totaled well over
19000 articles by 1990 and continues to expand rapidly (Jefferson, 1990). In
clinical practice, the importance of lithium can be measured by its widespread
use. In the United Kingdom, approximately one person per 2000 of the
population is taking lithium (Johnson, 1984).
Important advances have been made in understanding how lithium acts
and its biochemical, therapeutical and psychological effects. Despite 40 years
of lithium research, however, significant gaps still exist in our knowledge of the
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use of lithium in affective disorders and especially in depressive illness. These
gaps defined the aims of the present investigations.
AIMS
The main objectives of this study were to examine the usefulness of
lithium in unipolar depression; to assess the consequences of lithium
discontinuation; to investigate the addition of inositol as an alternative
treatment to lithium's thyroidal side effects; and to evaluate the augmenting
action of lithium in treatment resistant depression. The specific aims of the
study were:
1) to assess the efficacy of lithium in unipolar depression by comparing
readmission rates in patients after lithium discontinuation and in patients who
continued to take lithium as a prophylactic agent.
2) to consider whether a lithium withdrawal syndrome occurs in unipolar
patients during the first three months of discontinuation as has been found in
bipolar patients (Mander, 1986-b).
3) to examine whether there is an increase in the number of hospital readmissions
in autumn-winter versus spring-summer and spring-autumn versus summer-winter
in recurrent unipolar patients after lithium withdrawal, and to determine whether the
seasonal pattern in these patients is different from that observed in patients on
prophylactic lithium.
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4) to analyze quantitatively the results of lithium trials in the acute treatment and
prophylaxis of unipolar depression in order to estimate the therapeutic value of
lithium by measuring an overall effect size.
5) to investigate the neuroendocrine changes involving thyroxine (T4), thyroid
stimulating hormone (TSH) and Cortisol before and after lithium discontinuation
in bipolar patients and to test whether they are related to the withdrawal
syndrome observed in these patients.
6) to evaluate the effects of adding inositol to the diet of clinically stable bipolar
patients on prophylactic lithium, thyroxine (T4) and thyroid stimulating hormone
(TSH) concentrations and on other peripheral side-effects of lithium, comparing
the results to those found in a group of normal controls not taking lithium.
7) to assess the efficacy of lithium augmentation in treatment resistant
depression by reviewing, using quantitative techniques, the controlled trials on
the topic.
STRUCTURE OF THE THESIS
The structure of the thesis is briefly described below. Chapter 2 gives a
brief description of the historical, epidemiological, aetiological, classificatory,
and clinical aspects of affective disorders. Treatment and prophylaxis of
affective disorders including the role of lithium are briefly reviewed.
Chapter 3 briefly reviews the pharmacology of lithium. The history,
chemistry, metabolism, doses, levels, side effects, toxicity and contraindications
of lithium are described.
Chapter 4 presents the findings of the retrospective study comparing
readmission rates in unipolar depressed patients after lithium withdrawal and in
patients who continued to take lithium, using case notes from the Royal
Edinburgh Hospital. The possibility of a withdrawal syndrome in patients with
unipolar depression is discussed. The seasonal pattern of patients who had
their lithium discontinued is considered.
Chapter 5 shows the results of a meta-analysis of all studies on the use
of lithium in the treatment and prophylaxis of unipolar depression. The relative
advantages of lithium versus placebo, antidepressants, and lithium plus
imipramine in the treatment and prophylaxis of unipolar depression are
discussed in the light of the effect sizes found.
Chapter 6 reviews the studies undertaken in affective disorder patients in
which thyroid and adrenal function are reported to be altered. Studies
reporting hormonal alterations induced by lithium in affective disorder patients
are also reviewed. The TSH, T4 and Cortisol concentrations in bipolar patients
before and after lithium discontinuation are presented. The relationship
between hormonal status, lithium discontinuation and relapse is discussed.
Chapter 7 describes the rationale for the addition of inositol to the diet of
in affective disorder patients on prophylactic lithium. The results of a pilot study
on the dietary supplementation of inositol in bipolar patients is shown. The
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relationship between side effects of lithium, inositol and affective disorders is
analyzed.
Chapter 8 describes the results of a meta-analysis of controlled trials on
lithium augmentation in refractory depression. The concept of treatment
resistant depression and the mechanism by which lithium exerts its potentiating
action are discussed.
Chapter 9 draws the general conclusions from the studies and discusses






Mania and melancholia were described in the first treatise on psychiatric
nosology - Corpus Hippocraticum. Hippocrates distinguished various forms of
mania,melancholia and swings of mood. In the first century AD, the
Cappadodian physician, Arateus, described both conditions in detail and
pointed out a connection between the two conditions. He acknowledged the
intermittent character of the illness (Arieti, 1974). In the last century, Falret and
Baillanger, in Paris, described a circular form of insanity (folie circulaire) in
which patients suffered from episodes of mania and depression alternatively
with intervening normal periods (Jampala, 1988). The modern concept of
affective illness, however, was proposed by Kraeplin (1921) who described
bipolar and unipolar mood swings as manic depressive illness. He concluded
that mania and depression were part of the same illness, differing from
dementia praecox, by virtue of their episodic nature and preservation of
intellectual function despite chronicity. The term affective disorders was
introduced by Manfred Bleuler in the 1930's (Kaplan and Sadock, 1989).
2.2. PREVALENCE AND INCIDENCE OFAFFECTIVE DISORDERS
The use of different diagnostic criteria makes the estimation of
prevalence and incidence of affective disorders difficult. Only recently with the
use of standardized diagnostic schedules has it become possible to gather
reliable data in this area. Major depressive disorders are among the most
prevalent psychiatric disorders (Robins et al, 1984). Between 5-26% of women
and 2-12% of men will suffer from at least one episode of major depression at
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some time during their lives (Boyd and Weissman, 1981; Clayton, 1983). In
industrialized countries, the point prevalence is between 1.8 and 3.2 per 100 for
men and 2.0 and 9.3 per 100 for women (Boyd and Weissman, 1982).
Depression is certainly more common among women, but reports that
depression is found more frequently in the lower socioeconomic groups
(Kaplan and Sadock, 1989) has been disputed by Robins et al (1984).
Bipolar affective disorder is the least common of the principal psychotic
conditions. It has been estimated to occur less than half as often as
schizophrenia (Tsuang and Lyons, 1988). Boyd and Weissman (1982)
reported that the lifetime risk for bipolar disorder is just less than one percent,
and the incidence varies between 9-15 per 100 000 a year for men and
between 3-30 per 100 000 a year for women. Estimates of the male:female
ratio range from 1.3:1 and 2:1 (Krauthammer and Klerman, 1978).
2.3. AETIOLOGY
As with most psychiatric illnesses, the cause of mood disorders is
unknown. At present, all that can be said is that a number of aetiological
factors, which may be potentially linked, have been identified, such as heredity,
biochemical aspects and personality.
In order for a genetic aetiology of affective disorder to be proven, several
factors should be evident. Firstly, illness should cluster within families.
Secondly, studies of twins should show that the disorder is more prevalent
among monozygotic than dizygotic twins. Thirdly, adoption studies should
reveal that subjects with a biological parent with the illness would develop the
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illness even if raised in a foster home. The prevalence of affective illness in
relatives of affective disorder patients is higher than in controls (Goldin and
Gershon, 1988). A higher concordance rate for bipolar illness in monozygotic
(approximately 50%) compared to dizygotic (approximately 25%) twins were
reported by Berthelsen et al (1977) and Torgensen (1986). Adoption studies
have also suggested a genetic influence in affective disorders (Mendlewicz and
Rainer, 1977). Although methodological issues have been raised in relation to
the design of these studies, the available evidence is suggestive of a genetic
component in affective disorder.
Since the introduction of the first therapeutic drugs for depression in
1950's, the biochemistry of affective disorders has been an active area of
research. In order to explain the aetiology of affective disorders, several
biochemical hypotheses have been put forward: the catecholamine hypothesis,
the serotonergic hypothesis, the acetylcholine hypothesis (Schildkraut, 1965;
Meltzer, 1987; Kaplan and Sadock, 1989). Recently, it has been speculated
that second messengers, such as adenyl cyclase and phosphatidylinositol, are
involved in mood disorders (Wachtel, 1989).
Finally, a constellation of personality characteristics (cyclothymic,
hyperthymic, irritable temperament, subaffective dysthymic temperament) can
be implicated as predisposing factors for depressive illness (Akiskal et al,
1983-b). These factors might be associated with each other, so that
biochemical function may be a reflection of genetics and personality may be a
reflection of biochemistry.
2.4. CLASSIFICATION OF AFFECTIVE ILLNESS
The classification of affective disorders is undoubtedly controversial.
The debate whether depression, for example, is a single disease that varies
form mild to severe along a continuum or whether it represents subtypes that
differ in phenomenology, pathophysiology and aetiology has been long¬
standing among clinicians and researchers (Kendell, 1976). Three broad
approaches to classification of depressive disorders have been tried, based on
aetiology, symptoms, and course of the disorder, respectively.
A classification based on aetiology discriminates two groups:
endogenous and reactive or exogenous. Endogenous depression is defined
as an episode of depression which is precipitated by biological factors
independent of outside factors, and is unresponsive to the environment but
responsive to somatotherapy (Kendell, 1976). In reactive disorders, symptoms
are a response to external stress. Robins and Guze (1972) also proposed a
classification based on aetiology. They introduced the concept of
primary/secondary depression. A primary depression is defined as one that
has not been preceded by and is not associated with any other non affective
psychiatric disorder.
Based on symptoms, neurotic and psychotic depression have been
identified (Gelder et at, 1989). Neurotic depression is defined by the absence
of psychotic symptoms (delusions, hallucinations, thought disorder or grossly
inappropriate behaviour) which are the main features of psychotic depression.
Note the overlap with reactive/endogenous depression.
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Differentiation by course results in the classification of unipolar and
bipolar depression (Leonhard, 1957; Leonhard et al, 1962; Perris, 1966;
Winokur, 1973). This was slow to receive wide acceptance causing
inconsistencies in some of the earlier trials which may have used mixed groups
of patients. This distinction has been supported by several findings, reporting
familial and genetic factors (Leonhard et al, 1962; Winokur, 1979),
epidemiological factors (Weissman et al, 1984), biochemical and physiological
factors (Joyce et al, 1988), and verbal memory and fluency (Wolfe et al, 1987).
In unipolar probands, a bipolar heredity was estimated to occur in 0.5% and a
unipolar heredity in 10.6% of cases while in bipolar probands bipolar and
unipolar heredities were respectively 16% and 0.8% of cases (Perris, 1966).
Twin studies have revealed a greater concordance between bipolar
monozygotic pairs than between unipolar monozygotic pairs (Allen, 1976;
Berthelsen et al, 1977).
For research purposes, the Diagnostic and Statistical Manual (DSM-III-R)
and Research Criteria (RDC) classifications have been widely accepted. A
detailed comparison between DSM-III-R and RDC is found in Spitzer et al
(1985). The major affective disorders are referred to as mood disorders in
DSM-III-R, and are further classified as depressive (major depression) or
bipolar. The minimal criteria for major depression require the presence of five
symptoms lasting for a duration of two weeks. Bipolar illness is characterized
by a presence of one or more episodes of mania (bipolar I) or hypomania
(bipolar II) which are usually accompanied by a history of major depressive
episodes. RDC divides affective disorders into primary and secondary types.
Primary affective disorder consists of depression and mania of an endogenous
nature. A diagnosis of depression based on RDC, requires a psychiatric illness
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lasting at least one month and a diagnosis of mania requires a psychiatric
illness lasting at least two weeks. Operational criteria for these subtypes have
been an important step for ensuring greater reliability (Duggan et al, 1991).
The uniform acceptance of operationalized diagnoses is now to be
reflected in the International Code of Diseases (ICD). Its tenth revision is under
way (ICD 10) and in classifying affective disorders, ICD 10 will parallel DSM IV
in most aspects.
2.5. COURSE OF THE ILLNESS
Psychiatric theory held the view that affective disorders are characterized
by an episodic course, with periods of recovery likely but often followed by
relapse and recurrence while schizophrenia is considered to have a more
chronic course. These patterns of outcome have differentiated affective
disorders from schizophrenia (Kraeplin, 1921). Other researchers, however,
are opposed to this view of a clear distinction between these two entities, and
have proposed a continuum in which at some point they would merge into one
another (Kendell, 1970). Thus, longitudinal follow-up studies are important in
describing and differentiating the natural history of these disorders. For
psychiatric research, course and outcome are recognized as important external
validators of nosological classes (Robins and Guze, 1972). Accurate predictors
of course and outcome are also essential for clinicians responsible for patients'
care and for public health planning. Studying the course of affective disorders,
however, raises numerous methodological problems; for example, most of the
studies are based on hospitalized patients and hence they are biased toward
1 4
the more severe illnesses; and no prospective population surveys including the
course of untreated patients have been carried out, due to ethical reasons.
2.5.1. Unipolar Affective Disorder
The onset of unipolar depression is highly variable. Most typically it
emerges gradually over a few months: occasionally it develops over days or
weeks. Between 10 to 20% of patients previously diagnosed as unipolar will
subsequently suffer from a manic or hypomanic episode (Runck,1985). This
risk, however, decreases with longer illness duration (Winokur and Wesner,
1987). Akiskal et al (1983-a) have reported that a number of associated
features are present in these patients who switch from unipolar to bipolar
affective disorder, such as onset before age of 25, acute onset, and psychotic
depression.
2.5.2. Bipolar Affective Disorder
The first episode may be either manic or depressive, and about 10% of
patients may have only manic episodes. Unipolar manics are not different from
bipolar manics in terms of demographic and clinical characteristics. A majority
of patients can lead relatively normal lives between episodes, but some patients
may exhibit significant reductions in social functioning (e.g. inability to hold a
job) despite the absence of the manic syndrome. Mania may occur suddenly or
may be preceded by a prolonged hypomanic episode or a depressive state.
Some patients may have only hypomanic episodes (bipolar II). The somatic
treatment of depression may result in an abrupt switch of mood. Attacks of
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depression are much more common than those of mania. About 7% of bipolar
patients will be rediagnosed as schizoaffective (Kaplan and Sadock, 1989).
2.5.3. Age of Onset
The median age of the onset of unipolar disorder is late 40's for both
men and women. A prominent peak is observed at ages 50 to 60 and another
peak at 20 to 30 years (Kaplan and Sadock, 1989).
The average age of onset of bipolar illness is in the early 30's. Two
peaks have been identified, one before age 30 and another during the mid to
late 40's (Kaplan and Sadock, 1989). The peaks are not absolute as the range
of onset is broad in unipolar and bipolar disorders varying from childhood to
elderly population
2.5.4. Duration of Episodes
An untreated episode of mania or depression has an average duration of
6 months to a year before remitting spontaneously, but some episodes may last
for longer periods. More than two thirds of the episodes will last for less than 6
months. Eighty percent of patients with an episode of major depression
recover within two years (Keller et al, 1982).
2.5.5. Number of Episodes
The number of episodes experienced in manic-depressive illness is
variable. Bipolar disorder is associated with a greater number of episodes than
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unipolar disorder. Estimations of the proportion of patients who experience a
single episode of depressive illness with no recurrence vary greatly. Angst et
al (1973), in a 12 year follow-up, found only 5% of unipolar patients and 0.5%
bipolar patients had had a single episode, but Lundquist (1945), in a 10 to 13
year follow up, found that 61% of unipolar patients and 55% of bipolar patients
had had only a single episode. It has been reported that bipolar illness show
more hospital readmissions than unipolar patients (Perris, 1968). The course
of unipolar depression is more variable and less well established than bipolar
illness, but between 50 and 85% of patients with one depressive episode will
have at least one subsequent episode in their lives (Keller, 1985).
It has been reported that between 10 and 20% of all patients diagnosed
as having major depression will manifest a chronic course (Robins and Guze,
1972). In a proportion of patients, a major depressive episode is superimposed
on dysthymic disorder that preceded the onset of the major depression by at
least two years (Keller and Shapiro, 1982). Further discussion on recovery and
recurrence of depression is found in Chapter 4.
2.5.6. Cycle or Period Length
Cycle length refers to the length of time between the onset of one
episode and the onset of the next. There is a trend for the first several cycles to
become successively shorter. A shorter cycle has been associated with later
age of onset (Tsuang and Lyons, 1988).
2.5.7. Morbidity
There is a high rate of comorbidity of depression and alcoholism and
eating disorders (Keller et al, 1986-a). Around 15% of a cohort of patients with
unipolar depression will be dead after 10 years (Guze and Robins, 1970).
Suicides and accidents account for almost all the excess mortality.
2.7. OUTCOME
Between the extremes of full recovery and chronicity , depression shows
a wide variation of outcome. Often the boundaries between depressive and
manic phases and the intervening periods are blurred. Earlier studies have
found that affective disorders have a more favourable outcome than
schizophrenia (Kaplan and Sadock, 1989). More recent studies, however,
have shown that affective disorder patients may have a poorer outcome than
previously reported (Lee and Murray, 1988; Kiloh et al, 1988).
2.8. THERAPY OFAFFECTIVE DISORDERS
2.8.1. ACUTE EPISODE
For the treatment of affective disorder patients a variety of therapies have
been used: psychotherapies, sleep deprivation, electroconvulsive therapy, light
treatment, psychosurgery and psychopharmacology (Joyce and Paykel, 1989).
Three main classes of drugs have been used in the therapy of acute
depression: tricyclics, monoamine oxidase inhibitors (MAOI) and lithium. The
first two classes of drugs, however, are not reviewed here (comprehensive
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reviews are available in Meltzer, 1987; Kaplan and Sadock, 1989). This
review will focus on the use of lithium only.
2.8.1.1. Lithium
Lithium was first used in psychiatry by Lange in 1887 and has been
called the first psychotropic drug in western medicine (Johnson, 1984). Lithium
is the oldest psychotropic drug still in use, preceding chlorpromazine by three
years (Plenge and Mellerup, 1988). The modern use of lithium started in 1949,
when it was introduced by Cade in Australia for the treatment of manic patients
(Cade, 1949). Lithium, however, was rarely used in psychiatric practice before
1969. Several reasons appear to be responsible for this. Firstly, its discovery
in Australia and Cade's multiplicity of other interests did not promote its
acceptance. Secondly, there is a narrow range between therapeutic and toxic
dose. Thirdly, psychiatrists 40 years ago were not oriented to pharmacological
intervention. Fourthly, phenothiazines with their broader therapeutic
application were almost simultaneously introduced. Finally, ready availability
rendered it commercially nonprofitable.
2.8.1.1.1. Lithium in Acute Mania
Since its introduction into modern psychopharmacology by Cade (1949),
several studies and reviews have evaluated the usefulness of lithium in the
treatment of a manic episode. The findings of the initial studies were disputed
because of the uncontrolled design that had been used, but the benefit of
lithium in acute mania has also been consistently found in controlled trials
which are more methodologically sound. The full list of these studies is
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available elsewhere (see reviews by Schou, 1959; Noyes, 1969; Davis and
Fann, 1971; Goodwin and Ebert, 1973; Georgotas and Gershon, 1979;
Gershon and Goodnick, 1981; Lewis and Winokur, 1982). Regarding the
symptoms specific to mania, most showed the results with lithium were superior
to those obtained with conventional neuroleptics, such as chlorpromazine
(Gershon and Goodnick, 1981; Rosenthal and Goodwin, 1982; Prien and
Potter, 1990). Chlorpromazine is probably better than lithium in terms of having
a faster action and in controlling agitated patients more rapidly (Rosenthal and
Goodwin,1982; Prien and Potter, 1990). At the moment, however, lithium is
considered to be one of the best treatments for acute episodes of mania.
2.8.1.1.2. Lithium in Acute Depression
The indications for lithium in acute depression are less clear. Three
designs have been used to study the role of lithium in unipolar depression:
totally uncontrolled studies (e.g. case reports, single blind studies), cross-over
(a period on lithium followed by other treatment or vice-versa) and controlled
studies (double-blind randomized trial). Each of these will be discussed
separately. The methodology of the first two designs are flawed in several
ways, consequently subjected to bias. Firstly, the practice of separating
unipolar from bipolar depression only became widespread in late 1970's, so the
majority of the studies used heterogeneous populations comprising a mixture of
bipolar and unipolar depressed patients. This meant that no firm conclusion
could be drawn as to which group of patients found lithium more effective. All
the studies of this topic which satisfy the minimum methodological standards
will be discussed in detail in Chapter 5. The findings of other studies which do






















































































From 1949 to 1976, twelve uncontrolled studies of lithium in acute
depression were conducted (see Table 2.1). Four studies found lithium to be
ineffective in depression while eight studies have reported mild to moderate
improvement with lithium. A meta-analysis of these uncontrolled studies is not
possible due to a lack of comparison groups, but the numbers of patients
improving with lithium gives an idea of the effectiveness of lithium.
2.8.1.1.2.2. Cross-over trials
Eight cross-over trials have compared lithium with placebo in acutely
depressed patients (Hansen et al, 1958; Goodwin et al, 1969, 1972; Noyes et
al, 1971; Stokes et al, 1971; Noyes et al, 1974; Baron et al, 1975; Mendels,
1976). None of these studies reported an antidepressant effect of lithium in
acute unipolar depression.
Three studies were not included in the meta-analysis of Chapter 5
(Hansen et al, 1958, Noyes et al, 1971, Stokes et al, 1971). Hansen et al
(1958) studied 12 severely endogenous depressed patients who were given
lithium for two weeks and then switched to placebo. Only one patient suffered
a relapse synchronously with placebo substitution, after having improved on
lithium. No mention was made about the criteria to diagnose severe
endogenous depression nor to measure improvement. Furthermore, this study
was reported only in summary form and therefore can not be properly evaluated
(Schou, 1968). Noyes et al (1971) found that four of the five depressed
patients (2 unipolar, 3 bipolar) became symptom free with lithium but two
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relapsed with placebo substitution. Stokes et al (1971) also found no
significant difference for 18 patients who were treated with lithium or placebo for
26 depressive episodes. The drawbacks of this trial were that the treatment
period (7 to 10 days) may have been too short to allow lithium to have any
effect; the distinction between unipolar and bipolar patients was not made, no
mention of lithium doses and plasma concentrations was made and no details
of the rating scale used to classify the improvement of patients were given.
2.8.1.1.2.3. Controlled trials
Three trials were excluded from the analysis to be described in Chapter 5
(Fieve etal, 1968; Arieli and Lepkifker, 1981; and Bennie et al, 1983). Fieve et
al (1968) compared 17 depressed patients who received lithium with 12
patients who were treated with imipramine. Imipramine appeared to exert a
strong to moderate effect whereas lithium showed only mild antidepressant
effect after seven weeks of treatment. A number of short-comings were evident
in this study; for example, no information was given about the exact number of
unipolar and bipolar patients in the sample, nor were doses and plasma
concentration of lithium or imipramine given. Arieli and Lepkifker (1981) in a
double-blind study compared 12 patients on lithium, 10 on clomipramine and
10 on placebo. Lithium and clomipramine were found to be superior to
placebo, but no significant difference between them was detected. The studied
sample consisted of a mixture of unipolar, bipolar and involutional depressed
subjects. Some weakness were observed; such as there was no mention of
the method used to assign patients to each group and the number of patients in
these groups was very small making any inference meaningless. Bennie et al
(1983) compared lithium versus amitriptyline in a three week period in 60
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patients with different diagnoses; unipolar, bipolar and schizoaffective
depression. The numbers in each sub-group, however, were too small to
establish whether any particular type of disorder responded to either lithium or
amitriptyline. Overall, the results of these trials tend to support a moderate
effect of lithium in acute depression.
2.8.2. PROPHYLAXIS
The majority of patients who have had an episode of major depression
are likely to suffer a recurrence (Greenhouse et al, 1991). A variety of
approaches have been used to treat recurrent depression: psychotherapies,
sleep deprivation, electroconvulsive therapy, light treatment, psychosurgery and
psychopharmacology (Joyce and Paykel, 1989). The first modern prophylactic
treatment of depression was ECT. In 1943, a pilot study indicated that
prophylactic electro-shock might be effective in recurrent affective disorders
(Moore, 1943). This form of prophylaxis did not receive widespread
acceptance, however, due to the refusal of patients (Quitkin et al, 1976).
Probably the most used prophylactic approach is psychopharmacology. Drugs
which effectively prevent new episodes are a desirable tool in modern
psychiatry. During the 1960's, the possibility of an effective prophylactic
treatment for affective disorders arose with the advent of two classes of drugs;




Antidepressant drugs are one of the main options for treating moderate
and severe recurrent depression. Several trials have shown good results with
the use of antidepressants in depression. Hordern et al (1964) found that
patients on amitriptyline or imipramine for six months had a lower relapse
frequency than patients in a control group. The control group, however,
consisted of patients with more severe illness who were given ECT because
they did not respond to amitriptyline or imipramine. Seager and Bird (1962)
gave ECT followed by imipramine or placebo for six months. Eleven of 16
placebo patients relapsed while only 2 of the 12 imipramine patients relapsed.
The advantages of treating recurrent depression with antidepressants or lithium
will be discused in Chapter 5.
2.8.2.2. Lithium
Lithium has been used in a variety of other psychiatric illnesses such as
schizophrenia, paranoid reactions, catatonia, confusional states, epilepsy,
oligophrenia and delirious reaction (for a detailed review see Schou, 1979-b).
The efficacy of lithium in the prophylaxis of mood swings in affective illness,
however, has ensured that it is one of, if not the most important, drug in the
therapy of affective illness.
The prophylactic action of lithium in manic depression was first noted by
Noack and Trautner (1951) and Schou (1954) who observed that the
continuation of lithium treatment following remission of mania may prevent
recurrence. Hartigan (1963) and Baastrup (1964) were the first to report a
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similar finding concerning the prevention of recurrence in depression. Lithium
was the first drug to show a clear-cut prophylactic effect (Baastrup and Schou,
1967). The design of these first studies were far from ideal; trials were neither
controlled (random assignment to lithium and control groups) nor they were
evaluated blindly. The predominance of uncontrolled studies until the early
70's made clear interpretation of the data difficult. Another issue which also
made these studies difficult to interpret was the distinction between unipolar
and bipolar illness. The first studies did not separate unipolar and bipolar
illness and the term, manic depressive disorder, included patients who had
experienced both mania and depression and those with a history of depression
only (Schou, 1968). The first extensive study of lithium separating bipolar and
unipolar patients was by Baastrup and Schou (1967). In that study, a time
factor seemed to be involved. In one third of the cases, relapses occurred in
the first six months of treatment only. It was proposed that it might be months
before full stability could be obtained. The design of the study was open and
consequently a psychological effect could not be ruled out.
2.8.2.2.1. Lithium in Bipolar Illness
Numerous uncontrolled and controlled studies have provided strong
support for the prophylactic effect of lithium in bipolar illness (for a description of
these studies see the reviews by Gershon and Goodnick 1981; Murray 1984;
Prien 1988). It is so widely accepted that lithium is the treatment of choice in
the prophylaxis of bipolar affective illness (Baastrup et al, 1970; Zis and
Goodwin, 1979; Prien et al, 1973, 1984) that there has been no placebo
controlled study of maintenance lithium therapy in bipolar disorder since the
early 1970's (Prien and Potter, 1990).
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2.8.2.2.2. Lithium in Unipolar Depression
The prophylactic efficacy of lithium in unipolar depression, however, has
been the subject of considerable debate. The earliest report of lithium
prophylaxis in unipolar depression was in England. Hartigan (1963) reported
success in six of eight unipolar patients with long-term lithium treatment.
2.8.2.2.2.1. Uncontrolled studies
This initial report was followed by a number of uncontrolled studies which
also discerned a positive effect of lithium in reducing the frequency of relapse
(Baastrup and Schou, 1967; Melia, 1967; Fieve et al, 1968; Gottfries, 1968;
Zall et al, 1968; Laurrell and Ottosson, 1968; Angst et al, 1970; Persson, 1972;
Bennie, 1975; Lepkipker et al, 1985; Page et al, 1987; Souza et al, 1990).
Some studies were excluded from the analysis, as described in Chapter 5, due
to the absence of a comparison group (Gottfries, 1968; Zall et al, 1968; Bennie
1975; Page et al, 1987), lack of clarity as to how the comparison was made
(Fieve et al, 1968) or small sample size (Melia, 1967). Melia (1967) observed
that 2 out of 4 patients with recurrent depression who had been taking lithium
on a long-term basis had new episodes. Fieve et al (1968) found no difference
in five patients who were on both placebo and lithium and imipramine was more
effective in six patients who were on lithium and imipramine. Gottfries (1968)
described the effect of lithium in 4 patients as ++, in 4 other patients as + and in
seven as zero. Zall et al (1968) found that out of 12 subjects, eight were poor
responders, 3 showed moderate improvement and 1 was completely recovered.
Bennie (1975) followed 14 patients for six months and found that none had
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and found that none had recurrences. Page et aI (1987), in a group of 59
patients followed for 12 years, reported that 49% showed complete recovery,
41% partial recovery and 10% an insignificant response.
Four uncontrolled studies have failed to find such an effect (Stancer et al,
1970; Freyhan et al, 1970; Smigan, 1985; Bouman et al, 1986). Two trials
were excluded from the analysis in Chapter 5 (Stancer et al, 1970; Freyhan et
al, 1970). Stancer et al (1970) did not use a comparison group and only used
a small number of unipolar patients (2) in the sample. Freyhan et al (1970)
found that the rate of readmission in 7 unipolar patients while on lithium was
greater than during the pre lithium period, but the periods of observation were
not equal. Information was sought to clarify these points (see Chapter 5).
2.8.2.2.2.1. Controlled studies
Two trials were excluded from the meta-analysis reported in Chapter 5
due to the small numbers of unipolar patients in the samples (Laurell and
Ottosson, 1968; Cundall et al, 1972). Laurell and Ottosson (1968), in an
eleven months double-blind randomized trial, observed the following rates of
recurrence: lithium (2/4), amitriptyline (4/6) and placebo (5/6). Cundall et al
(1972) reported, in a cross over design of lithium and placebo (six months on
each drug), that of the five unipolar patients, two withdrew from the trial, one
preferred placebo and the other two showed no clear preference.
One controlled trial lithium versus antidepressant was excluded from the
analysis in Chapter 5. Platman (1970) compared 49 patients on lithium versus
21 on imipramine, but the number of unipolar patients could not be estimated
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since the entry criteria required patients to have two previous episodes of mania
and/or depression, so no meaningful interpretation of this study can be made.
In summary, several problems prevented a consensus on the role of
lithium in the treatment and prophylaxis of unipolar depression. Firstly, the
poor design used in many trials. Secondly, the inclusion of patients with
different diagnoses. Finally, different drugs were compared with lithium.
Based on different criteria of study inclusion, or even analysing the same
sample of studies, traditional reviewers reached opposite conclusions as
demonstrated in Chapter 5. A meta-analysis of these studies was, therefore,






In the beginning of the 18th century, the Father of the Brazilian
Independence, Jose' Bonifa'cio de Andrada e Silva, discovered the mineral
petalite (Johnson, 1984). In 1817, a Swedish researcher, Johann August
Arfvedson, isolated lithium from petalite. The name lithion was proposed by
Berzelius since it was found in a rock. In 1843, Ure presented a successful
reduction of a urinary calculus (which contained uric acid) by immersion of the
stone in lithium carbonate solution. In 1859, influenced by the experiments of
Ure, Sir Alfred Baring Garrod introduced lithium in medicine by recommending
lithium bromide for gout, rheumatism and allied disorders (Johnson and
Amdisen, 1983). He also proposed the use of lithium carbonate in combination
with uric acid to dissolve urate deposits in the cartilage, but the salt proved to be
of no therapeutic value in these disorders (Schou, 1968). Garrod also
suggested the use of prophylactic lithium to prevent the symptoms of uric acid
diathesis, including the mood disturbances, which was thought to be related to
the excretion of uric acid. But, it was Carl Lange, in 1886, who gave the first
unequivocal account of lithium prophylaxis for a psychiatric condition when he
observed that, in conditions involving both gout and depression, the use of
lithium improved depression. It is interesting to note that Lange's ideas,
despite being accepted at the time, were subsequently forgotten for more than
60 years (Johnson, 1984).
3.2. CHEMICAL CHARACTERISTICS
Lithium is a monovalent cation and it is the smallest of the alkali metals.
It has the highest electrical field density and it is the hardest of this group. It is
the lightest of the solid elements. Lithium is extremely reactive and it never
occurs freely in nature, usually it is found as salt. It accounts for 0.006% of the
earth's crust (Lazarus,1986). It is found in various minerals, plants and animals
in small quantities. There are two stables isotopes: 6Li and 7Li and three
radioactive ones: 5Li, 8Li and 9Li (Schou, 1968). Since it is the lithium ion that
is the active agent, any soluble salt might, in principle, be used for treatment
(Schou, 1968).
3.3. ABSORPTION
Lithium is not metabolized; its pharmacokinetics are determined only by
absorption, distribution and excretion (Schou, 1976-b). It is absorbed mainly
from the intestine but also from subcutaneous, intramuscular and intraperitoneal
depots. Peak levels occur about 2 to 3 hours after an oral dose and absorption
is complete in 8 hours.
3.4. DISTRIBUTION
Lithium is distributed in many tissues in the body but it has a different
pattern from those exhibited by sodium and potassium. Lithium is not bound to
proteins and it has been reported to be actively transported across cell
membranes (Lazarus, 1986). In most tissues, the tissue/serum ratios are less
than one. Values greater than one, indicating lithium accumulation, are found
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in bone, thyroid and salivary glands (Lazarus, 1986). The equilibrium is rapid
in some tissues (e.g. liver, kidney, and skin) and slower in others such as bone,
muscle and brain. Lithium concentration in the brain is the same as that in the
blood serum whereas the concentration in the spinal fluid is about one fourth of
that (Schou, 1976-b). The lithium concentration in cerebro-spinal fluid is about
half of that in the blood stream (Schou, 1968).
3.5. EXCRETION
Excretion occurs almost exclusively by the kidneys. Lithium excretion is
dependent on glomerular filtration rate and proximal reabsorption. Like
sodium, it is freely filtered at the glomerulus and 75% is reabsorbed in the
proximal tubules and loop of Henle. Less than one percent is excreted in
faeces. The amount of lithium loss in the sweat is negligible. In normal adults,
the renal lithium clearance rate is 15-30 ml/min. Lithium clearances decreases
with age and clearances of 10-15 ml/min are not unusual in older persons. In
the average adult the half life for lithium is around 24 hours, but in older people,
it may be as much as 30-36 hours. 45 to 75% of a given dose is excreted in 24
hours. Little is retained after five days (Schou, 1968). An important
implication for the renal handling of the lithium ion is that it is not possible to
increase its rate of removal by the administration of most saluretic drugs
(Baldessarini and Lipinski, 1975).
3.6. FORMULATIONS
Given in equal dosage, lithium carbonate, lithium citrate and lithium
acetate are of equal therapeutic value but the carbonate has one practical
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advantage: its anion weights half as much. This means that relatively large
amounts of lithium can be contained in one lithium carbonate tablet making
lithium carbonate the most used form of lithium. Lithium chloride is an
extremely hygroscopic substance and therefore unsuitable for incorporation into
tablets (Schou, 1968). There are several formulations of lithium carbonate on
the market, e.g. Priadel, Camcolit, and Phasal (Shelley and Silverstone, 1988).
Because differences in pharmacokinetic profile among the different formulations
are found, care should be taken in choosing which formulation should be
prescribed for any individual patient (Shelley and Silverstone, 1988).
3.7. DOSAGE
In adults with normal kidney function maintenance dosage may vary from
25 to 50 meq per day, corresponding to 900 and 1800 mg of lithium carbonate,
respectively (Schou, 1968). There are also slow release forms of lithium. The
major disadvantages of conventional lithium carbonate are the frequency of
dosage that is required (2 or 3 times a day) and the resulting erratic peak levels
of lithium (up to 2 fold variations). The slow absorption lithium formulations
were developed to decrease the adverse effects associated with peak and
rapidly rising serum concentrations as well to increase compliance (Lazarus,
1986). The delayed release formulations have also been associated with less
renal damage (Perry and Alexander, 1988).
3.8. LITHIUM LEVELS
Plasma lithium should be measured 12 hours after administration of the
drug. The recommended lithium levels for acute treatment is 0.8 to 1.2 meq/l.
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Lower serum levels between 0.4 and 1.0 mEq/l is sufficient for prophylaxis
(Lazarus, 1986).
Atomic absorption spectrometry (AAS) and flame emission spectrometry
(FES) are the two most widely used analytical chemistry instruments for the
determination of metals. Recent developments in the atomisation source has
improved the sensitivity of the AAS and FES measurements. Other methods
are also available to measure lithium levels: spetrophotometry, molecular
fluorescence and lithium ion-selective electrode method (Xie and Christian,
1988).
3.9. MECHANISMS OFACTION
The mechanism of action of lithium is unknown. Several tentative
hypotheses have been put forward (Wood and Goodwin, 1987). For a detailed
discussion see Chapters 7 and 8.
3.10. SIDE EFFECTS
Adverse effects of lithium are common in the first 2 or 3 weeks of
treatment. These signs are usually transient, but in some patients they may be
more persistent and this is the main reason for discontinuing lithium therapy
(additional discussion on the topic is found in Chapter 4 ). T-wave flattening or
inversion of electrocardiogram (ECG) recordings are the most common cardiac
alterations. Approximately 20% of patients show some alterations in the ECG
(Lydiard and Gelenberg, 1982). A fine tremor in the hands is the most common
neurological sign, and it can be alleviated by dose reduction or administering a
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low dose of propanolol. Some patients may complain of memory loss and
reduced performance in some learning tasks (Vestergaard et al, 1988).
Nausea, vomiting, and diarrhoea are commonly reported (Vestergaard et al,
1980, 1988; see also Chapter 8). The most frequent haematological change is
a benign leukocytosis (Lydiard and Gelenberg, 1982). This leukocytosis may
persist or decrease over time and it is reversible. The renal effects of lithium
have prompted more than 2400 reports in the literature (Jefferson, 1990).
Polyuria and polidpsia are the most common side effects. Lithium blocks the
effect of the antidiuretic hormone on adenylate cyclase, which in turn reduces
water reabsorption. The risk of developing chronic renal damage with
therapeutic doses of lithium, however, is small (Jefferson, 1990). Lithium
concentration in the thyroid is 2 to 5 times the concentration in serum and
causes a decrease in the secretion of thyroid hormones which may lead to
hypothyroidism (Schou, 1976-b). The effects on the thyroid will be discussed in
detail in Chapter 6. About 15 to 20% of patients on prophylactic lithium gain
weight (Teixeira and Karniol, 1985). This is quoted as one of the most
troublesome effects in young women (Vestergaard et al, 1980, 1988). Lithium
may cause muscular weakness and fatigue and exacerbate a variety of skin
conditions (Vestergaard et al, 1980, 1988). Lithium passes freely through the
placental membrane and is excreted in low concentration in the milk (Schou,
1976-b). Teratogenic effects of lithium have been demonstrated in mice and
rats.
3.11. TOXICITY
If lithium concentrations are high (that is, above 1.5 meq/l, lithium
poisoning may occur (Schou, 1968). There are some practical steps that
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should be taken to to avoid lithium intoxication, such as: a) frequent monitoring
of lithium levels; b) educating patients and their families about the early signs of
lithium intoxication; and c) special care of possible patients who are more
susceptible to this condition due to old age, kidney disease or the use of
diuretics.
3.12. CONTRAINDICATIONS
The strongest contraindications of lithium are: a) severe renal disease;
b) acute myocardial infarction; c) myasthenia gravis; d) first trimester of
pregnancy; and e) breast feeding mothers. Other situations where lithium
intake requires special attention are: cardiac conduction defects, Parkinson
disease, second and third trimester of pregnancy, and concomitant intake of
thiazide diuretics.
In prescribing lithium for depression, its effectiveness has to be
counterbalanced by its possible adverse effects. Firstly, side effects are
frequent and distressing. Young women may feel discouraged to continue
therapy because of the weight gain. Other patients due to the severity of some
side effects need to stop the treatment. Secondly, there is the danger of
teratogenesis. Discontinuation of the therapy is recommended during
pregnancy, especially during the first three months. The possibility of
pregnancy should always be investigated by direct questionning and laboratory
testing. Thirdly, the risk of toxic levels is always present due to its low
therapeutic window, therefore determinations of lithium levels should be
performed frequently. Finally, its use in patients with renal and cardiac
syndromes should be carefully monitored.
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CHAPTER 4
LITHIUM PROPHYLAXIS AND DISCONTINUATION IN UNIPOLAR
DEPRESSION: EFFICACY, WITHDRAWAL SYNDROME AND
SEASONAL PATTERN OF READMISSION
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4.1. INTRODUCTION
4.1.1. LITHIUM PROPHYLAXIS IN UNIPOLAR DEPRESSION
The prophylactic efficacy of lithium in unipolar depression has been the
subject of considerable debate. The conflicting findings are reviewed in Chapters
2 and 5. The findings from lithium withdrawal are reviewed here.
4.1.2. DISCONTINUATION AND WITHDRAWAL SYNDROME
A withdrawal syndrome, characterized by an increase in the
symptomatology and readmission rates, has been described after the
discontinuation of antidepressants in major depression (Dilsaver and Greden,
1984; Dilsaver, 1989). Kramer et al (1961) estimated in their retrospective studies
that 55% of patients experience withdrawal symptoms after discontinuation of
imipramine. The evidence of a similar a similar syndrome after lithium withdrawal
has been the subject of intense debate.
The first lithium discontinuation studies in affective disorders, using mainly
bipolar patients, focused on the efficacy of lithium as a prophylactic agent rather
than the possibility of relapse being caused by its withdrawal. Little attention was
paid to the possible causal relationship between discontinuation and relapse. The
natural course of illness was assumed to be the cause of these relapses rather
than a drug-related state. Later studies have tried to answer this question of a
possible withdrawal syndrome after lithium discontinuation.
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In bipolar illness, an apparent withdrawal syndrome has been reported in
some uncontrolled studies (Lapierre et al, 1980; Mander, 1986-b). Lapierre et al
(1980) reported an open study in which lithium was withdrawn for five days; of the
20 cases, four patients relapsed within this time. Mander (1986-b) studied 29
patients who had their lithium discontinued and 50 patients who continued to take
the drug. He found a significant difference in the relapse rate in the first three
months (8 patients in the discontinuation group and 4 in the control group). Three
uncontrolled studies, however, have failed to replicate these findings. No
withdrawal syndrome was found by Sashidharan and McGuire (1983) who studied
20 bipolar and two unipolar patients nor by Goodnick (1985) who studied a small
group of 12 bipolar patients. Molnar et al (1988) also failed to find evidence of a
lithium withdrawal syndrome (Table 4.1). Failure to replicate the findings could be
explained in the later study by the high motivation of patients to stay off the drug
with a possible failure to report minor affective episodes to General Practioners.
Controlled studies have also reported a lithium withdrawal syndrome in
bipolar patients (Baastrup et al, 1970; Melia, 1970; Cundall et al, 1972; Fyro and
Peterson, 1977; Margo and McMahon, 1982; Mander and Loudon, 1988).
Baastrup et al (1970) showed that 12 out of 22 patients relapsed within 5 months
after lithium discontinuation. Melia (1970) reported four relapsed out of eight
patients within two months off lithium. Cundall et al (1972) found that 10 patients
out of 12 had relapsed after six month of placebo substitution. Fyro and Peterson
(1977) divided 18 patients into pairs (one on lithium the other on placebo). They
reported that all nine patients on placebo were first to relapse (seven within three
months). Margo and McMahon (1982) showed that all 4 patients relapsed within
11 days after substitution of lithium for placebo but none of the 11 patients who
continued to be treated with lithium. Mander and Loudon (1988) studied 14
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bipolar patients randomly assigned to 4 weeks each of placebo or continued
lithium treatment under double blind conditions. They found that seven patients
relapsed within the first two weeks of placebo substitution.
Some controlled trials failed to find evidence of a lithium withdrawal
syndrome, for example Christodolou and Lykouras (1982) reported that only three
out 17 patients relapsed. These conflicting results may also be attributed to
heterogeneity of patient population, especially the proportion of bipolar I and
bipolar II in the sample (Mander, 1986-b).
Other withdrawal studies, although reporting withdrawal syndrome in
affective disorder, are unreliable due to their methodological deficiencies. Klein et
al (1981) reported a discontinuation syndrome in 21 patients, but the use of
unspecified diagnostic criteria of affective illness and the loose definition of the
nature of relapse were serious methodological shortcomings. King and Hullin
(1983) reported the finding of a withdrawal syndrome in a survey of patients who
had discontinued their lithium, but their findings are marred by various
methodological pitfalls, including a biased, very low response rate and a
dependence on the subjective recall of elderly subjects of their withdrawal
symptoms with a mean of 4.45 years of lithium discontinuation. Other publications
are flawed by small samples (five patients or less) and case reports, mostly
involving bipolar patients (Small et al, 1971; Wilkinson, 1979; Cordess, 1982;
Margo and Mahon, 1982), and also by poorly defined patient population such as
'unstable character disorder' (Rifkin etal, 1975).
In unipolar depression, the literature regarding the existence of a withdrawal
syndrome in patients with recurrent illness discontinuing lithium is sparse. Earlier
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relapses were noted but not in sufficient numbers to warrant further investigations
(Baastrup et al, 1970; Melia, 1970). In a double blind discontinuation trial
involving 17 unipolar patients on lithium and 17 on placebo, Baastrup et al {1970)
observed earlier relapses but there was no indication of a rebound or abstinence
effect. Melia (1970) studied in a double blind trial nine (7 bipolar, 2 unipolar)
patients on lithium and nine (8 bipolar, 1 unipolar) on placebo. He reported that
one recurrent depressed patient relapsed after 24 days of stopping lithium (see
Table 4.1). The only study with reasonable numbers (seventeen recurrent
depressed patients) provided no evidence of a lithium rebound or withdrawal
phenomenon (Baastrup et al, 1970).
Overall, there appears to be some reliable evidence to suggest that a lithium
withdrawal syndrome does occur in some bipolar patients, but the proportion of
patients presenting the syndrome and the time that it occurs is a matter of dispute
(Table 4.1). In unipolar depression, there was no reliable evidence for a lithium
discontinuation syndrome and this justified further investigation.
TABLE4.1





























































































4.1.3. SEASONALITYAND AFFECTIVE DISORDERS
The observation that affective disorder is sensitive to seasonal influences
has been made since ancient times (Hippocrates, transl. 1979). At present, the
issue of seasonality in affective illness has been highlighted by the inclusion in the
revised edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-
lll-R; American Psychiatric Association, 1987) of the term "seasonal pattern" as a
description of recurrent major depression and bipolar disorder. In considering the
possible relevance of biological rhythms in depression it is important to remember
that, because of its inherent cyclicity, depression itself is a kind of abnormal
biological rhythm spanning weeks,months or years (Wehr and Goodwin, 1983).
Circadian rhythms are implicated in some of the symptoms of depression, such as
early awakening and diurnal variation of mood. The role of seasonal patterns,
however, has not yet been fully investigated.
A variety of events which are associated with depression have been shown
to have a seasonal distribution, for example suicide rates, use of electroconvulsive
therapy (ECT), consultations for depression, prescription of antidepressants and
hospital admissions for depression (for a review see Wehr and Rosenthal, 1989).
For these phenomena, most studies find two seasonal peaks, one in spring and
one in autumn. Suicide has been observed to have a maximum incidence in the
spring and in the autumn in countries of the northern hemisphere, such as
Scotland (McKinlay, 1948) and Canada (Eastwood and Peacocke, 1976).
Electroconvulsive therapy is given most often in May and from November to
January (Eastwood and Peacocke, 1976). The number of consultations for
depression in London was greatest in spring and autumn (Harris, 1984). The
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prescribing of antidepressants by general practioners again shows peaks in spring
and autumn (Harris, 1986).
Seasonal variations in the number of admissions to hospital for depression
have long been observed (Slater,1938; Hare and Walter, 1978; Wehr and
Rosenthal,1989). Peaks have been observed mainly in spring (Eastwood and
Stiasny,1978; Frangos et al, 1980; Rihmer, 1980), in autumn (Eastwood and
Stiasny,1978) and in winter (Parker and Walter, 1982). Absence of seasonal
pattern has also been noted (Zung and Green, 1974). Unfortunately, the majority
of these studies did not take into consideration the heterogeneity of depressive
illness and bipolar patients were studied together with unipolar patients (Zung and
Green, 1974; Hare and Walter, 1978). The failure to record whether patients were
taking medication or not is another drawback in these studies (Eastwood and
Stiasny,1978; Parker and Walter, 1982). Studies where these aspects have been
taken into consideration, such as Rosenthal et al (1984), are mainly based on
samples of bipolar patients.
Studies reporting seasonal influences in the rate of readmission of
individuals with recurrent unipolar depression are rare. These patients are usually
receiving some form of drug therapy which may modify the natural course of illness.
Therefore, withdrawal from medication represents an interesting opportunity to
observe the natural history of severe unipolar depression since one would expect
factors such as seasonality to be more clearly expressed. Discontinuation of
lithium prophylaxis for this purpose is particularly favourable for two reasons: first,
no short term withdrawal syndrome of lithium discontinuation has been reliably
found in unipolar patients, as already discussed and second, lithium prophylaxis is
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commonly used in patients with regular recurrence of depressive illness
(Consensus Development Panel, 1985).
It was hypothesized that unipolar patients on lithium would not show
seasonal differences in readmission as the prophylactic effect of lithium would
mask any seasonality effects. Such seasonality effect, if there are any, would,
however, be evident in unipolar patients who had discontinued taking lithium.
4.1.4. AIMS OF THE PRESENT STUDY
The present study aimed to examine retrospectively the outcomes of lithium
discontinuation in a clinic population of unipolar depressed patients. These were
all patients who had been previously admitted to the Royal Edinburgh Hospital,
who had been taking lithium and who met the criteria for the study. Outcome was
defined as the rate of recurrence of a depressive episode. A group of patients who
discontinued lithium was compared with another group of patients who continued
to take it. The specific aims of the study were: (i) to assess the efficacy of lithium
by comparing outcome in these two groups; (ii) to consider whether a lithium
withdrawal syndrome occurs in unipolar patients during the first three months of
discontinuation as has been found in in bipolar patients (Mander, 1986-b); (iii) to
examine whether there is an increase in the number of hospital readmissions in
autumn-winter versus spring-summer and spring-autumn versus summer-winter in
recurrent unipolar patients after lithium withdrawal, and to determine whether the




4.2.1. COLLECTION OF DATA
Any retrospective study is dependent on the accuracy of records. In this
respect, the Royal Edinburgh Hospital is an excellent centre for retrospective
studies, because all clinical notes are typewritten and comprehensively
assembled. In addition, demographic details are recorded in a computerized data
base by the Lothian Psychiatric Case Register (LPCR). The lithium office
separately records biochemical data for all patients taking lithium, noting the serum
levels and reminding doctors of the need for further checks. These data bases
enabled identification of all patients with a diagnosis of manic depressive illness -
depressed type (World Health Organisation, ICD-9, 296.1), who were discharged
on lithium between 1st January, 1970 and 31st December, 1986. These records
formed the source from which information for the present study was obtained.
4.2.2. SUBJECTS
Patients were included in the study if, at the index admission (admission
when lithium was introduced), they:
(i) satisfied DSM-III criteria for major depression (American Psychiatric
Association, 1980).
(ii) Had remained symptom free for at least three months following discharge.
(iii) Had no diagnosis other than unipolar depression prior to starting lithium.
(iv) Were established at this index admission on lithium alone for prophylaxis of
their recurrent unipolar illness for at least three months.
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The number of lithium treated patients was 158 out of a total of 2301 patients
identified over the study interval with a diagnosis of unipolar depression. They
were further divided into those who eventually discontinued lithium (53) and those
who continued to take it (105). Both groups had to be on lithium only. Patients
who discontinued lithium had also to fulfil an additional criterion: a) they had not
used any psychiatric medication after lithium withdrawal. Thirteen patients from
this group failed to meet the above criteria and were excluded because:
(i) Other psychotropic medication was being taken at the time of subsequent
discontinuation of lithium.
(ii) It was not clear from their case notes or contact with the patient's general
practitioner when lithium treatment was discontinued.
(iii) They were clearly unwell at the time of lithium discontinuation.
The remaining group consisted of 40 patients.
4.2.3. OUTCOMEAND DISCONTINUATION CRITERIA
Outcome was determined by time to readmission (again with unipolar
depression). Since the patients remained resident in Edinburgh, they were
unlikely to be admitted to any other centre. Although this could not be determined
with certainty, no particular bias should have been introduced if any admissions
were lost in this way. Since multiple readmissions in a single individual are not
independent events, only the first readmission of each patient in each interval
analysed was counted. In other words, only the first readmission in the period
between admission to the study and time zero (as used in survival analysis
described in the statistical analyses section) and only the first readmission in the
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second interval (after time zero) were used. Only the first discontinuation was
taken into account when patients stopped lithium on more than one occasion.
After discharge, three months without readmission was required to exclude
the possibility of early relapse. After this period, any readmission was considered
to be a recurrence.
4.2.4. LITHIUM LEVELS
Lithium levels were available from routine monitoring and provided a check
on compliance. Most levels will have been determined 12-14h following the last
lithium dose. The normal range of these measurements was considered to be 0.4
-1.2 mmol/l.
4.2.5. SEASONS
Seasons were defined by equinoxes and solstices, i.e. spring (23rd March -
22nd June), summer (23rd June - 22nd September), autumn (23rd September -
22nd December) and winter (23rd December - 22nd March).
4.2.6. STATISTICAL ANALYSES
Survival analysis is a method to examine data where the outcome of interest
is length of time until an event occurs, in this case readmission to a hospital. The
survival function or survival curve represents the cumulative proportion of patients
who have not responded, i.e. were not readmitted to a hospital, by a fixed point of
time, say t, for T>0. For time =0, the survival function take the value of 1, because
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by definition the proportion of patients who have not responded at T=0 is 100%.
Over time, as subjects are readmitted, the survival curve decreases. If all subjects
eventually respond, the survival curve will decrease to zero. For patients who
discontinued lithium (Group A), the first phase was defined as the time from
admission to the study (three months after index admission) to the time of lithium
discontinuation. For patients who did not discontinue lithium (Group B), the first
phase was defined as three months after the index admission, exactly as for
patients who discontinued to duration of lithium treatment in A plus/minus 2 years
for a matched patient from group A. This allowed an arbitrary time (time zero) in
the follow-up of the patients in group (B) to be defined equal to the time of
discontinuation of cases in group A. Their outcome could then be determined in
two intervals of time equivalent exactly to those for group A but not including lithium
discontinuation.
Calculation of the life table was performed as recommended by Fliess et al
(1976). The estimation of the 95% confidence intervals for the cumulative
probability of remaining continuously well in each interval is described in Appendix
4.1. Cumulative probabilities from life table analysis have been compared as a
summary chi square and individual probabilities from a critical ratio derived from
their standard errors, and this is also demonstrated in appendix 1 (Mantel, 1966;
Fliess et al, 1976). The variance estimate of the survival curves was measured by
Greenwood's (1926) formula.
Clinical data have been compared for the group taking lithium and the
lithium discontinuation group using Student's t-test and Mann Whitney test for
parametric and non-parametric data, respectively. Both tests were two-tailed.
Categorical data was analysed by chi-square. Cox regression model (1972) was
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applied to the life table in search of predictors of outcome and discontinuation.
One-way analysis of variance and the chi-square with Yates correction were used
to compare the various demographic, historical and clinical parameters of the
readmitted, remained well and dropout groups. The Scheffe's multiple
comparison test was used to determine significant differences on the ANOVA
between the groups (dropout vs readmitted plus remained well, readmitted vs
remained well). The SPSS-X statistical software program was used for most of the
data analysis (Nie et al, 1975).
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4.3. - RESULTS
4.3.1. CLINICAL CHARACTERISTICS OF PATIENTS BEFORE STARTING
LITHIUM
The patients in this study were middle aged, predominantly female, and had,
on average, at least three admissions to hospital with unipolar depression before
starting lithium (Table 4.2). The group who subsequently discontinued lithium
were entirely comparable with those who did not. There were no statistically
significant differences in sex ratio, the duration since the first illness episode, the
annual admission rate, the time spent hospitalised, the number of admissions that
had occurred prior to lithium introduction or their lithium levels after its introduction.
The only factor on which the groups differed was age at first episode; those who
subsequently discontinued lithium were slightly younger (51.8 (14.9) vs 44.8 (15.3),
p=0.03) (Table 4.2). The mean duration of treatment with lithium of all patients was
29 months (range 4 months - 11.5 years).
160
TABLE 6.4
Demographic and clinical characteristics of patients discontinuing lithium.
Values are mean ± standard deviation.
Age at trial (years) 52.7 (16.4)
Sex (M,F) 5, 9
Illness duration (years) 9.8 (4.7)
Episode frequency (per year) 0.2 (0.2)
Duration of lithium therapy (years) 9.7 (4.9)
Last lithium level before
discontinuation (nmol/l) 0.72 (0.1)
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4.3.2. PHASE I: BOTH GROUPS TAKING LITHIUM
Life tables of discontinued and continued groups during phase one are
displayed in Tables 4.3 and 4.4. The analysis of these life tables revealed that
patients who subsequently discontinued their lithium had been significantly more
likely to stay well in the two years after starting it than those who continued it.
Because of this, the probability of being well after two years of lithium prophylaxis,
as shown in figure 4.1, was significantly higher in the group who then discontinued
(0.92 vs. 0.57, z = 5.20, p < 0.01). The annual rate of readmission of this group
during this phase was significantly lower (0.22 (0.69) vs 0.54 (0.88), p=0.023). In
other words, discontinuation was strongly associated with successful treatment.
4.3.3. PHASE II: GROUP A DISCONTINUES, GROUP B CONTINUES
Tables 4.5 and 4.6 display the life tables of discontinued and continued
groups during phase II. The cumulative probability of remaining well for the group
who discontinued lithium after two years shows a poor outcome (Figure 4.2). This
is true when comparing their probability (0.42 after 2 years) with that of Group A at
the end of phase I (0.92) and with the probability of Group B in phase I (0.57) and
phase II (0.65) after two years of follow-up.
The risk of recurrence over the first three months following withdrawal (the
period when lithium withdrawal admissions occur in bipolar patients) is not
significantly increased (Figure 4.2). After three months of discontinuation, the















































































































































































































































































































































































































































































Life table presentation of the cumulative probability of recurrence of Group A
(above) is shown after starting lithium (filled symbols) and after its discontinuation
(open symbols). The difference between the two profiles was unlikely to have
arisen by chance (Chi-square = 11.85, p < 0.001).
FIGURE 4.2
Group B is shown for two treatment phases in both of which the patients took
lithium. Phase I (closed symbols) shows the probability of recurrence after starting
lithium prophylaxis and is directly comparable with the phase of lithium treatment
for Group A. Phase II (open symbols) shows the probability of recurrence in Group
B for a second period of continuing lithium treatment. Its start was arbitrarily
defined by matching to the times of lithium discontinuation of patients in Group A.
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4.3.4. COMPARISON BETWEEN TWO SURVIVAL CURVES
Table 4.7 displays the significance levels when comparing between the two
groups in both phases (the tables are presented in Appendix 4.2). The summary
chi-square for the discontinued group comparing before and after lithium
withdrawal shows a significant difference (x2= 11.85, p< 0.001) while the
equivalent analysis for the continued group was not significant (x2= 0.74, NS).
The comparison between phase I of the discontinued group with phases I and II of
the continued group were both significant (x2 = 9.74, p<0.005 and x2 = 5.71, p<
0.025x respectively). The comparison between both groups after lithium
discontinuation was also significant (x2 = 5.20, p<0.025). However, the
probability of detecting a difference between the groups when no true difference
exists (Type I error) increases with the number of comparisons conducted between
groups. Bonferroni's technique is used to compensate this inflation in type I error
(Lachin, 1982). Comparisons of four phases would required a p= 0.008 to achieve
a true type I error of 0.05. Using this more rigourous criterion, only the comparison
















*=p<0.05,*=p . 1,*=p< .00
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4.3.5. CLINICAL CHARACTERISTICS AND OUTCOME
The findings of the previous sections suggest that lithium withdrawal was the
major factor associated with the probability of recurrence. However, the clinical
features of patients who were readmitted were also of interest and are shown in
Table 4.8. Fifty-three patients from both groups (21 discontinuing, 32 continuing
lithium) who were readmitted in phase II were compared to the 50 in either group
(10 discontinuing, 40 continuing lithium) who remained well and were followed up
throughout the 24 month follow-up interval. As would be expected, there were
more cases admitted in phase II from the group who discontinued lithium (x2 = 3.8,
df=1, p < 0.05). They did not differ on any of the other factors examined (Table 4.8)
when the Scheffe's test was used.
4.3.6. DROPOUTS
There were no statistical differences in the clinical and demographic
characteristics of patients dropping out (patients that discontinued lithium for
reasons not related to clinical outcome - moved away, death, etc.) during phase I
were compared with patients who were readmitted or remained well for 24 months.
The only significant ANOVA was the number of admissions before prophylaxis
(F=3.8, df=2,133, p=0.05), where the group who were readmitted had a slight
increase in the number of previous admissions (Table 4.8). However, when the
readmitted and remained well group were combined, the comparison with the
dropping out group was not significant. A similar pattern was observed with no
significant differences emerging when the clinical features of patients dropping out
during phase II when compared with either patients who were readmitted or
remained well for 24 months (Table 4.9).
TABLE4.8














































































4.3.7. PREDICTION OF OUTCOME AND DISCONTINUA TION
The readmitted - remained well groups and the discontinued - continued
groups were very similar in almost all clinical and demographic variables (see
Table 4.2 and Table 4.8). As would be expected, no clinical or demographic
predictor of outcome and discontinuation of lithium using the Cox regression
analysis could be found. The dependent variables included in the analysis were:
age at first episode, sex, number of previous episodes, duration of illness, weeks in
hospital before lithium therapy duration. Age at first episode, which was
significantly different in the continuation and discontinuation group, is only of
marginal importance in the discontinuation of lithium (p<0.10: risk of
discontinuation decreases with age).
4.3.8. SEASONALITY
Of 105 patients on prophylactic lithium 62 were readmitted during the follow-
up period of 4.5 (3.4) years and of the 40 patients who discontinued lithium 28
were readmitted in a follow-up period of 3.7 (3.0) years. These follow-up periods
were not significantly different (t= -1.35, df= 78.2, p=0.18). The clinical and
demographic characteristics of the patients who were readmitted on lithium and
those who were readmitted after its withdrawal were entirely comparable. There
were no significant differences in sex ratio (19:43 vs. 7:21, x2= 0.08, p=NS), time
since the first illness episode (6.9 (8.5) vs. 6.8 (7.5) years, U=772.0, p=0.62), the
time spent in hospital 17.9 (19.1) vs. 16.7 (17.5) weeks, 11=531.0, p= 0.73), or
number of admissions before the introduction of lithium (3.1 (2.6) vs. 2.5 (2.2),
11=734.0, p= 0.46). The only factor on which the groups differed was age at first
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episode: those who subsequently discontinued lithium were slightly younger (42.1
(15.7) vs. 51.6 (15.5) years, U= 610.0, p<0.02).
Table 4.10 summarizes the months of the first readmission after the
introduction of lithium in both patients who continued to take lithium and those in
whom lithium was discontinued. All readmissions in March, June, September and
December occurred before the 22nd, therefore they were included in the winter,
spring, summer and autumn, respectively.
In the continued group, the comparisons between the observed and
expected number of readmissions in autumn-winter and spring-autumn were non
significant (x2 = 1.2, and x2 = 0.37, respectively). The 95% confidence interval of
these proportions (autumn-winter 44-69%, and spring-autumn 41-66%) again
suggesting a non significant finding. In the discontinued group, no comparisons
were significant (x2 = 0) and their 95% confidence intervals ranged from 31 to 69%,
indicating a non significant result. When the two groups were compared, no
seasonal pattern was identified when the readmissions in the autumn-winter were
compared with the readmissions occurring in the spring-summer (x2 = 0.13, NS),
nor did a seasonal pattern emerge from the comparison between spring-autumn
and summer-winter (x2 = 0.01, NS).
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4.4.1. WHY PA TIENTS DISCONTINUE LITHIUM?
There is no single concept or definition of adherence and compliance (for a
review see Jamison and Akiskal, 1983). In this study, the term "nonadherence"
describes the discontinuation of lithium prophylaxis while "non-compliance" implies
the irregular intake of medication or the premature discontinuation of the treatment
(Maarbjerg et al, 1988). The expression "drop-out" refers to patients being
censored from the continued and discontinued groups.
Adherence and compliance to lithium therapy is dependent on several
factors: 1) patient variables - patient's understanding of disease; the quality of the
illness free interval, the patient general attitude to psychiatry,e.g. label of mentally
ill; 2) illness variables - chronicity, severity and frequency of episodes; 3) drug
variables - side effects, reminder of being ill; 4) delivery of care - availability of
service, physician attitudes towards lithium; 5) cultural factors - anti-drugs
campaigns, health system seen as repressive and punitive (Blackwell, 1976;
Muller-Oerlinghausen, 1982; Jamison and Akiskal, 1983).
A major problem in patients continuing to take lithium on a long-term basis is
their adherence to treatment. In practical terms, the effects of lithium non-
adherence are equivalent to those of lithium non-responsiveness. The only
difference is that lithium nonadherence is reversible and carries the possibility of
change while lithium nonresponse does not (Jamison and Akiskal, 1983).
Because of the vast clinical repercussions the study of lithium discontinuation is an
interesting area of research in psychopharmacology.
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The problem of lithium discontinuation is as old as the treatment of affective
disorders with lithium, and in fact the first patient ever treated successfully with
lithium discontinued the medication after six months (Cade, 1949). This
phenomenon occurs in spite of many lithium clinics providing information about
therapy with lithium (Frank et al, 1985; Schou, 1989-b; Walker, 1981). However,
written information may only be effective in the short term but not in the longer term
(Stitt and Trinca, 1979). Earlier estimates of non-adherence to lithium treatment
ranged from 20-30% (Van Putten, 1975; Bech et al, 1976), and have been recently
revised to 20-50% (Jamison et al, 1979; McCreadie et al, 1985; Frank et a!,\985).
Education of patients about their disease was reported to improve adherence
(Seltzer et al, 1980).
An increased risk of recurrence is associated with non-adherence; 20-30%
of bipolar patients stop prophylactic treatment against medical advice (Blackwell,
1976) and seventy-five percent of recurrences among lithium users were thought to
be due to poor adherence (Baastrup, 1971). Later reports found similar results
(Frank et al, 1985). The present study supports these findings which show a
poorer outcome being associated with lithium discontinuation.
The main reasons for non-adherence to prophylactic lithium in unipolar
depression are lithium's side-effects and the belief that they no longer need the
treatment (Jamison and Akiskal, 1983; McCreadie et al, 1985; Aagaard et al,
1988; Schou, 1988). Due to the retrospective nature of this study, we were not
able to measure with certainty the proportion of patients who discontinued lithium
because of side-effects, and the existence of a state of well-being while on
medication. In most cases, no clear reasons for discontinuation were given in the
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hospital notes. However, the reduced rate of readmission in the discontinued
group suggests that the main reason for lithium discontinuation was the feeling that
the medication was no longer necessary. This finding is in agreement with other
authors (Schou et al, 1970; Maj et al, 1989-a) who found the conviction of being
cured was the most frequently reported reason for interruption of prophylaxis in a
group of bipolar and unipolar patients. In other long-term medical treatments, the
absence of symptoms is again regarded as a very important factor in the
nonadherence of patients (Becker and Mainman, 1980). A contributory factor in
the process of refusing to take the medication is the denial of having a serious life¬
long illness reinforced by the absence of episodes (Jamison and Akiskal, 1983).
4.4.2. ARE UNIPOLAR PATIENTS COMPLIANT WITH LITHIUM?
Different methods to measure compliance have been proposed:
interrogation, tablet estimates, drug markers and drug detection (for further
discussion see Blackwell, 1976; Jamison and Akiskal, 1983), but all methods have
problems of reliability and validity. The non-compliance category is composed of
two types of patients: the first group consists of patient who discontinue lithium
prematurely (in this study, prematurely means less than three months of lithium
therapy). It has been estimated that around 40% of patients discontinue lithium in
the first month (Vestergaard, 1983). This group was excluded from this
investigation because one of the criteria for inclusion is to have taken lithium for at
least three months with the objective of separating true recurrences from relapse of
the ongoing episode.
The second group is composed of patients who take lithium intermittently.
Patients who continued to take lithium were regarded as compliant judged by the
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periodicity of their lithium checks (usually every two-three months) and results of
their lithium levels within the normal range (0.40 to 1.2 mmol/l). As these
measurements were spaced, we were not able to measure compliance between
laboratory measurements, but there was no reason to believe that the pattern of
intake was modified in those periods.
4.4.3. IS DISCONTINUATION OF LITHIUM ASSOCIATED WITH ITS
EFFICACY?
The probability of remaining well for those that continued lithium was found
to be similar to the previous results of Schou (1979-a) who reported a one year
probability of 78%, but greater than that of Peselow et al (1982) whose two year
probability was only 37%. These figures illustrate the quite poor prognosis of
many patients with recurrent depressive illness.
Aagaard and Vestergaard (1990) reported that a mixed group of affective
disorder patients (unipolar, bipolar and uncertain diagnosis) who later discontinue
lithium had more admissions during the two year lithium prophylaxis. The findings
of the present study point in the opposite direction, that is patients who stopped
their lithium were those who were deriving the most benefit. Further, they may be
more likely to do so when young. It is reasonable to assume that psychiatrists are
also more likely to agree in these circumstances. Furthermore, patients who
continued to take lithium did not derive as much benefit from lithium treatment as
did the patients who chose to discontinue. While this appears paradoxical, it is a
corollary of what was discussed above: those patients who are doing rather less
well, and are slightly older, may be prevailed upon to continue the drug more
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readily. Nevertheless, their prognosis on continuing lithium was significantly better
than that for patients who stopped lithium.
It is unlikely that the discontinued group had less severe illnesses, since
they had spent the same time in hospital as the continued group before the
introduction of lithium. Even if their illnesses had been less severe, this would
result in a bias in phase II against the demonstration of a deleterious effect of
lithium withdrawal.
The possibility that a subtherapeutic level of lithium might explain the poorer
outcome of the continued group in either phase compared with the discontinued
group before time zero was excluded because no difference in the mean lithium
levels could be found when these groups were compared (see Table 4.7). The
lack of association between lithium level and outcome is is in agreement with other
studies where the lithium levels of responders and non-responders are similar (Maj
et al, 1985; Smigan, 1985).
The importance of controlling for duration of lithium therapy during phase I
refers to the fact that the recurrence rate is dependent on the length of follow-up
and a bias could be introduced if one group had a longer follow-up than the
second. The definition of a time zero when both groups were matched for duration
of lithium therapy avoided this bias.
There have been anecdotal reports that some patients have a poorer
outcome in spite of an initial good response to lithium prophylaxis (Dotti and
Bernini, 1979). Recurrences after four years of successful treatment with lithium
were observed in 11 patients of the continued group; this outcome happened
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despite an apparently good compliance to prophylaxis. Until more data are
disclosed in relation to these matters, further speculation is of limited value.
4.4.4. IS THERE A LITHIUM WITHDRAWAL SYNDROME IN UNIPOLAR
PATIENTS?
The terms withdrawal symptoms and rebound phenomenon have been
discussed (Lapierre et al, 1980; Christodolou and Lykouras, 1982). The first have
been defined by a withdrawal state - hyperactive deep tendon reflexes, tremor of
hands and fatigue (Christodolou and Lykouras, 1982) while the second would
explain the relapse after lithium discontinuation. In this study, we are unable to
measure the first category and consequently only the second is analysed.
The life table shows no excess of recurrences of illness in the first three
months in phase II. Therefore, there is no evidence of admissions occurring purely
as a result of lithium withdrawal as seen in bipolar patients. Bipolar patients
showed an appreciably increased rate of readmission in the three months following
lithium withdrawal in a retrospective study fully comparable with this one (Mander,
1986-b). Furthermore, the early appearance of manic symptoms following the
withdrawal of lithium was confirmed in a prospective, double-blind, placebo
controlled design (Mander and Loudon, 1988). We cannot conclude that
depressive symptoms do not appear after lithium withdrawal in unipolar patients,
only that the recurrence of symptoms is not severe enough to cause admission, but
this is still an important finding. It may explain some of the controversy in the
literature regarding the lithium withdrawal syndrome because in different studies,
different proportions of bipolar and unipolar patients have been used (e.g.
Sashadhiran and McGuire, 1983).
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4.4.5. WHICHARE THE PREDICTORS OF OUTCOME AND DISCONTINUATION?
Demographic,clinical, neurochemical, neuroendocrine, physiological, and
psychological predictors of response to lithium therapy have been investigated but
with no consensus about their importance (for reviews see Abou-Saleh and
Coppen, 1986, 1990; Joyce and Paykel, 1989). In studies of clinical prediction of
outcome and lithium response in bipolar affective disorder, conflicting results are
shown. Good outcome was not correlated with demographic and clinical variables
(Kocsis and Stokes, 1979). Nonetheless, poor outcome has been associated with
more frequent admissions before starting lithium (O'Connell et al, 1991). Illness
duration was the only factor that predicted readmission in a multiple regression
analysis where the introduction of lithium was one of the independent variables but
it account for only 4% of the variance (Mander, 1986-a).
In this sample, the only difference in the clinical and demographic
characteristics was in the number of previous admissions (see Table 4.7). Patients
who were readmitted after time zero had been hospitalized more frequently, but no
significant difference emerged when this group was compared with the remained
well group using the Scheffe's test. As no demographic or clinical variables were
found to be significantly different between the groups, the search for factors that
would predict outcome in unipolar illness was fruitless. However, this is consistent
with other studies which have addressed the question of who is at high risk of
recurrence in lithium prophylaxis (Bouman et al, 1986).
Similarly, the findings of this study could not predict which patients would
discontinue lithium. Of the clinical and demographic variables pre lithium
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prophylaxis, only age of first episode was significantly different between the group
who continue and the group who discontinue lithium. It should be mentioned that
in the discontinued group, outcome was not related to duration of lithium therapy.
Of 12 patients who discontinued lithium after being on the drug for over 24 months,
five patients remained well for two years, six were readmitted and one dropped out.
In summary, after 40 years of lithium use, its clinical indications are still
empirical. No predictive factor has yet been found that would lead any clinician to
advise for or against lithium treatment and a clinical trial with the drug is the only
way to determine who will respond (Carroll, 1979). Similarly, no predictive
variable to identify who will discontinue lithium prophylaxis has been identified.
4.4.6. SHOULD LITHIUM EVER BE DISCONTINUED?
Possible indications for the discontinuation of lithium include the judgement
that the risk of relapse is low, the development of intolerable side-effects, the
availability of more effective or safer drugs and the ineffectiveness of lithium
(Jefferson et al, 1983). Different approaches are observed in relation to the
possibility of lithium discontinuation. Lithium may be discontinued after some
months of therapy if the current episode has been controlled and there is no history
of previous episodes (Jefferson et al, 1983). Baastrup (1980) recommended that
the therapy should be continued for 3 to 4 months following the first acute episode.
Krauthammer and Klerman (1978) suggested that lithium could be discontinued in
cases where the affective disorder is secondary and the primary cause is
successfully treated. Another alternative proposed by Ayd (1981) is the partial
discontinuation of lithium through the institution of lithium holidays (e.g.,
withholding lithium for a period of time).
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4.4.7. IS THERE A SEASONAL PATTERN OF READMISSION?
This study provides no evidence for an increased number of readmissions
during the autumn-winter months or in the spring-autumn in unipolar depression,
either on or off lithium. Winter and summer recurrences were equally likely in
patients continuing on lithium. The concept of seasonal affective disorder
(Rosenthal et al, 1984; Thompson, 1989-b) implies that depression should occur
more frequently in the autumn and winter. Seasonal affective disorder has been
reported to occur in 16 to 38% of patients with recurrent depression (Wehr and
Rosenthal, 1989). Clearly, this does not appear to be true for patients with
unipolar depressive disorder at high risk of recurrence on or off lithium. Seasonal
peaks for hospital admission for depression in spring and autumn have also been
proposed (Thompson, 1989-a; Wehr and Rosenthal, 1989). This study could not
confirm the occurrence of this pattern in hospital readmission rates of recurrent
depressed patients.
A possible reason for the absence of a seasonality effect found in this study
relates to the characteristics of the sample - a homogeneous group of recurrent
unipolar depressed patients. Depression is not a unitary condition, and unipolar
patients might have a different seasonality of depressive episodes to bipolar
patients (Thompson, 1989-a). Considering this hypothesis, two alternative
explanations for this negative finding may be raised: first, unipolar patients do not
show seasonality at all or alternatively, if a seasonal effect is present it may be
restricted to the milder forms of the disease. In seasonal affective disorder, the
relative proportions of patients who have a diagnosis of unipolar and bipolar
depression have been the subject of controversy and it illustrates conflicting views
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about which group more clearly shows a seasonal effect. Some studies have
argued that the majority of the patients with seasonal affective disorder were
bipolar (Rosenthal et al, 1984; Garvey et al, 1988), while other groups have found
a greater proportion of unipolar patients in their samples (Wirz-Justice et al, 1986).
At the present moment, it is not yet clear to what extent unipolar depression, or
some subgroups of this disorder, show a seasonality effect.
The role of lithium itself in modifying seasonal patterns, e.g. circadian
rhythms, has been investigated. Lithium slows or delays circadian rhythms in
plants (Engelman, 1973), animals (McEachron et al, 1982), and humans (Kripke et
al, 1979). In fact, the therapeutic effects of lithium in affective disorders have been
suggested to arise from a slowing of their uncoupled accelerated circadian rhythms
(Tupin, 1970). The influence of lithium in seasonal or annual rhythms is not yet
fully understood but there is not enough evidence to permit us to endorse the view
that these rhythms are altered by lithium in a significant way.
Some methodological considerations concerning this study of the
seasonality of readmission in unipolar depression have to be discussed. First,
numbers of patients in the discontinued group are small. Nevertheless, they are
relatively homogeneous and representative of recurrent unipolar depression. To
examine the natural course of unipolar depression for any length of time without
the contamination of prophylactic medication poses serious difficulty for any study.
In the present case, the use of lithium provides a more controlled example.
Secondly, there is a potential lag between onset of an episode and
admission to hospital. It was observed that some depressive episodes began in
the autumn but the hospital admission occurred only in the following spring
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(Rosenthal et al, 1983). However, in the present patient group, the need for
medical supervision of lithium treatment and its withdrawal meant such delays
were unlikely to have occurred.
Thirdly, how many seasons are required to establish a seasonal pattern?
The period of follow-up was only four years and consequently it may not have been
long enough to establish a seasonal pattern.
Fourth, the year might be divided in other ways, but from the monthly
distribution of readmission (see Table 4.10) it does not seem plausible that by
defining seasons in a different way, a seasonality effect would appear.
4.4.8. IS THE SAMPLE HOMOGENEOUS?
Between 10 to 15% of patients previously diagnosed as unipolar will
subsequently suffer from a manic or hypomanic episode (Runck, 1985), but, this
risk decreases with longer illness duration (Winokur and Wesner, 1987). As this
sample had a mean of 2.5 (2.3) previous admissions, this risk is minimised but not
completely ruled out.
4.4.9. WERE THE INCLUSION CRITERIA BIASED?
A selection bias in the patient sample occurred because the inclusion
criteria required that patients should have been on lithium only for at least three
months. During the 18 years of the study, 2301 patients of the Royal Edinburgh
Hospital were at some point prescribed lithium. However, most of them were
excluded because: 1) they did not take lithium at all; 2) they did not take lithium
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long enough (less than three months); or 3) they took lithium together with other
antidepressants and antipsychotics.
4.4.10. IS THREE MONTHS ENOUGH TIME TO DEFINE READMISSION AS
RECURRENCE?
An issue that is still unresolved with regard to discontinuation strategies
relates to the natural course of the index episode. Discontinuation designs have
the potential to confuse the distinction between a relapse and a true recurrence,
and consequently a clear definition is critical for any evaluation of study results (for
a review of these terms see Frank et al, 1991 and Prien et al, 1991). Our definition
of the end of the index episode was somewhat arbitrary. We relied upon the
conservative interpretation of case notes to determine whether patients had been
symptom free for at least three months following discharge. The choice of an
arbitrary time limit is a compromise. If a period is too short the number of early re-
admissions that were likely to have been relapses of the index admission may be
increased, if too long, some genuine recurrences may be missed.
It is debatable if three months is enough time to postulate that if a
readmission occurs after this period it is due to a new episode rather than a relapse
of the index episode. Some authors have preferred shorter periods, for instance in
the National Institute of Mental Health - NIMH (Maryland, USA), a recovery from an
affective episode was defined as a minimum of eight consecutive weeks with an
absence of or only mild affective symptoms (Keller et al] 1984; Coryell et at, 1987)
and even four weeks have been used (Fleiss et al, 1976; Fieve et al, 1979;
Peselow et al, 1982; Quitkin et al, 1984). Coppen efa/(1971) considered an
intervening period of 4 months before classifying an attack as a new episode.
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Longer periods have been used based on the fact that the prophylactic effects of
lithium may be felt only after six months to one year of therapy (Baastrup and
Schou, 1967; Dunner and Fieve, 1974). Nevertheless, our choice of the three
month period seems reasonable and it is unlikely to have invalidated our
comparison between patient groups or our interpretation of the effects of lithium
withdrawal.
4.4.11 WHEN DOES ACUTE LITHIUM TREATMENT STOP AND LITHIUM
PROPHYLAXIS START?
Therapy has been divided in three different phases: acute treatment,
continuation and prophylaxis. Short-term treatment is the initiation of
psychopharmacologic and psychotherapeutic treatment following a relapse or
recurrence until an adequate therapeutic response is achieved. Continuation
treatment refers to the consolidation of the acute treatment response. Prophylaxis
or maintenance therapy describes the prevention of new episodes on a long-term
basis (Thase, 1990). By definition, for a patient to be eligible for prophylactic
treatment at least one previous episode has to be diagnosed. Duration of each
phase, although distinguishable in theory, is often blurred in clinical practice (Prien,
1987), because of the difficulty in determining when continuation treatment ends
(i.e., when the episode is over) and when preventive treatment begins (Prien and
Kupfer, 1986). This study considers the continuation period to be the first three
months after discharge of the index admission since the patient remains well
during that period and the prophylactic period is defined as the following months of
therapy after the continuation period.
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4.4.12. IS READMISSION A GOOD CRITERION OF RECURRENCE?
One of the major methodological weakness in lithium research is the lack of
a consensus morbidity index. A number of ways have been used: 1) recurrence
frequency, 2) number of hospitalizations, and 3) overall morbidity measured
expressed by a simple or complex rating scale. In research, higher rates in rating
scales (e.g. Hamilton) have been used but this is impractical in retrospective
studies. This study included only patients who had been admitted to hospital,
hence, it focused on the more severe end of the depression spectrum. The choice
of readmission rather than recurrence of symptoms was chosen as the outcome
measure since it is more definable in a retrospective study. This criterion of
recurrence was conservative but more reliable. However, this approach does not
allow any inference about the beginning of the episode since it does not take into
consideration the fact that some patients have subtle warning symptoms several
weeks before the full syndrome appears (Molnar et al, 1988) and a readmission is
delayed in relation to the exact time of the episode.
The distinction between inpatient-outpatient is important since it may reflect
factors such as severity of psychopathology, level of functional impairment,
treatment seeking behaviour and a decision by the clinician about the need of a
more intensive therapy. The decision to admit to a hospital is also clearly
influenced by the availability of social support and alternative community services
but the relative homogeneity of the services provided in the area served by the
Royal Edinburgh Hospital will have protected us from what might be described as
artefacts of patient management. Thus, it would be most surprising if the rate of
hospital admission within a given patient group were not directly related to the level
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of symptoms. A practical advantage of using readmission as a criterion is that it
carries direct implications for the use of expensive in-patient resources.
Another possible source of bias in a retrospective study is the fact that many
different psychiatrists were involved in the management of the patients and
different criteria of severity might have been used as a criterion of readmission. In
practical terms, reduced frequency and reduced severity of episodes run a parallel
course but occasionally the decision to readmit may be taken based on different
levels of illness severity (Grof et at, 1983). However, the relative homogeneity of
clinical assessment and psychiatric practice in the Royal Edinburgh Hospital gives
a partial protection against substantial differences in psychiatric assessment.
4.4.13. ARE RETROSPECTIVE DESIGNS USEFUL IN THE STUDY OF LITHIUM
PROPHYLAXIS?
The most important limitation of retrospective studies is that patients do not
enter different treatment groups at random. The groups were defined based on a
joint decision by clinician and patient and were not controlled in any way by the
investigators. Therefore, bias could be introduced which might contaminate the
findings. Indeed, we suspect that bias was introduced in the present study,
because the patients who discontinued lithium tended to be younger, and were
doing better as a group than the control population; such patients might have been
expected to do well after discontinuing lithium, whereas they actually did badly. In
other words, the bias introduced by non-random discontinuation could have
prevented our finding an effect of lithium prophylaxis but was unlikely to account for
what we did observe. However, we believe that the age difference is unlikely to
have affected our overall results since the seven year difference is clinically
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unimportant. In any event, age was not significantly related to recurrence in this
study, a finding that agrees with other work (Carroll, 1979). Randomised studies
do not have these disadvantages but may, nevertheless, recruit unusual and hence
unrepresentative samples of patients, are often extremely expensive and difficult to
organise because they require a multicentre basis, and may have to accept softer
definitions of recurrence. Other shortcomings found in this study due to its
retrospective design are:
a) Gradual vs. abrupt discontinuation. There is no consensus about the merits of
gradual vs abrupt discontinuation in clinical trials (Greenhouse et al, 1991). In this
particular study we are not able to determine how lithium was discontinued due to
its retrospective design.
b) Double depression. There have been reports that a degree of chronicity in
some depressed patients is observed, i.e. a moderate persistence of symptoms not
severe enough to require hospitalization (Keller et al, 1984). This phenomenon
has been called double depression (Keller et al, 1982) but we are unable to
comment on this because of the study design.
c) Biological and psychological predictors. These predictors can not be properly
evaluated in a retrospective study.
The advantage of retrospective studies of this sort is that they describe what
actually happens in delivery of care, and so are crucial in complementing the
findings from randomised trials, for instance, patients with severe personality
disorders are often not eligible for participation in a long-term controlled
investigation but are treated on an uncontrolled basis. If effects described in
research trials fail to be translated into clinical practice, then it is important to
determine why not. In a different sense, the success with which an effect can be
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translated from research to practice offers one of the more meaningful ways in
which a quantitative audit of treatment efficacy could be devised.
4.4.14. HOW GOOD IS THE LIFETABLE METHOD IN SURVIVAL ANALYSIS?
Life-table techniques were first developed by Halley (1693) in the
description of mortality. They are by no means new to medical research
(Greenwood, 1926) but it was only in the 1970's that researchers begin to apply
these techniques for data analysis derived from trials of treatment of affective
disorders (Fleiss et al, 1976). Life tables are described in details elsewhere
(Gross and Clark,1975; Lawless, 1982). There are two methods of analysing
survival curves: parametric and non-parametric (Gross and Clark,1975; Lawless,
1982). Parametric methods, such as exponential and Weibull, make assumptions
about the distribution of data considered normal whereas non-parametric methods,
such as the Kaplan-Meier (Kaplan and Meier, 1958) and the actuarial life table
(Fleiss et al, 1976), are distribution free in the sense that no specific form for the
survival curve is assumed (Woolson et al, 1978). We adopted the non-parametric
model because it is based on a more conservative approach to the analysis of data
and because of previous studies using this technique.
The difference between the Kaplan-Meier estimator and the actuarial
estimator of the survival curve is that the Kaplan-Meier curve is used when the
exact times of recurrences are known, whereas the life table estimator is used
when responses and withdrawals are only known to have occurred during an
interval of time (Greenhouse and Stangl, 1989). The estimates in any method will
be similar but we prefer to use the actuarial life table because we were interested
in examining the two year survival.
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The actuarial life table assumes that all patients are last observed in the
middle of the interval. Other solutions have been proposed (Chiang 1968; Kaplan
and Meier, 1958) but this one is the simplest (Fleiss et at, 1976). One of the
advantages of the life table technique is the fact that it allows the comparison of
survival curves in the presence of censorship (Rubinstein et al, 1981). A second
advantage is that it permits the analysis of the entire curve instead of comparing
each time point separately (Mantel, 1966). A third advantage is that it uses all the
survival information accumulated up to the closing date of the study (Cutler and
Ederer, 1958).
The mean duration of the intervals of the patients observed to relapse is
usually biased and it is dependant on the observation time, therefore the number of
episodes in a population increases as the duration of observation is lengthened
(Zis and Goodwin, 1979). The description of a sample mean in survival analysis
may be affected by some extremely long well intervals and can be misleading.
This finding lead Peto et al (1977) to state that average times should almost never
be cited. To obtain unbiased comparisons of response rates it is necessary to use
a method that utilises the total length of follow-up for all patients even when the
length of follow-up differs among patients, such technique is called the life table
which is a more appropriate way of describing survival data (Greenhouse and
Stangl, 1989). Life table methods free the investigator from the necessity of
arbitrarily choosing a cross-sectional point on which to report by presenting the
continuous description of the pattern of events during the whole follow-up (Keller et
al, 1982). This method is a powerful tool in analysing data from longitudinal
studies in which the outcome is binary (in this case readmission or no-
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readmission), patients enter and leave the study at different times and the outcome
can occur at any time during the follow-up (Fleiss et al, 1978).
The approach of considering all the data in life tables instead of comparing
simple points deserves some comment. This approach is more appropriate
because it takes into consideration the whole pattern of the curves instead of a
specific point estimate. However, this chi-square is especially sensitive to
differences in early failures rates (Fleiss et al, 1976). This is important when there
is crisscrossing such as when one curve is superior in one interval equals in
another and inferior in a third one. As can be observed in figures 1 and 2 this
pattern did not occur, and therefore, the summary chi-square is adequate.
Limitations of the life table method are: first, the reduced precision when
sample sizes are small; second, the formula used in this study to calculate the
variance (Greenwood, 1926) is the most employed formula, but it underestimates
the variance when the withdrawal rate is high (Chiang, 1968). In spite of these
limitations, the life table method is robust for analysing survival curves (Lawless,
1982).
4.4.15. HOW SHOULD DROPOUTS BE ANALYSED?
If the data from all patients were available the calculation of the response
rate would pose no problem. However, in the life tale analysis, this is not often the
case because a proportion of subjects do not respond, that is, they are not
readmitted to a hospital, or do not complete the observed period. These
incomplete observations are known as censored observations, and they occur for
various reasons: some are censored simply because the study ends before the
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event of interest is observed, while others are censored because subjects withdraw
or are lost to follow-up. Because of censoring, the relevant data for a survival
analysis consists of two components: a) the subject's status at the last point of
observation, that is, whether the subject responded or was censored; b) the length
of time the subject was followed. In working with these data, two assumptions
were made: first, neither the treatment nor the characteristics of patients changed
during the period of study, therefore censoring was not related to any of these
factors and second censoring was independent of the time of response.
Because dropouts are lost to follow-up (move to other places, failed to
return to appointments, etc), it is impossible to determine their clinical status at
the time of dropping out, they could be better, the same or worse than
individuals who remain under observation. However, for the dropouts who are
withdrawn at the closing date of study, there is no reason to believe that their
survival experience is not similar to individuals who remain under observation.
In any case, some degree of bias is inevitable no matter how the problem is
handled statistically (Fleiss et al, 1978). In this study, only the analysis where
no assumptions are made about the clinical status of drop-outs is reported, and
therefore, it was assumed that patients withdrawing from the study did so for
reasons not associated with clinical status. This approach has been advocated
by Lawless (1982) on the grounds that if censored observations are fairly
distributed along the intervals and they are independent of lifetimes then the
standard life table should behave reasonably, and also by Cutler and Ederer
(1958) on the basis that there is no reason to believe that patients withdrawing
from the study are different from patients observed for a longer period. The
power of life table analysis depends mainly on the total number of responses
observed and is little affected by the degree of censoring (Lininger et al, 1979).
CHAPTER 5
LITHIUM TREATMENT AND PROPHYLAXIS IN UNIPOLAR
DEPRESSION : A META-ANALYSIS
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5.1. INTRODUCTION
Two decades ago, due to the poor methodological design of lithium trials
at that time there was little convincing evidence to support the efficacy of lithium
in the treatment of unipolar depression. This was reflected by the statement of
Blackwell and Shepherd (1968) who wrote "...the results obtained with lithium in
depressive illness are almost uniformly bad". They suggested that any
reported beneficial effects of lithium were not in reality due to lithium itself but to
an expression of the natural history of the illness. They based their argument
on three factors: firstly, the recurrent nature of the illness was in some doubt in
patients who had suffered only a few spaced episodes; secondly, some
patients while not on lithium had had periods of remission longer than the
relatively short period of lithium treatment; thirdly, some patients actually
appeared to become worse while they were receiving lithium treatment. Other
opponents of lithium also based their scepticism of the apparent efficacy of
lithium in clinical observations on the lack of controlled trials. Proponents of
lithium at the time, however, opposed controlled trials as it would be unethical to
withhold what was observed to be clinically effective treatment for patients at
risk of suicide. Even now, the role of lithium in the acute treatment and
prophylaxis of depressive illness remains less supported than its role in the
management of bipolar illness and mania.
5.1.1. REVIEWS OF THE USE OF LITHIUM IN UNIPOLAR DEPRESSION
The role of lithium in the acute treatment of depression is disputed.
Several studies have reported positive findings while other studies have failed
to demonstrate such an effect. Some of these studies have already been
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described in Chapter 2 (Table 2.2 ). Reviews which support the clinical efficacy
of lithium include those of Murray (1984) and Doyal and Morton (1984).
Conflicting conclusions, however, were reached by Christodoulou (1968) and
Schou (1968, 1976-a), and these were reinforced by official bodies. By the end
of the last decade, the WHO Mental Health Collaborating Centres concluded
there was not enough evidence to recommend lithium in the treatment of acute
depression (WHO, 1989).
Conflicting conclusions have also been reached for lithium prophylaxis in
unipolar depression, and some of these have been described in Chapter 2. In
support of lithium prophylaxis, Schou (1968) concluded that lithium prevented
relapses with equal efficacy in patients suffering both mania and depression
and in patients with a history of depression only; Davis (1976) opined that
lithium is almost equally effective in unipolar and bipolar patients; and Schou
(1976-a) claimed that the evidence for a prophylactic action of lithium in
recurrent depression was very strong. On the other hand, Gershon (1974)
commented that the case for lithium prophylaxis is not clear and concluded that
the studies he reviewed did not imply clear efficacy.
In 1979, Prien and Schou reviewed the available range of publications
and reached different conclusions. The six studies included in the Prien (1979)
review involved 81 lithium-treated patients and 84 placebo-treated patients.
Although four studies found statistically significant differences in favour of
lithium, Prien concluded that the evidence was inconclusive. Schou's review
(1979-a) included five trials of lithium versus placebo in unipolar samples.
Lithium reduced the percentage of patients falling ill within a year from 70% to
20% which Schou concluded to be effective.
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Most of these reviews have employed a narrative design in which studies
were compared critically, on a qualitative basis. Using this approach, the
conclusions tend to reflect those of individual studies which are judged to be the
best. This type of review usually ignores the issue of relationship strength, that
is they do not assess the size of effect under study, although Davis (1976)
attempted some statistical comparisons. He emphasized the distinction
between effect size and statistical significance but could not try to combine the
results because "different statistical indices were used and it is difficult to
combine statistical tests for differences in degree of association" (Davis 1976).
Schou (1976-a) also did some statistical analyses but again no combination of
the results was sought. To the author's knowledge, there has been no previous
review using the techniques of meta-analysis to address this problem.
Further doubts about the effectiveness of lithium prophylaxis were
introduced by the reluctance of official bodies in the United States to
recommend lithium use in unipolar depression. In 1975, the
Neuropsychopharmacology Advisory Committee to the Food and Drug
Administration of the United States and the American Psychiatric Association
(APA) Task Force on Lithium Therapy concluded that there was still insufficient
evidence to warrant an indication of lithium in the prophylaxis of unipolar
depression (Prien, 1979). The FDA and APA committees cited two reasons for
not recommending lithium for that disorder: a) the definition of unipolar
depression was disputed; b) evidence for lithium's effectiveness was based on
relatively small samples of patients (Prien, 1979). In that country, the
reluctance of these official bodies to recognize lithium maintenance following
short-term tricyclic treatment for unipolar depression has an important clinical
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implication, which is that lithium is not widely employed and may even be
underutilized for this disorder (Schou 1989-a). The small number of patients
involved in the trials and the contradictions between the narrative reviews, e.g.
Prien (1979) and Schou (1979-a) reinforce the need for a quantitative method
to integrate the findings of these small trials.
5.1.2. AIM
The main objective of this review is to analyze quantitatively the results of
lithium trials in the acute treatment and prophylaxis of unipolar depression.
5.2. METHOD
5.2.1. META-ANALYSIS
The aim of meta-analysis is to employ quantitative techniques to combine
the results of different trials. Combining the findings across studies, that either
might be too small or too limited to enable conclusions about the effect of
treatment to be generalized, provides an attractive alternative to extend the
evidence about the treatment's efficacy. The major difficulty in integrating
studies comes from the diverse nature of designs and methods employed in the
different studies. A primary emphasis can be placed upon measuring effect
size rather than simply significance level. It is only by obtaining large numbers
of patients that trials can convincingly measure the size of treatment effects and
this is often feasible only by combining the results from several similar trials
(Peto, 1978). While this is the basis for large prospective multi-centre studies, it
can also be applied to the retrospective analysis of a number of small trials that
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share a similar but not an identical design. It is, of course, essential that the
source trials are satisfactory in the first place; treatment should be randomized
and outcome both well-defined and evaluated blind to treatment. However, if
these criteria are met the statistical techniques for pooling data are relatively
simple and deserve to be more widely known among psychiatrists and general
physicians (Yusuf et al, 1985). Furthermore, trials of much less satisfactory
design can also be quantitatively compared. This is of interest because if
treatment effects in poorly controlled clinical studies are comparable with the
better trials, it allows us to do greater justice to the clinical observations of an
earlier generation of psychiatrists and to make more meaningful comparisons
with real clinical conditions (for a detailed discussion of the advantages and
disadvantages of meta-anlysis see Appendix 5.2).
Basically, two approaches are used in meta-analysis: combination and
comparison of significance levels and effects sizes (Rosenthal, 1983).
Although significance level and effect size are correlated they provide distinct
information (Strube and Hartmann, 1983; see Section 5.4.8.). The methods of
combining and comparing statistical significance used in the analysis of
uncontrolled studies are based on those described in detail by Rosenthal
(1980,1983). These methods are necessary when studies report solely the
significance level and the effect size must be worked out from the p level.
Effect sizes can be measured by different methods: a) the standardized
difference between the treatment and control outcome means divided either by
the standard deviation of the outcome in the control group (Glass, 1976) or by
the pooled standard deviation of both groups (Cohen, 1977); b) percentage of
overlap between treatment and control distributions (Cohen,1977); c) logistic
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regression (Cox, 1970); d) correlation coefficients (Rosenthal, 1984); and e)
the Mantel Haenszel method (1959). The choice of the meta-analytic
procedure depends on whether the outcome is continuous or dichotomous.
The first two methods are based on the means of the control and experimental
group divided by the mean of the control group or the pooled variance of the
control and experimental group. When data gathered from the studies are
published in terms of means, these methods are very useful to integrate the
findings. But, when the outcome of treatment is a binary result rather than a test
score (or similar number) the Mantel Haenszel method or the logistic regression
could be used. The logistic regression model has the advantage of controlling
for covariates, such as age and sex. This is important when the assumption of
homogeneity is rejected (which is not the case in this meta-analysis). The
choice of the technique is usually not crucial since they give similar results.
Only when the heterogeneity of the studies is high or the magnitude of effect is
just significant may they yield different results (Streiner, 1991).
The Mantel Haenszel method was chosen to measure the effect sizes for
a number of reasons: firstly, the measurement of the observed minus the
expected number of failures is readily understandable and it is optimally
sensitive to any real effects (Yusuf et al, 1985). Secondly, each treatment is
compared with its own control (Sacks et al, 1987). Thirdly, studies are
weighted by sample sizes. Therefore, from the statistical point of view the
simple difference between the observed and expected (O-E) number of events
is not only more understandable, but it is also more justifiable. It is both
unbiased and assumption free (Peto, 1987-a).
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The (0-E) divided by the variance gives a good estimate of the odds ratio
where the results either favour lithium (odds ratio between zero and one) or the
comparison treatment (odds ratio above one). These intervals are
asymmetrical because the interval indexing the "negative" effect of lithium
treatment is infinitely wide while the interval for indexing the "positive" effect of
lithium association is finite. When the logarithm of the log ratio is taken,
however, symmetry results. Zero becomes the value indicative of no differential
risk, and the whole range of negative values (favouring lithium) is now
compared with the whole range of positive values (favouring the comparing
treatment) (Fleiss, 1979).
The typical odds ratio provides a useful approximation to the likely size of
any effect of treatment in patients not studied. The degree to which such results
can be reasonably extrapolated, however, must remain a matter of judgement
rather than one of mathematical calculation (Peto, 1987-b).
In the analysis of uncontrolled studies, the z-transformation (Fisher,
1921) was used to normalize the distribution and to make the variance
independent of the significance level. The transformation is reported to have a
positive bias giving larger weights to larger effect sizes than to small ones. The
Fisher transformation expands large effect sizes relative to small ones which
causes the confidence interval around large effect sizes to be smaller than
those around small effect sizes. The confidence interval around large effect
sizes should be smaller because sampling error is smaller. Thus the
expansion has the desired effect on confidence intervals, as was originally
intended by Fisher (Hunter et at, 1982).
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The present study illustrates the power of this method for assessing the
value of lithium in the treatment and prophylaxis of unipolar depression. The
magnitude of the treatment effects may be useful both in guiding the actions of
clinicians and better informing patients.
5.2.1.1. Data Collection
An effort was made to gather data from all trials written in English,
published or not, comparing lithium to other treatments in depressive illness
before 1990. The following means were employed: a) a formal computer-
aided search using the MEDLINE system of the recent English language
medical literature to identify studies comparing lithium to other treatment or
placebo in unipolar depression in the period of 1966 to 1989; b) an informal
search through Index Medicus, previous reviews, quoted references in
published studies and personal questioning of colleagues.
5.2.1.2. Criteria for Inclusion
Controlled and uncontrolled studies were reviewed separately, as
suggested by Peto (1987-b). Controlled studies were required to have a
prospective or discontinuation design with random assignment of treatment,
double-blind evaluation of outcome and serum lithium levels within the range
0.4-1.5 mmol/l. Uncontrolled studies were included if they had some kind of
group comparison. The contrast could be based on different designs, e.g.
cross-over, mirror ( pre- versus post-lithium intervals), retrospective or historical
controls. The following details were collected from each publication: name of
the study, design, population characteristics, duration of the trial, inclusion and
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exclusion criteria, treatments given, and number of drop-outs (see Table 5.1
and 5.3).
In classifying studies, terminology follows conventional usage
(Consensus Development Panel, 1985). Acute treatment refers to the use of
drugs in a period measured in weeks; prophylactic use is understood as the
use of a drug for months or years in an attempt to prevent depressive
recurrences. A recurrence is understood as a "new" episode.
5.2.1.3. Criteria for Exclusion
No study satisfying the entry criteria was excluded ad hoc. The criteria
for exclusion which were established a posteriori were: a) only one publication
from each study was included in the analysis. The most updated version was
used when several papers were based on a single project; this is not
uncommon (e.g Goodwin et al, 1969, 1972; Quitkin et al, 1978; Kane et al,
1982); b) some controlled studies were not included because data were
described in a way that did not permit quantification of the effect size (e.g.
Bennie et al, 1983) or they had studied too small a number of unipolar patients
(e.g. Melia, 1970; Cundall et al, 1972; Peselow et al, 1982; Johnstone et al,
1988).
5.2.1.4. Statistical Analysis of Controlled Studies
Meta-analysis has the purpose of quantifying findings from different
studies in terms that are strictly and formally comparable (Glass, 1977). To
quantify findings a common measure of outcome must be defined. In treatment
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studies, both the significance and the magnitude of effects can be determined
for categorical data from 2X2 tables, e.g. treated / control x failure (no response
or recurrence) / success (acute response or remained well). The Mantel-
Haenszel method is the best known (1959), and lends itself particularly well to
the calculation of effect sizes in clinical studies. This method is based on the
calculation of the odds ratio. In this particular case, the odds ratio represents
the possibility of failure (or success) on lithium versus the possibility of failure
(or success) on the comparative treatment. As the raw odds ratio does not take
sample size into account, a procedure developed by Mantel and Haenszel
(1959) in which sample sizes are considered was used. The confidence
interval of the odds ratio gives an estimate of the stability of the conclusions
(Yusuf et al, 1985). This approach was used for controlled studies (acute
treatment and prophylaxis) and uncontrolled studies (acute treatment) in which
categorical data were presented. The method of calculating the odds ratios is
presented in Appendix 5.1.
The chi-square of heterogeneity is also reported. It tests whether
between study differences are significant. It affirmative, it demands explanation
by careful post hoc examination of the data. Its method of calculation is also
presented in Appendix 5.1.
5.2.1.5. Statistical Analysis of Uncontrolled Studies
Uncontrolled studies have tended to use a variety of methodologies from
which to derive a statistical interpretation. The Mantel-Haenszel is not
commonly used. Instead the declared p values must be used to assess
significance of effects and also to make estimates of effect size (Rosenthal,
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1984). Assessment of significance levels requires the calculation of individual
Z scores for each study from the one-tailed significance equivalent to that
declared in the study (usually two-tailed). They are combined to derive an
overall probability of effect.
Effect size in these studies is calculated by transforming published
statistics into a common measure such as Pearson's r. From this an estimate of
average effect size can be made by a transformation of r into Fisher Z (Zr). The
Pearson product moment correlation coefficient r measures the degree of
association between two variables, in this case lithium and good outcome. It is
often preferred for uncontrolled studies because it can be derived from the least
published information. Large, medium and small effect size correspond to r =
0.5 , 0.3 and 0.1; this can be more easily understood in terms of a binomial
effect size display - BESD (Rosenthal, 1984). Using the BESD, the correlation
coefficient (r) is translated in the percent improvement, for instance a correlation
of 0.30 is equal to 30% clinical improvement. From that a success rate can be
calculated, according to the formula (success rate = 0.50 ± r/2). Therefore, a
30% improvement means that the success rate is increased from 0.35 to 0.65.
The studies were also compared to ensure that the pattern of results was
homogeneous (Appendix 5.1).
5.2.1.6. File drawer problem
A common criticism of meta-analysis is the possible bias introduced by
the failure to publish negative results, also known as the file drawer problem.
To counter this potential bias, a fail safe number can be estimated (Appendix
5.1). This is the number of studies with a null result that must be "in the file
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drawers" to reduce the overall summed probability below the desired level of
significance (by convention p=0.05) (Rosenthal, 1984). The fail safe N allows a
reader to easily evaluate the strength exhibited in a review against the assumed
completeness of the review's sampling procedure. The Z values, previously
calculated, can also be used to estimate a so-called "fail safe N", or the number
of unpublished statistically non-significant studies that would invalidate the
overall trend of the published findings (Cooper, 1979).
5.2.1.7. Power Calculation
Power represents the probability of obtaining a statistically significant
result if a difference in efficacy of a specified magnitude really exists. For each
individual study whose sample size was above 25 subjects, the power was
calculated according to the formula described by Cohen (1977; Appendix 5.1).
The result was referred to Table 7.3.15 in Cohen (1977) with level of
significance equals to 0.05 and one degree of freedom. When the number of
the sample was below 25 subjects tables by Detsky etaI (1985) were used.
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5.3. RESULTS
5.3.1. ACUTE TREATMENTOF DEPRESSIVE ILLNESS WITH LITHIUM
Table 5.1 summarizes the design of controlled and uncontrolled studies
included in this review. It also describes the duration, admission criteria,
exclusion criteria and number of drop-outs. Most studies involved only unipolar
patients. Where possible, the data from bipolars have been abstracted from the
studies for separate analysis. Almost all the comparisons involving lithium and
placebo were of cross-over design; studies comparing lithium with another
antidepressant (imipramine, desipramine or tryptophan- see Table 5.2) were
prospective. There have been no adequate prospective randomized
comparisons with placebo which one might wish to see in evaluating any drug
for its efficacy in depressive illness. One of the best designed studies was
provided by Johnstone et al (1988) where the primary purpose of the study was
not the inclusion of unipolar patients, who were consequently not in sufficient
numbers to be informative, and by Khan et al {1987) who employed
minimisation (Taves, 1974) rather than simple randomization in allocating
treatment and for ethical reasons allowed patients to drop-out on clinical
grounds. The criteria for this were not defined clearly in advance, but the drop¬
outs dominated the pattern of response and provided the only unambiguous
way of comparing lithium and placebo; the advantage of lithium compared to
placebo was not statistically significant (Table 5.2).
Table 5.2 summarizes the findings in detail. The prospective studies
comparing lithium with placebo, desipramine, imipramine or tryptophan showed
a modest advantage for lithium but this did not reach statistical significance
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either individually or in total. No individual placebo cross-over study showed a
statistically significant effect favouring an antidepressant action for lithium
either. The chi-squares of heterogeneity for the comparisons lithium versus
antidepressants (controlled studies) and lithium versus placebo (uncontrolled
studies) both with three degrees of freedom were not significant (x2=0.98 and
x2=1.58, respectively) demonstrating a common direction of the findings.
Overall patient numbers are small and the results inconclusive.
Effect size was calculated as the odds ratio (± 95% confidence interval)
for each study individually and as a pooled summary statistic (Figure 5.1). Only
one trial showed a clear advantage of lithium over antidepressants (Worrall et
a!, 1979). That brought the pooled odds ratio in favour of lithium. However, all
studies tend to show an advantage for lithium and hence the treatments were
homogeneous (x2=2.45). This finding suggests that there is no difference in
efficacy between lithium and other antidepressants which is sometimes
interpreted positively, i.e. that lithium is "as effective" as other treatments. The
95% confidence interval is wide and reaches 1.0, or no difference level.
The result of the comparisons of lithium versus placebo in bipolar
depressed patients does indicate a statistically significant effect. Overall effect




STUDIES OF THE ACUTE TREATMENT OF UNIPOLAR AND BIPOLAR
DEPRESSION WITH LITHIUM.
Controlled studies were prospective, randomized with double-blind evaluation.
Only Khan et al (1987) was placebo controlled; the others compared lithium
with another antidepressant. The design used in uncontrolled studies of lithium
versus placebo was cross-over with either single- blind (only Noyes et al, 1974)
or double-blind evaluation; in most of them the process of randomization is not
clearly stated. In the uncontrolled trials the duration of the lithium period was
usually greater than the placebo period. In Watanabe et al (1975) 25% of
patients withdrew from the trial.
1 Only the studies by Baron et al (1975) and Mendels (1976) give information for
bipolar patients. In Mendels et al (1972) unipolar and bipolar groups could not
be separated and only the first phase of the study has been included (cross¬
over phase omitted).
TABLE5.1






























































LITHIUM VERSUS OTHER TREATMENTS IN ACUTE DEPRESSION.
Lithium was compared with other antidepressants in trials using only unipolar
patients. Lithium was compared with placebo in cross-over trials including
unipolar and bipolar depressed patients. (O - E) is the difference between the
observed and expected number of failures in the lithium group. Variance (V) is
given as described in Methods, p is the two-tailed probability corresponding to
each normal deviate which is given by (O - E) / Vv. Outcome was designated in
Watanabe et al (1975) improved group= fairly to markedly effective, not
improved group= ineffective or worse and in Noyes et al (1974) improved
group= recovered, marked or moderate, not improved group= slight or worse.
TABLE5.2























































































































The odds ratio with the 95% confidence intervals for individual and pooled data
from acute treatment studies. The left side (< 1.0) favours lithium and the right
side (>1.0) gives advantage to the other treatment; lithium versus other
antidepressants in controlled studies of unipolar illness gives a just advantage
to lithium; lithium versus, placebo in cross-over studies of unipolar illness
showed no statistically significant effect; lithium versus placebo in bipolar
depressed patients showed an advantage to lithium. No chi-square of
heterogeneity was significant for individual group of studies.
The only significant chi-square of association was found in studies of bipolar
patients (x2 = 6.37 p < 0.05). Some studies had 95% confidence intervals
which extended beyond 4.0 and are not drawn in full: Watanabe et al 1975
from 0.19 to 4.93; Khan 1981 from 0.12 to 7.9; Mendels 1976 from 0.25 to 26.5.
UNIPOLAR DEPRESSION


































5.3.2. PROPHYLAXIS OF DEPRESSIVE ILLNESS WITH LITHIUM
Table 5.3 summarizes the design and clinical characteristics of the
controlled and uncontrolled studies of the prophylaxis of unipolar depression
with lithium. Ten studies are of randomized design and examine follow-up
intervals of 5 months to 3 years. They are further analysed in Table 5.4 which
summarizes outcome in terms of treatment success or failure.
5.3.2.1. Lithium vs Placebo
Most trials of lithium versus placebo have shown a statistically significant
benefit from lithium. However, the largest, by Prien et al (1984), did not. The
particular advantage of the analysis presented in Table 5.4 and Figure 5.2 is
that, the effect size in this study is shown to be compatible with that of other
studies and to favour lithium treatment. However, because the rates of
recurrence in both groups were high, the variance and hence the confidence
interval were increased. The summary statistics for the pooled data are
powerfully in favour of a benefit from lithium compared with placebo (Figure
5.2). The pooled odds ratio when lithium was compared to placebo was 0.22
with 95% confidence interval 0.13 to 0.36. In other words, lithium prophylaxis
reduced the odds of recurrence over about one year (the average duration of
the trials) by 78 % (confidence interval 87% to 64%). This result corresponds to
the sum for O-E of - 22.3, suggesting that 45 recurrences had been avoided with
the use of lithium (out of a total of 137 patients treated; there were 126 untreated
controls). This summary combines data from discontinuation studies with that
from randomized prospective treatment (Table 5.3). If discontinuation studies
are excluded, the effect size is 0.26 (95% C.I. = 0.15 to 0.47) and so remains
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essentially unchanged. The chi-square of heterogeneity with eight degrees of
freedom was not significant (x2=13.9). The Spearman's correlation coefficients
between effect size and duration of the trial (0.54) trial size (0.31), disc¬
prospective (0.32) and year of publication (0.39) were all non significant.
5.3.2.2. Lithium vs Other Antidepressants
In contrast to the results with placebo, lithium is not demonstrably
superior to antidepressant treatment in preventing recurrence. The pooled
odds ratio of the comparison lithium versus other antidepressants was 0.74 with
95% C.I. = 0.47 to 1.17 (Figure 5.2). The confidence interval leaves much room
for debate about the relative efficacy. Some antidepressants may be less
effective than others (e.g. mianserin, see Table 5.4). The chi-square of
heterogeneity with seven degrees of freedom was significant (x2=19.1, p<0.02)
with some trials favouring lithium while others favoured the antidepressant. For
the prophylactic controlled studies, the Spearman correlation coefficients were
not significant between effect size-sample size (0.61) and effect size-year of
publication (0.29). The Spearman correlation coefficient between effect size-
duration of trial (0.72) just missed significance (0.06). Lithium alone has been




CHARACTERISTICS OF STUDIES IN THE PROPHYLAXIS OF UNIPOLAR
DEPRESSION WITH LITHIUM.
Glen I refers to the study of Glen et al (1984) comparing lithium and amitriptyline
in recurrent unipolar depression; Glen II was the other half of the study in which
first episodes depressives were treated with lithium, amitriptyline or placebo.
Mirror design means that patients were studies before and after the introduction
of lithium; in many of these trials the length of the lithium period was different
from the placebo period. In Hullin et al (1972) unipolar and bipolar patients
could not be separated. In Prien et al {1973) only the second phase is reported
(5-24 months); the first phase (1-4 months) was omitted but showed similar
results.
1 Research Diagnostic Criteria.
TABLE5.3







































































































































PROPHYLAXIS WITH LITHIUM IN UNIPOLAR DEPRESSION: CONTROLLED
STUDIES.
The pooled results for the comparison lithium versus placebo indicates a
powerful treatment effect for lithium (p<0.00006) while the result obtained with
the comparison lithium versus other antidepressants was not significant. Only
two studies compared lithium with the combination lithium + imipramine and the
pooled result favoured the combination (p<0.02). Glen I data are from patients
with more than one previous episode, Glen II data are from patients with one
previous episode. Chi-square of heterogeneity was found significant in lithium
versus antidepressant treatment (x2= 19.1, d.f.=6, p<0.01), where different trials
show different results.
(O - E) is the observed minus the expected number of failures in the lithium
group. V is the variance of (O - E) , p is the two-tailed probability corresponding
to each normal deviate given by (O - E) / /V.
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TABLE 5.4
PROPHYLAXIS WITH LITHIUM IN UNIPOLAR DEPRESSION: CONTROLLED STUDIES.
STUDY LITHIUM COMPARISON CALCULATIONS
TREATMENT
FAILED WELL FAILED WELL (O-E) VARIANCE P
(O-E)
LITHIUM X PLACEBO
A) Baastrup et al 0 17 9 8 -4.5 1.70 <0.0006
(1970)
B) Coppen et al 1 10 12 3 -4.5 1.65 <0.0004
(1971)
C) Hullinefa/ 1 17 6 12 -2.5 1.45 <0.03
(1972)
D) Prien et al 9 13 11 2 -3.5 2.06 <0.01
(1973)
E) Fieve et al 8 6 9 5 -0.5 1.73 ns
(1976)
H) Kane et al 2 5 6 0 -2.3 0.82 <0.01
(1982)
I) Glen etal 5 6 8 1 -2.1 1.18 <0.04
(1984)
J) Prien etal 21 16 24 10 -2.4 4.17 ns
(1984)
TOTAL 47 90 85 41 -22.3 14.76 <0.00006
LITHIUM X OTHER ANTIDEPRESSANTS
D) Prien et al 9 13 6 15 1.33 2.49 ns
(1973)
F) Coppen et al 3 9 6 2 -2.40 1.25 <0.03
(1976)
G) Coppen et al
(1 Q7£\
0 15 7 6 -3.75 1.35 <0.001
\ I c? / O;
H) Kane etal 2 5 5 1 -1.76 0.86 <0.84
(1982)
1-1) Glen etal I 32 14 39 16 -0.33 5.28 ns
(1984)
I-2) Glenefa/ II 5 6 4 3 -0.50 1.13 ns
(1984)
J) Prien et al 21 16 16 22 2.74 4.74 ns
(1984)
17.10TOTAL 72 78 83 65 -4.67 ns
LITHIUM X LITHIUM + IMIPRAMINE
H) Kane et al 2 5 1 7 0.6 0.64 ns
(1982)
<0.03J) Prien et al 21 16 12 25 4.5 4.63
(1984)
<0.02TOTAL 23 21 13 32 5.1 5.27
109
FIGURE 5.2
The 95% confidence intervals (C.I.) of the individual and pooled odds ratios in
the controlled studies of prophylaxis. The pooled odds ratio of the comparison
lithium versus placebo totally favoured lithium (the whole 95% C.I. is below 1.0).
The comparison lithium versus other antidepressants gives a pooled odds ratio
which is inconclusive (the 95% confidence interval extends from 0.5 to 1.2).
The 95% C.I..of the comparison lithium plus imipramine versus lithium favours
the combination but the 95% C.I. is too wide (from 1.1. to 6.1) for a firm
conclusion. The 95% confidence intervals in one lithium v. other
antidepressants trial (Prien et al, 1984) extended beyond 4.0, from 0.7 to 4.3.
Glen I data is from patients with more than one previous episode, Glen II data is
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5.3.2.3. Uncontrolled Prophylactic Trials
Table 5.5 summarizes the findings of the uncontrolled prophylactic
studies. As explained in Section 5.2.1.5, the wide differences in mode of data
analysis and presentation make an approach based on the Mantel-Haenszel
method impracticable. Instead, following Rosenthal (1984) significance levels
were compared and combined and effect sizes estimated from the Rvalues
declared in each trial. Significance levels differ significantly indicating study
heterogeneity (Chi square = 11.43, df = 6, p<0.05), but all support a similar
positive treatment effect from lithium. Thus the combination of probabilities was
highly significant (Z = 6.5). The combined effect size was found to be in the
medium range, r = 0.41. The combined effect size of the controlled studies
expressed in the same terms was r = 0.42. These values of r can also be
understood in terms of proportional outcome ( Rosenthal, 1984). A value of
r=0.4 corresponds to an improvement in positive outcome from 30 to 70%.
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TABLE 5.5
PROPHYLAXIS WITH LITHIUM IN UNIPOLAR DEPRESSION:
UNCONTROLLED STUDIES.
Pearson correlation coefficient (r) for the uncontrolled studies were
homogeneous, and the overall correlation was r = 0.41. P is the reported level
of significance (one-tailed); Zis the normal deviate (one-tailed) corresponding
to each p; n is the number of patients studied; V is Pearson product moment
correlation coefficient, given by Z/VN; 'Zf is the transformation of r in Fisher z,
where Zr = 1/2 loge ((1 + r)/(1 - r)). The 'mean' value for r (given in brackets) is
derived from the mean for Zr.
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TABLE 5.5
PROPHYLAXIS WITH LITHIUM IN UNIPOLAR DEPRESSION:
UNCONTROLLED STUDIES.
STUDY P z N 7 N r Zr
Baastrup and Schou <0.0005 3.3 22 4.69 0.70 0.86
(1967)
Angst et al (1970) 0.0005 3.3 58 7.61 0.40 0.42
Persson (1972) 0.01 2.3 32 5.65 0.40 0.42
Lepkifker et al (1985) 0.001 3.1 33 5.74 0.54 0.60
Smigan (1985) 0.37 0.3 19 4.35 0.07 0.07
Boumanefa/ (1986) 0.26 0.6 20 4.47 0.13 0.13
Souza et al (1990) 0.001 3.1 40 6.32 0.49 0.53
Total 16.0 3.03
Mean 2.3 (0.41) 0.43
2
5.3.3. FAIL-SAFE N
The number of additional studies showing no treatment effect that would
be necessary to reverse the main findings illustrated in this meta-analysis
necessarily vary according to the effect size obtained in each comparison.
Only one statistically non-significant study needs to be published to invalidate
both the conclusion that lithium is more effective than other antidepressants in
unipolar depressed patients and the finding that lithium plus imipramine is
superior to lithium in maintenance treatment of unipolar depression. Three
statistically non-significant studies need to be published to invalidate the
conclusion that lithium is more effective when compared to placebo in bipolar
depressed patients. However, for the strongest effect, lithium versus placebo in
the prophylaxis of unipolar illness, 108 'negative' studies would be needed to
invalidate the conclusion currently favouring lithium. It should be appreciated
that a negative study for these purposes need not show an opposite effect to
that currently seen; assuming random treatment effects, some would favour a
treatment effect, some not.
5.3.4. POWER CALCULATION
Table 5.6 shows the power of the treatment studies. In all lithium versus
other antidepressants comparisons the power was low with the exception of
one case (Worrall et al, 1979). This means that the possibility of missing a
difference when such a difference truly exists, i.e. of making a type II error, was
in one study over 90 percent (Watanabe et al, 1975). In other words, if a
difference really exists in that study it would have one chance in ten of being
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detected. All the cross-over trials of lithium versus placebo showed a similar
pattern, in none of them was power greater than 0.20.
The power of prophylactic studies is shown in Table 7. Most of the trials
comparing lithium against placebo had enough subjects to detect a difference
in outcome between the groups. The only exceptions were the trials by Fieve
et al (1976) and Prien et al (1984) which showed low power. The picture in
relation to the comparison of lithium with other antidepressants is mixed with
three studies showing power over 0.50 and four power below 0.30. One trial
which compared lithium with the combination of lithium and imipramine showed
a lack of power (Kane et al, 1982).
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TABLE 5.6
POWER CALCULATION OF ACUTE TREATMENT LITHIUM STUDIES.
The low power to detect a significant difference was the main feature of the
treatment studies. All lithium versus other depressants trials had power around
0.20 with the exception of Worrall et al (1979) which had enough power. In all
cross-over trials the possibility of failing to detect a true difference was over
70%. In bipolar depression, one of the trials had a 70% chance of comitting a
type II error.
STUDY N W POWER
Unipolar depression: controlled
Lithium x placebo
Khan et al (1987) 27 0.20 <20
Lithium x other antidepressants
Mendels et al (1972) 24 0.25 20
Watanabe et al (1975) 45 0.01 <10
Khan et al (1981) 30 0 <10
Uncontrolled: cross-over
Goodwin et al (1972) 24 0.20 <20
Noyes et al (1974) 23 0.13 <10
Baron et al (1975) 20 0.11 <10
Mendels (1976) 12 0.26 <20
Bipolar depression
Lithium x placebo
Mendels (1976) 12 0.34 30
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TABLE 5.7
POWER CALCULATION OF LONG TERM LITHIUM STUDIES.
Power calculation of prophylactic studies showed significant differences among
studies. Only two trials of the lithium versus placebo studies did not show good
power (Fieve et al, 1976; Prien et al, 1984). The comparison lithium with other
antidepressants exhibit four trials with inadequate power. One of the trials
comparing the combination lithium plus imipramine versus lithium display a lack
of power (Kane et al, 1972).
STUDY N W POWER
Lithium x placebo
Fieve et al (1976) 28 0.06 <0.10
Prien et al (1984) 71 0.12 <0.20
Lithium x other antidepressants
Prien et al (1973) 43 0.12 0.10
Glen ef al (1984) (I) 101 0.19 0.10
Glen et al (1984) (II) 18 0.10 <0.10
Prien et al (1984) 75 0.15 0.30
Lithium x lithium + imipramine
Kane et al (1972) 15 0.20 0.20
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5.4. DISCUSSION
5.4.1. IS LITHIUM EFFECTIVE IN THE TREATMENTOF UNIPOLAR
DEPRESSION?
Acute treatment with lithium alone in unipolar depression has rarely been
subject to satisfactory evaluation and the methodological sound trials which
have been carried out have used too few patients. The absence of adequate
trials which have compared the effects of lithium with the effects of placebo
gives rise to understandable doubts about the efficacy of lithium alone in
unipolar patients. The conventional wisdom that it is without effect may,
however, be misleading. The finding of "no difference" from other established
antidepressant treatments is traditionally sufficient to launch new alternative
antidepressants. Since this is the position for lithium, the case in unipolars
remains unproven. The confidence intervals illustrated in Figure 5.1 show that
it is not possible to ascertain how effective lithium is compared either with
placebo or other antidepressants in unipolar depression. There does appear
to be an acute treatment effect in bipolar patients who are depressed, but the
magnitude of the effect is equally uncertain.
5.4.2. IS LITHIUM EFFECTIVE IN THE PROPHYLAXIS OF UNIPOLAR
DEPRESSION?
Positive findings of lithium's therapeutic efficacy were remarkably
homogeneous. Across different studies, be it those examining discontinuation
of lithium in patients who may have been selected lithium responders (e.g.
Baastrup et al, 1970; Hullin et al, 1972), or those in which lithium was being
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started prospectively, the effect size was large and consistently in favour of
lithium compared with placebo. Follow-up was often short, and may sometimes
have included patients who were relapsing rather than recurring; but there is,
overall, no reason to doubt the efficacy of lithium as an active compound versus
placebo in unipolar illness.
No distinctions among different antidepressants were made but they all
met current recommendations in terms of dosage and duration of treatment.
Schou (1979-a) reported that one year recurrence rate among unipolar patients
treated with tricyclic antidepressants was 50% higher than among those treated
with lithium (35% vs 22%). In the present study, the efficacy of lithium in
comparison with other antidepressants provides less ground for confidence. In
contrast, the pooled effect suggests a tendency for lithium to be more effective,
and individual trials strongly supported this (e.g. lithium versus mianserin,
Coppen et al, 1976). Comparison with conventional tricyclic drugs, however,
tended to show no advantage for lithium, albeit with wide margins of error. It is
not possible to conclude on the basis of the available evidence whether the
choice of lithium in recurrent unipolar depression is a better prophylaxis than
amitriptyline or imipramine.
The trials which reported the superiority of lithium over antidepressants
were those which selected patients who remained episode-free for at least six
months while the studies which reported antidepressants were equally effective
or superior to lithium were those which required only a two or three month
period of stabilization (Prien, 1985). The implication is that lithium is more
effective in patients whose inter-episode rate of depression is low (Keller and
Shapiro, 1982).
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The NIMH Consensus Development Conference(Consensus
Development Panel, 1985) concluded that both lithium and tricyclic
antidepressants had been shown to be effective prophylactic treatments, each
with advantages for certain populations. It was proposed that the use of
tricyclic antidepressives had three advantages: a) as most acute episodes are
treated with tricyclics, continuation with the antidepressants avoids the question
as to when or how to switch from the antidepressant to lithium; b) tricyclics are
less toxic and have less renal and thyroid side-effects, than lithium; c) it has
been claimed that tricyclics provide a greater protection against severe
depression. On the other hand, it was proposed that lithium had the advantage
of preventing future episodes of depression and mania. This is an important
factor on the basis of the knowledge that 10 to 20% of unipolar depressed
patients will subsequently develop a manic episode (Runck, 1985).
Furthermore, it has been suggested that some tricyclics may, in fact, precipitate
a manic episodes or rapid cycling in some patients (Bunney, 1978).
One strategy to improve prophylaxis is to combine lithium and a standard
antidepressant in the maintenance regimen. The rationale behind this is the
possible synergistic neurochemical effects. Even though these results
supported the combination of lithium plus antidepressants the degree of
certainty is very small due to the small effect size. The finding reported by Prien
et al (1984) that both imipramine and the combination of lithium plus imipramine
are more effective than lithium and placebo in preventing new episodes of
depression in unipolar depressed patients is questioned in a recent re-analysis
of the data (Greenhouse et al, 1991). The outcome could have been obtained
either because the design is biased in favour of imipramine responders or
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because of the abrupt discontinuation of therapy between the preliminary and
maintenance phases. Further studies are need to replicate the present findings
and to clarify contentious issues such as those described.
A limitation in trials assessing the effectiveness of prophylactic drugs is
that frequently they only measure recurrence rates leaving out changes in
severity and duration of episodes.
5.4.3. WERE THE FINDINGS HOMOGENEOUS?
Some degree of variability in protocol between studies in a meta¬
analysis may be beneficial because this will increase generalizability, but
marked heterogeneity will tend to invalidate data pooling. When heterogeneity
is detected, the studies should be clustered into homogeneous groups and
analysed separately (Abrami et at, 1988). The range of different tests to
estimate the homogeneity among studies include the Mantel-Haenszel test and
regression techniques (Rosenthal, 1984). In the analysis of treatment and
prophylactic studies no significant statistical differences in effect sizes were
found but the p values of the prophylactic uncontrolled trials differ significantly
indicating heterogeneity of studies. Any differences found in the other cases
were of degree rather than direction.
5.4.4. HOW GOOD IS THE RESEARCH DESIGN OF THESE STUDIES?
The interpretation of prophylactic studies is complicated by a number of
methodological characteristics, such as differences in diagnostic criteria, length
of study and methods to estimate improvement. An example of the criticism
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levelled at uncontrolled trials was given by Blackwell and Shepherd (1968)
about the study of Baastrup and Schou (1967). They said that the comparison
of the frequency of episodes in the pre lithium period with the frequency in the
lithium period was based on the assumption that the frequency of episodes in
the pretreatment period can be used as an index to the frequency in any
subsequent period of equal length. Since manic depressive illness is
characterized by episodes that occur unpredictably they claim that this
assumption was invalid and the only way to clarify the situation was to conduct
trials with stronger research designs.
The next research design used in lithium trials was the cross-over
design. Although, most of the cross-over studies were conducted double-blind
and the assignment of patients was random, they were not regarded as
controlled trials because of the short-term carrying over effect; in other words,
lithium may have started a chain of events that led to resolution of the illness so
that the patient was indeed "improved" at the time of placebo substitution
(Mendels, 1976).
Finally, a number of prospective controlled trials with double-blind
evaluation and randomized assignment of patients was conducted. But, even
with these good quality studies the efficacy of lithium as a prophylactic agent
was inconclusive (see Chapter 2). The main reason for this was the small
number of patients involved in each trial. Again, the need for an appropriate
method to summarize the findings is needed. Meta-analysis has the specific
purpose of combining these studies to reach a meaningful conclusion.
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In the NIMH/NIH trial (Prien et al, 1984), as already stated, the finding that
imipramine and the combination of lithium plus tricyclics are more effective than
lithium and placebo in preventing recurrence in unipolar depression could have
been obtained either because the two-phase design is biased in favour of
imipramine responders or because of the abrupt discontinuation of therapy
between the preliminary and maintenance phases (Greenhouse et al, 1991).
In that study, over half of the patients who entered the preliminary phase were
not eligible to be randomized to maintenance therapy, of these 10% did not
tolerate imipramine and over 20% did not stabilize on the usual treatment of
tricyclic antidepressants. Therefore, a selection bias may have happened in
the preliminary phase with an over-representation of imipramine responders
who were more likely to have a recurrence after imipramine discontinuation.
An increase in early recurrence has been associated with abrupt withdrawal
from imipramine. Therefore, patients assigned to the lithium and placebo
groups who had a recurrence within the first eight weeks of maintenance
therapy may, in fact , have been experiencing a drug withdrawal reaction that
precipitates or displays symptoms that mimic a depressive episode
(Greenhouse et al, 1991).
The methodological short-comings of the acute treatment studies will be
discussed under specific headings:
a) Inclusion criteria - patients were included under different criteria. For
example, Watanabe et al {1975) included neurotic depression and reactive
depression in their sample.
b) Duration of treatment - this may have been too short (for example, Goodwin
et al, 1972; Baron et al, 1975). Most of the controlled trials lasted for 3 weeks,
but a six week trial has been proposed as an adequate period because it takes
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into consideration that some patients improve between the fourth and sixth
week (Quitkin et at, 1984). However, this alleged change in improvement
which led Quitkin et al to detect a 25% response between weeks four and six
was very small, mean (SD) Hamilton scores were reduced from 9.6 (±4.5) to 8.5
(±5.6). Furthermore, the sample was constituted of outpatients with mean
Hamilton scores at trial entry under 16. Different periods of treatment were also
observed - Mendels (1976) used 7 to 22 days of placebo substitution.
c) Patients included in the analysis - the analysis may be based on the
outcome of the patients who remained in the trial, even when an appreciable
number of patients dropped out (Watanabe et al, 1975; Khan, 1981).
d) Polarity not stated - Mendels efa/(1972) did not mention how many
patients of the sample were unipolar and bipolar.
e) Doses and plasma concentrations - failure to report doses and plasma
concentrations were observed in some trials (Goodwin et al, 1972; Mendels et
al, 1972).
f) Absence of placebo group - there was no control for spontaneous remission
in some studies (Mendels et al, 1972).
All these methodological shortcomings threatened the internal validity of
these studies.
The prophylactic trials also have methodological weaknesses:
a) Previous use of lithium - a bias is introduced if it is already known that these
patients are good lithium responders. This pattern was observed in
discontinuation trials (Baastrup et al, 1970; Coppen et al, 1976).
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b) Patient population - the study by Prien et al (1984) included a greater
proportion (two-thirds) of patients with substantial impairment or persistent
symptoms between episodes.
c) Blindness - in Coppen et al (1971) and Prien et al (1973) the raters were
blind but the treating doctors were not and many decisions regarding the
treatment of the patients were taken by the doctor in charge.
d) Withdrawal - a variable number of patients withdrew from trials and they
were often excluded from the statistical analysis (see Table 5.3). There is
controversy about how drop-outs should be treated in the analysis. Some
authors believe that the the intention-to-treat approach should be adopted, i.e.
the outcome of all patients who entered the study regardless of how long they
stayed in the trial should be included (Yusuf et al, 1985), while others favour the
exclusion method, i.e drop-outs should be excluded (Levitt et al, 1977). As
there was no unanimous approach in dealing with the drop-outs (some trials do
not even mention the numbers of patients dropping out, see Table 5.3), the
reported results were analysed no matter how the authors treated the drop-outs.
e) Different follow-up periods - were observed both between studies (from 5
months to three years) and even within studies (Fieve et a/,1976; Kane et al,
1982). The different length of follow-up may obscure differences in the
outcome observed on a medium and long term (months vs years) basis. The
only advantage of the relatively short duration of these trials was to reduce as a
possible confounding problem the worsening prognosis that may develop with
disease progression (Zis and Goodwin, 1979).
f) Rejection log - the list of all patients considered for the study but not entered
is hardly mentioned (the exception was Prien et al, 1984).
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The argument that non blind trials should be excluded due to their
obvious methodological deficiencies from the analysis of the prophylactic effect
of lithium has been disputed by Stallone et al (1975) and Schou (1979).
Stallone et al (1975) reported that side-effects did not help the patients to guess
their medication in a double-blind procedure. The placebo effect present in the
non blind discontinuation was not powerful enough to exert a detectable
prophylactic action, therefore the relapse rates after double-blind and non blind
discontinuation of lithium were similar (Schou, 1979-a).
5.4.5. MUSTA META-ANALYSIS AIM TO LOCA TE ALL A VAILABLE
STUDIES?
The majority of researchers believe that a complete search is
fundamental in meta-analysis (Wachter and Straf, 1990). Others, however,
take the opposite view and emphasize the loss of time in locating the complete
set of studies (Laird, 1990). The location of 'all' studies is generally
impracticable but when samples are large they become more representative
and this representativeness necessarily determines the range of valid
generalizations. Five retrieval methods have been described by Cooper
(1982): a) computer search (such as Medline); b) abstract service (such as
International Pharmaceutical Abstracts); c) descendency (indexes that identify
studies pertinent to a topic); d) ascendency (references citations from research
articles are tracked to find more studies); and e) invisible college networks (an
informal exchange of reprints and information among colleagues). A sixth
approach is to to identify major publishers of primary research studies on the
review topic. The target population was all trials in which lithium was
compared to other treatments. Thus, an attempt was made to collect
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information from all these possible sources on the use of lithium in affective
disorder. Computerized searches were used to locate published studies while
the other sources of information were used to locate both published and
unpublished trials. In relation to published studies located by these searches, it
does not seem that bias was introduced since all trials were included either in
the controlled group or in the uncontrolled group, unless it met one of the
criteria of exclusion. As computerized searches are available only from 1966
onwards, if a trial was published before that period it could not have been
located, but that is doubtful in this particular review. There was good
agreement between computerized searches and the ascendency approach,
which reinforce the belief that most, if not all, of the trials that satisfied the
inclusion criteria were obtained. Unfortunately the other available sources of
information for location of unpublished studies failed to locate any such trials.
Information was sought from the authors when the details of the
published material were insufficient to clarify the methods or results. This
occurred in some cases (Fieve et al, 1968; Freyhan et al, 1970; Worrall et al,
1979; Johnstone et al, 1988; Khan, 1981; Khan et al, 1987; Glen et al, 1984).
Examples of the type of information requested were: equations instead of
number of patients were mentioned as outcome measure (Freyhan et al, 1970),
the criteria used to measure outcome (Worrall et al, 1979), and the numbers of
unipolar patients involved in the trial (Khan, 1981); Johnstone et al, 1988). In
all but two (Fieve etal, 1968; Freyhan et al, 1970), these supplementary were
obtained. As these studies were published 20 years ago, it is probable that the
researchers are retired or the data have been destroyed. Freyham's study
(1970) used only seven patients in a before lithium-on lithium design, showing
a slight reduction in the hospitalization rate before lithium (0.18) when
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compared with the period patients were on lithium (0.22). It would be
surprising if the exclusion of this study in the final analysis of the uncontrolled
prophylactic studies would significantly alter the conclusions in favour of lithium.
The possibility of some bias remains. However, another way to deal with this
exclusion is to include this study in the fail safe number of trials necessary to
revert the conclusions (see below).
5.4.6. HOW BIG IS THE PUBLICATION BIAS IN LITHIUM TRIALS IN
UNIPOLAR DEPRESSION?
Because of the selective reporting of studies, some studies are not easily
accessible and their data may not be determined by the reviewer. Two
concrete steps are used to deal with the publication bias: first, to use all
available retrieval methods to locate published and unpublished studies; and
second, to estimate the extent of the publication bias (Light and Pillemer, 1984).
The study selection problem associated with meta-analysis is similar to the
missing data problem in particular studies. Of course, a major distinction
between publication bias in meta-analysis and the standard missing data
problem is the fact that in the latter the number of nonrespondents is generally
known whereas in the former the number of unpublished studies is not (Laird et
al, 1988). The exact quantification of the extent of publication bias is difficult to
assess because published studies may not be representative of the studies
conducted, and therefore any estimate must be regarded as a rough guide.
Various sources have been attributed in causing this publication bias.
First, a publication bias toward positive results has been reported (Rosenthal,
1979) while negative findings stay in the "file drawer" (Cooper, 1979). The
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underreporting of negative trials is influenced by researchers, who fail to report,
and editors, who refuse to publish, based on the general view that negative
results never make an exciting reading. In fact, some journals have explicitly
included statistical significance as one of the criteria to accept studies (Melton,
1962). Surveys among reviewers of psychology journals have confirmed the
trend (Greenwald, 1975). Studies with negative results have also been
regarded as having poor research design weakened by small sample sizes and
type II error (Freiman et al, 1978).
Secondly, the study research quality may be an important factor as to
whether studies are published or not. Unpublished studies may be less
reliable since they may have been found unacceptable by peer reviewers and
may not have been collected with the same rigour and accuracy as published
results (Sacks et al, 1987). This view is not shared by Greenwald (1975) who
reports that rarely are these differences a reflection of the methodological
quality of published and unpublished research, nor by Easterbrook et al (1991)
who found no difference in quality between unpublished and published clinical
trials.
Thirdly, the risk of not publishing the study is greater if the sample size is
small. Small trials with large effects tend to be published, however, large trials
are likely to be published regardless of the outcome (Dickersin, 1990). It has
been argued that the investment in time and effort in conducting large
randomized clinical trial is so great that there is an incentive to publish the
results regardless of the outcome (Begg, 1985).
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Fourthly, there is evidence that unpublished studies have smaller effect
sizes than published ones (Smith and Glass, 1977; Rosenthal and Rubin,
1978). Finally, the funding source may be an important source. The non
publication of negative studies supported by pharmaceutical companies has
been reported (Davidson, 1986). Because of concern about this issue, many
journals, e.g. the Journal of the American Medical Association, require the full
disclosure of the financial support of the trial (Dickersin, 1990).
Publication bias may lead to incorrect inferences. Frequently, the
incorrect inferences affects only the strength rather than the direction of
association. In some cases not only the magnitude but the direction is different
in published studies and unpublished trials (Smith, 1980). In either case, there
is a risk that publication bias will leads to the conclusion that a specific
treatment is either more effective than in fact it is or, more seriously, that the
treatment is effective when it is ineffective. The failure to publish an adequate
account of a clinical trial is a form of scientific misconduct that may lead
clinicians to make inadequate therapeutic decisions which are based on only
the published literature (Chalmers, 1990).
Publication bias may not be always severe enough to invalidate meta¬
analyses which are based only on published articles (Light and Pillemer, 1984;
Hedges, 1984). Attempts to minimize the problem of locating unpublished trials
have been made, however, by establishing guidelines for the publication and
reporting of the results of the studies and the creation of a registry of clinical
trials. The advantages of these registers are: first, to reduce publication bias.
Secondly, they should help to reduce the unnecessary duplication of studies
and promote more collaboration among researchers. Thirdly, they provide a
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basis for methodological research and facilitate meta-analyses of clinical trials
(Dickersin, 1988).
In this meta-analysis, publication bias did occur because the search for
unpublished trials was not successful. A second source of bias was introduced
because only trials written in the English language were included. Finally,
some studies are inadmissible because their findings are not amenable to
quantitative summarization. This often precludes the inclusion of studies that
are non statistical such as case studies.
In the field of clinical cancer research where thousands of studies are
conducted each year many may never be published (Bangert-Drowns, 1986),
but it would be surprising if the number of unpublished trials of lithium therapy is
on the same scale. Even though this possibility is remote, some mechanism is
necessary to protect the validity of the conclusions of a meta-analysis because
of the problem of non-localization or non-inclusion. One of these instruments is
"the fail safe N". Rosenthal (1984) suggested that a meta-analysis can be
considered resistant to the file drawer problem if the fail safe N exceeds 5k +10,
where k is the number of reported effects. Adopting this approach, the
comparison of lithium versus placebo in prophylactic studies is the only one to
give this degree of confidence. In other words, there is firm evidence that
lithium is effective in long-term treatment of unipolar depression when
compared to placebo.
There is a limitation of the fail safe N. It is an appropriate guide only if
the assumption of a summed null relation in undiscovered studies is
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acceptable. It is always possible that some studies have a negative pooled
size effect compared with those reviewed.
In addition to Rosenthal's (1984) formula for the estimation of the fail safe
N, two other methods have been suggested: an analogous procedure was
designed by Orwin (1983) and the the maximum likelihood approach proposed
by Iyengar and Greenhouse (1988). The advantage of Rosenthal's approach is
the simplicity of calculation and its use of the combined statistical significance
but it has one drawback because it does not take into consideration the sample
size of the unpublished trials. Orwin's (1983) approach uses the same
principles of Rosenthal (1984) and makes an attempt to calculate the sample
sizes of the unpublished trials. The maximum likelihood method uses a
weighted distribution to model the selection bias in the generation of the data
but it has two disadvantages: the scarce empirical evidence to guide the choice
of weight functions and the amount of computation. But it is probably more
robust than the other two methods (Iyengar and Greenhouse, 1988). Taking
into consideration the pros and cons of these methods, Rosenthal's approach
was preferred due to the easy understanding of its concepts. But, at the
moment, the choice of a particular model to calculate the number of
unpublished studies is still a "murky business" (Hedges, 1988).
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5.4.7. WHA T SHOULD BE REPORTED: STA TISTICAL SIGNIFICANCE,
POWER, CONFIDENCE INTERVALS OR EFFECT SIZES?
Different conclusions reached by traditional reviews may be the result of
differences in the importance attached to whether or not the studies produced
statistically significant findings. If the probability that the result was due to
chance was below a certain level, e.g. 5%, it was concluded that the effect
would occur in situations similar to to those in which it had been observed.
Statistical significance is a product both of the treatment's effect and sample
size. A weak effect can be statistically significant if observed in a large sample
or on a sensitive scale. A strong effect would fail to be significant under the
opposite conditions. It must be questioned if this small but statistically
significant effect is large enough to have practical significance as well, i.e.
clinical significance. The conclusion based on statistical significance provides
no direct information about the magnitude of the effect. The estimation of the
size of the difference in response probabilities is essential. In summary,
statistical significance measure reliability of the effect of treatment not its efficacy
(McConaghy,1990). Measurement of effect sizes, as in meta-analysis,
provided a technique which has the advantage of being independent of the
number of subjects investigated (see Gardner and Altman, 1990) for a recent
plea to the psychiatric community to concentrate more on this aspect of
statistical procedure).
Power calculations depend on the size of the effect size and on the
number of patients in the sample. The greater the effect size the smaller the
number of patients necessary to detect it. The best way to ensure that a non
significant difference will be obtained is to use an inadequate sample size. The
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probability of type I error is always 0.05 regardless of the sample size, but the
probability of of a type II error increases dramatically as the sample size
decreases (Hunter et al, 1982). The purpose of the calculation of the power in
each trial was to show that in many clinical trials, no matter how carefully
conducted, if the number of subjects involved is too small it is not possible to
draw firm conclusions and this highlights the need to integrate findings from
different studies.
Confidence intervals also have advantages over significance tests.
Firstly, the interval is correctly centred on the observed value rather than the
hypothetical value of the null hypothesis. Secondly, it gives a better picture of
the extent of uncertainty that surrounds results computed from small sample
trials, i.e. the bigger the interval the less confidence in the result. The only way
to eliminate uncertainty is either study large-sample, single studies or combine
results across many small studies. Given the limited resources in many
medical areas, this means meta-analysis is usually more practicable (Hunter et
al, 1982).
5.4.8. HOWMUCH CHANGE IS CLINICALL Y SIGNIFICANT?
Effect sizes and statistical significance share one drawback which is that
is none of them provide direct information about the clinical significance of a
treatment effect (McConaghy,1990). The measurement of clinical significance
as a criterion for evaluating clinical outcomes is still an unresolved problem.
Clinical significance can be defined as the extent to which clinical outcomes
achieve a meaningful magnitude of change (Nietzel et al, 1987), but there is
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little consensus as to what clinical significance is, except the universal
agreement that it is not merely statistical significance (Jacobson et al, 1984).
In short-term treatment, a binary outcome (not improved / improved) was
adopted. The objection may be made that the use of a binary outcome scale in
assessing trials is too crude, but this probably reflects clinical decision making.
Inevitably, trying to transform continuous quantitative data, such as degrees of
clinical improvement, into some sort of qualitative classification is more arbitrary
than a classification where outcome is either death or survival.
In the controlled studies of prophylaxis, outcome was expressed in terms
of recurrence. This meant different things in different studies; some used
readmission to hospital as the criterion of failure (Hullin et al, 1972) while others
used introduction of other treatment such as ECT or antidepressants (Fieve et
al, 1976) or a change in an index of morbidity (Coppen et al, 1976; Kane et al,
1982; Prien et al, 1984).
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CHAPTER 6




6.1.1. THYROTROPIN (TSH) AND THYROXINE (T4) INAFFECTIVE
DISORDERS
The association between thyroid disease and mental illness has been
acknowledged since the last century. In 1825, Caleb Parry referred to fright as
a cause of thyrotoxicosis. In 1888, the Clinical Society of London observed that
myxoedema could result in mania, melancholia or psychosis (Clinical Society of
London, 1888). In 1938, Gjessing reported that periodic catatonia improved
with thyroid extract. The identification of T4 and T3 in 1926 and 1952
respectively increased the interest in this area (Gross and Pitt-Rivers, 1952;
Condliffe and Weintraub, 1979), which was, however, restricted by two factors:
the lack of sensitive methods to assay small amounts of complex molecules and
the failure to identify a substance clearly linking the central nervous system
(CNS) to the hormonal system. In the late 1970's, the identification of the
thyrotropin releasing hormone (TRH) by Guillemin (1978) and Schally (1978)
and the development of reliable methods of measurements provided the
necessary stimulus to further psychoneuroendocrine investigations.
The hypothalamic pituitary thyroid axis by itself is a complex and highly
integrated network. The hypothalamic peptide thyrotropin releasing factor
(TRH) stimulates the release of TSH which regulates the production of the
thyroid hormones -thyroxine (T4) and triiodothyronine (T3). The thyroid
hormones exert a feedback control over the axis, which means that when their
concentration falls, TSH secretion is stimulated, and when their levels are
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raised TSH release is inhibited (for a comprehensive review on HPT axis see
Kaplan and Sadock, 1989).
A special area of interest in these investigations is the relationship
between affective disorders and thyroid function. It has long been
acknowledged that hypothyroidism can mimic depression (Whybrow et al,
1969), but some patients with affective disorders show laboratory signs of
functional disturbance of the hypothalamic-pituitary-thyroid axis without clinical
manifestation of altered thyroid function (Unden et al, 1986). The exact
mechanism of this interaction continues to be poorly understood (Baumgartner
et al, 1988; Bauer and Whybrow, 1988; Smith and Goodwin, 1988). Hormonal
changes in affective disorders have been studied using two approaches: the
first one studies the unipolar-bipolar dichotomy while the second one considers
the depression-mania distinction.
6.1.1.1. Unipolar versus Bipolar Depression
Regarding the first approach, most studies have failed to find significant
differences between unipolar and bipolar illness (see Table 6.1). Takahashi et
al (1974) did not find significant differences in T4 and TSH concentrations
between 20 unipolar and 9 bipolar patients. Kirkegaard et al (1978) found
higher T4 but not TSH in 19 unipolar depressed when compared with 12
bipolar depressed, but when the values were corrected for differences in
thyrotropin binding proteins no significant differences in T4 were found.
Amsterdam et al {1979) did not find any difference in T4 and TSH levels
between 12 unipolars, 6 bipolars and 6 controls. No significant differences was
found between 11 bipolar and 35 unipolar patients in T4 and TSH levels before
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and after electroconvulsive therapy (Kirkegaard and Faber, 1981). Kjellman et
al (1983) reported no differences between eight unipolars, eight bipolars and
22 normal controls in any thyroid test including T4 and TSH. One of the rare
significant finding was reported by Linnoila et al (1982) who found that 4
unipolar depressed women had significantly higher T4 concentration than 8
controls or 9 bipolar depressed women.
A meta-analysis of these studies gives additional information on the
differences between bipolar and unipolar depression (for details of the
calculation of effect sizes, 95% CI and tests of heterogeneity see Appendix 6.1).
The comparison between TSH concentrations of these two groups yields a
mean effect size of 0.17 in favour of the bipolar group. In other words, bipolar
patients were found to have higher TSH levels, however, the 95% confidence
interval (CI) of -0.23 to 0.57 is too large to allow any certainty. The chi-square
of heterogeneity, however, is not significant {x2z = 7.2, NS).
The corresponding mean effect size for T4 levels is 0.33, indicating
higher levels in the bipolar group, but again the 95% CI is large (from -0.10 to
0.76). Because part of the 95% CI favours the unipolar group, no definite
conclusion can be drawn. The chi-square of heterogeneity (x2$ =
18.1 ,p<0.001) is highly significant. Possible moderating variables which might
explain the heterogeneity found in some analysis of this meta-analysis are
discussed in Section 6.1.3.
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6.1.1.2. Depression versus Control
Depression has been studied to a much greater extent than mania. The
picture emerging from the studies reporting on the TSH alterations in affective
disorders is still unclear (see Table 6.1). The majority of the studies comparing
depressed patients with controls have reported reduced TSH levels in
depression (Takahashi et al, 1974; Kirkegaard et al, 1978; Linkowski et al,
1981; Kjellman et al, 1983; Orsulak et al, 1985; linden, 1986). Yamagushi et
al (1977) was the only study to report elevated TSH levels in the depressed
group. The mean effect size of -0.37 (95% CI -0.20 to -0.54) reflect this finding.
The whole CI remains in the area favouring a reduction of TSH levels in
depression, however the degree with which this reduction is observed varied
among the studies resulting in a significant heterogeneity of effect sizes (x2q=
24.2, p<0.005). Eight studies would be needed to reverse this conclusion
The pattern which emerges from the studies of T4 levels in depression is
shown in Table 6.1. Some studies have shown reduced T4 levels in the
depressed group when compared to a control group (Yamagushi et al, 1977;
Kirkegaard et al, 1978 - bipolar; Rinieris et al, 1978; Linnoila et al, 1982 -
unipolar), while others have reported an increase in T4 levels in the depressed
group (Takahashi et al, 1974; Kirkegaard et al, 1978 - unipolar; Linnoila et al,
1982 - bipolar; Kjellman et al, 1983; Joffe et al, 1985; linden et al, 1986;
Rubin et al, 1987). A small effect size of 0.22 with 95% CI (0.08 to 0.36)
favouring an increase in T4 levels was observed. The heterogeneity of effect
sizes is shown by a significant chi square (x2io = 94.9, p<0.001). Thus,
reduced TSH, increased T4 implies peripheral activation of thyroid axis.
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6.1.1.3. The Effects of Treatment on TSH and T4 Levels
Most studies comparing depression before and during treatment show
augmented TSH concentrations after treatment (Kirkegaard et al, 1978; Weeke
and Weeke, 1978; Linkowski et al, 1981; Roy-Byrne et al, 1984; Unden et al,
1986; Muller and Boning, 1988) with the exception of Kirkegaard et al (1975).
The mean effect size was 0.17 represents a modest increase in TSH levels with
treatment. As the 95% CI -0.03 to 0.37 expands over zero no firm conclusions
can be drawn. The chi square of heterogeneity is not significant {x2j = 11.1,
NS).
The comparison depression before and during treatment, however,
shows consistently a reduction in T4 concentrations with treatment (Whybrow et
al, 1972; Kirkegaard et al, 1975; Kirkegaard et al, 1978; Roy-Byrne et al, 1984;
Muller and Boning, 1988) with the exception of Weeke and Weeke (1978). The
mean effect size of 0.82 (95% CI -0.61 to -1.03) reflects this fact. Although
most studies favoured a reduction in T4 levels, their effect sizes were
heterogeneous {x2-j- 36.7, p<0.001). To reverse this conclusion, 16 studies
would be necessary.
6.1.1.4. Depression versus Mania
Alterations in the hypothalamic pituitary thyroid axis of patients with
mania have also been reported, although these effects have been studied to a
much less extent. One of the first reports claimed that manic patients had
higher and depressive patients had lower iodine levels than normal controls
(Neudstadt and Howard, 1942). TSH concentrations have been found higher
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in mania compared to depression (Gold et al, 1979), but reduced TSH in manic
patients have also been reported (Kirkegard et al, 1978; Muller and Boning,
1988). The mean effect size was only 0.03 with the 95% CI varying from -0.46
to 0.52). In other words, this result is wholly inconclusive. The chi square of
heterogeneity was significant (x22 = 13.7, p<0.001).
Most studies have reported reduced T4 levels in depression when
compared to mania (Rybakowski and Sowinski, 1973; Kirkegaard et al, 1978;
Rinieris et al, 1978; Linnoila et al, 1982) with the exception of Muller and
Boning (1988). As a result the mean effect size of 0.51 (95% CI from 0.15 to
0.87) favours a reduction of TSH levels in depression. The effect sizes were
heterogeneous (x2^ = 20.8, p<0.001). Eleven studies would be necessary to
reverse this finding.to a non significant value.
The TRH stimulation test has aimed to probe the HPT axis in patients with
affective disorders (Loosen, 1987). A decreased or blunted TSH response to
TRH in 25-70% of depressed patients has been reported.(Kaplan and Sadock,
1989). Gold et al (1979) proposed that it was possible to distinguish unipolar
and bipolar illness by means of the TSH response to thyrotropin stimulating
hormone (TRH), based on their finding that unipolar patients had an abnormally
low TSH response to TRH in comparison with bipolar subjects. This finding
was based on small groups (both unipolar and bipolar groups had less than ten
patients). Other studies using bigger samples, however, have not replicated
this result; similar TSH response to TRH in unipolar and bipolar patients were
shown by Takahashi using 18 unipolars and 8 bipolars (1974), Kirkegaard et al
with groups of 19 unipolars and 12 bipolars (1978), Amsterdam et al comparing
12 unipolars and 6 bipolars (1979), Bjorum et al in 21 bipolars and 35 unipolars
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(1979), and Mendlewicz et al comparing 31 unipolars and 27 bipolars (1979).
To date, there is not enough evidence to establish thyroid function test as a
diagnostic instrument which can separate unipolar and bipolar disorders.
Another aspect of the relationship of mania and thyroid function is the
TRH-induced TSH response in manic patients which has also been studied with
conflicting results (Kirkegaard, 1981; Loosen and Prange, 1982). An
exaggerated (McLarty et al, 1975; Tanimoto et al, 1981) and reduced
(Takahashi et al, 1974; Kirkegaard et al, 1978; Gold et al 1977,1980) TSH
response to TRH has been reported in manic patients. The doses and
procedures used in these studies are too different to allow a quantitative
synthesis.
Triiodothyronine (T3) levels in endogenous depression have been found
to be normal (Kiekegaard and Faber, 1981; Roy-Byrne et al, 1984) or
decreased (Weeke and Weeke, 1978; Linnoila et al, 1979). A lower T3 level is
consistent with the euthyroid sick syndrome which is characterized by low T3,
increased reverse T3 and normal T4 concentrations (Chopra et al, 1983). This
syndrome has been reported to occur in some depressive patients (Joffe et al,
1985). Some features of the syndrome, such as low free T3 and increased
reverse T3, have been proposed to represent a biological difference between
bipolar and unipolar illness (Linnoila et al, 1979,1982; Orsulak et al, 1985;
Joffe et al, 1985). It is not widely accepted, however, that affective illness is
commonly marked by the euthyroid sick syndrome (Bauer and Whybrow, 1988).
It seems that the most frequent abnormality in iodothyronine economy is a
relative increase in T4 levels during the acute episode which tend to decrease
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after recovery without clear alterations in T3 concentrations (Bauer and
Whybrow, 1988).
In summary, some trends can be observed from these studies. Firstly,
there is no reliable evidence that TSH and T4 levels can differentiate unipolar
and bipolar depression. Secondly, TSH concentrations in depressed patients
is reduced and T4 levels are raised when compared with controls and other
medically ill patients. Thirdly, antidepressant treatment frequently induces a
consistent reduction in T4 concentrations. The effects of treatment on TSH
levels are more variable, but an increase in its levels is frequently detected.
Fourthly, T4 levels in depression seems to be lower than in mania but the data
on TSH concentrations is inconclusive. Finally, T4 and TSH concentrations are
usually within the normal range even when a significant difference in T4 or TSH
concentrations is reported. Thus, the evidence to date suggests that if any
reduction does take place, it is within the reference limits.
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6.1.2. CORTISOL IN AFFECTIVE DISORDERS
The hypothalamic-pituitary adrenocortical (HPA) axis functions in a
similar way as the hypothalamic pituitary thyroid axis. Corticotropin releasing
factor (CRF), a hypothalamic peptide, stimulates the release of
adrenocorticotropic (ACTH) from the anterior pituitary which causes the adrenal
cortex to secrete Cortisol. The prevailing plasma Cortisol concentration may
influence the activity of the HPA system at pituitary, hypothalamic, and limbic
cortical levels. Such negative feedback control results in stimulation of the
system when plasma Cortisol is low, and inhibition when plasma levels are high.
The system has a circadian rhythm, with most Cortisol being secreted in the
morning. The regulation of CRF is complex and involves various
neurotransmitters and neuromodulators (noradrenaline, acetylcholine and
serotonin). A wide variety of nonspecific stresses can influence the system
activity. Affective disorders are one of the best known factors that can alter
Cortisol secretion (for comprehensive reviews on HPA axis see Streeten et al,
1984; Pepper and Krieger, 1984).
The pituitary adreno-cortical axis has been the most extensively studied
endocrine system in psychiatry. In depression, Cortisol hypersecretion is
probably the best established biochemical abnormality (Board et al, 1957;
Gibbons, 1964; Sachar et al, 1973; Carroll et al, 1976). Between 25 to 75% of
patients with endogenous depression shows hyperactivity of the hypothalamo-
pituitary-adrenal cortical (HPA) axis reflected by increased circulating
corticotropin and Cortisol concentrations, increased cerebrospinal fluid Cortisol
levels, increased urinary free Cortisol disinhibition of nocturnal secretion of
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Cortisol, loss of the normal circadian variation and Cortisol resistance to
dexamethasone (Rubin et al, 1987).
Reports studying the Cortisol status in the dichotomy of unipolar-bipolar
depression has produced inconsistent results. An absence of bipolar-unipolar
difference in mean urinary free Cortisol has been observed (Rubinow et al,
1984). But another study found that bipolar endogenous depressed patients
have a significantly higher prevalence of Cortisol hypersecretion compared with
unipolar patients, schizophrenics and normal controls (Asnis and Lemus, 1987).
In mania, conflicting findings are reported on the status of Cortisol.
Earlier studies have shown lower levels of adrenal activity during the manic
than during the depressive phase of the illness (Rizzo et al, 1954; Fox et al
1958; Gibbons and McHugh, 1962; Bunney et al, 1965), but more recent
studies have reported normal (Sachar et al, 1972) and elevated (Platman and
Fieve, 1968; Stokes et al, 1984; Rubinow et al, 1984; Christie et al, 1986)
levels of Cortisol in the manic phase. Generally, this disorder has been the
focus of less attention and fewer studies have been carried out than in
depression (Copolov and Rubin, 1987).
Cortisol levels in depression have also been studied by challenge tests,
such as the dexamethasone suppression test (DST; Carroll et al, 1976). This
endocrine function test utilizes the ability of dexamethasone to suppress the
endogenous secretion of corticotropin and consequently of corticosteroids. A
positive DST test occurs when dexamethasone fails to inhibit Cortisol secretion.
This finding has been observed in many endogenous depressive patients. The
DST is probably the most utilized and studied biological test in psychiatry, but
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the initial enthusiasm for the test has given way to more prudent and cautious
utilization due to doubts about its real sensitivity. The sensitivity of this test for
melancholic depression (positive finding in a true case) is between 30-70%
depending on the number of measurements (Carroll et al, 1981; APA, 1987).
The overall specificity for that condition (negative result in a patient without
melancholic depression) is about 80%.
A close relationship between HPA and HPT has been proposed (Rubin
et al, 1987). Because of the effect of glucocorticoids on the TRH test, the
blunted TSH response to TRH in depressives may be secondary to the increase
in HPA activity (elevated plasma Cortisol) that occurs in about 50% of patients
with major depression. Two studies support this possibility (Loosen et al, 1978;
Rush et al, 1983). Other studies, however, have failed to confirm this finding
(Kirkegaard and Carroll, 1980; Extein et al, 1981; Larsen etal, 1985).
All the methodological aspects described in Section 6.1.3 have posed
great difficulty in making meaningful interpretations of the results. However,
some conclusions may be drawn from the available data. Firstly, an increase in
Cortisol levels is observed in many patients with depression, but this increase is
not characteristic of depression and it occurs in varying proportions. Secondly,
Cortisol levels have not been shown to distinguish the dichotomy unipolar-
bipolar reliably. Thirdly, there is some evidence that the Cortisol levels in manic
patients are greater than those observed in depressed subjects. Fourthly, the
initial claim that a blunted TSH response to TRH might be linked to an increase
in HPA activity has not been confirmed.
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6.1.3. METHODOLOGICAL ASPECTS
These conflicting findings in the study of hormonal change in affective
disorders may be explained by several methodological issues. Firstly, the
diagnosis factor may account for some of the variance of the results. Examples
of possible contributory factors are: the ratio of unipolar vs bipolar patients; the
inclusion of psychotic (versus neurotic or reactive) depressives, endogenous
depressives, major depressives or depressives not otherwise classified; the
proportion of depressed, manic or euthymic patients; the different stages of
chronicity and the different stages of episode or remission. Secondly, different
comparison groups were used: nondepressive medically ill groups (Takahashi
et al, 1974), less severely ill (Kirkegaard and Faber, 1981) and healthy controls
(e.g. Rubin et al, 1987). Thirdly, the sample size varied widely between studies
and in some studies the samples consisted of small numbers (see Table 6.1).
Fourthly, different methods of assay with different coefficients of variation were
used. Finally, there is the question of circadian rhythms. T4,TSH and Cortisol
have their own circadian rhythms. Measurements made in the morning are not
comparable to measurements made during other periods of the day. Another
possible explanation for the difference between studies may be the fact that in
the studies where a significant reduction in TSH concentrations were found
multiples samples were taken, whereas in those studies in which no difference
was found the TSH values were taken from single samples (Rubin et al, 1987).
Finally, the use of prophylactic medication, such as lithium or tricyclics, may act
as confounding variables. Ideally, the patient sample studied should be
homogeneous and completely free of confounding variables in order to assess
the changes induced by the illness itself and not those triggered by these
variables.
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6.1.4 THE EFFECTS OF LITHIUM ON TSH, T4 AND CORTISOL LEVELS
Long-term lithium therapy has been associated with changes in thyroid
function in a series of ways. In 1968, the first accounts of lithium effect on
thyroid was made by Sedvall eta! (1968) who demonstrated an antithyroid
effect of lithium in rat and man and by Schou et al (1968) who reported that 12
of 330 patients treated with lithium developed goitres. Lithium is concentrated
in the thyroid gland. In vivo and in vitro studies have shown thyroid/serum
lithium ratios ranging from 2.5 to 5 (Lazarus et al, 1986). The effects of lithium
have been studied using different parameters of thyroid function, such as iodine
uptake and peripheral hormone measurements.
The effects of lithium on thyroid iodine uptake have been controversial.
In rat, acute administration of lithium has been reported to reduce (Berens et al,
1970) and to increase (Hullin and Johnson, 1970) iodine uptake. Chronic
administration of lithium has been shown to stimulate (Berens and Wolff, 1975)
and to inhibit (Hullin and Johnson, 1970) iodine uptake. In man, Sedvall et al
(1968) reported increased iodine uptake while Burrow efa/(1971) showed no
effect.
Several studies have reported on the acute effects of lithium therapy on
TSH and T4 concentrations (Table 6.2). In terms of TSH concentrations, the
mean effect size of the differences between the concentrations before vs on
lithium (expressed in standard deviation units) was found to be 0.84 (95% CI
from 0.24 to 1.06) in favour of an increase in TSH levels with lithium. The chi
square of heterogeneity was not significant (x2io = 8.9, NS). To reverse this
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conclusion 33 negative studies would be necessary. T4 concentrations are
reduced with lithium. This fact is reflected by the mean effect size of 0.27 with
95% CI varying from 0.05 to 0.59. The chi square is not significant (x2-|2 = 13.0,
NS). 35 studies would be necessary to reverse this conclusion. In summary,
the majority of these studies have demonstrated an increase in TSH
concentrations and a decrease in T4 levels with lithium treatment, but rarely
beyond the normal range.
Alterations in the thyroid status have also been shown with chronic
lithium therapy (Table 6.3). In terms of TSH concentrations, the mean effect
size is 0.51 (95% CI 0.09 to 0.93). The chi square of heterogeneity, however, is
just significant (x22= 7.5, p<0.05). T4 concentrations are normally reduced with
the exception of Maarbjerg etaI (1987). The mean effect size is 0.04 (95% CI -
0.06 to 0.14). No definite conclusion can be drawn because the 95% CI
spreads around zero. The chi square of heterogeneity is not significant (x2i2 =
11.7, NS). In summary, the long term effects of lithium show a similar pattern as
in studies of acute effects of lithium (elevation of TSH levels and reduction of T4
concentrations).
Most reports showed a direct inhibitory effect on thyroid secretion which
may result in abnormal laboratory findings (reduction in plasma levels of T4,
increase in serum TSH concentrations and a blunted TSH response to TRH
stimulation) in euthymic patients or goitre formation and clinical hypothyroidism
in severe cases (Transbol et al, 1978) while other studies have found no
significant reductions in T4 concentrations or increases in TSH (McLarty et al,
1975; Lazarus et al, 1981). Animal studies have shown a decrease in TSH
values with lithium therapy (Ruzsas et al, 1980; Bagchi et al, 1982). This
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decrease has not been replicated in any study using human samples. The
alterations induced by lithium are usually within the accepted range but lithium
prophylaxis has been associated with a reduction in thyroid function in 4 to 30%
of bipolar patients (Hullin, 1978; Amdisen and Andersen, 1982). Rapid-cycler
bipolar patients have also been reported to show an increased incidence of
clinical hypothyroidism during lithium therapy (Bauer and Whybrow, 1990).
Normalization of plasma Cortisol concentrations has been associated
with successful treatment with antidepressants and electroconvulsive therapy
(Carroll et al, 1976; Christie et al, 1982). Long-term lithium therapy also
induces alterations in Cortisol secretion. Early works have shown that lithium
administration either increases plasma Cortisol (Platman and Fieve,1968;
Noyes et al, 1971) or does not change Cortisol values (Brooksbank and
Coppen, 1967; Sachar et al, 1970), but more recent studies have demonstrated
that prolonged administration of lithium in fact diminished plasma Cortisol
content (Meltzer et al, 1984; Smigan and Perris, 1984; Muehlbauer and
Mueller-Oerlinghausen,1985). It is probable that lithium acts at the level of the
hypothalamus, pituitary and adrenal glands or at all three to modulate adrenal
function (Lazarus, 1986) but as many variables (e.g. severity of depression,
presence of psychotic symptoms) influence the regulation of the hypothalamo-
pituitary-adrenal cortical (HPA) axis interpretation of the results is difficult
(Meador-Woodruff and Greden, 1988).
Lithium prophylaxis has provided a typical example of the complex
relationship between illness management and drug characteristics because it is
largely used in the long-term management of affective disorder patients and it
affects thyroid and adrenal function. The administration of lithium induces
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changes in many hormonal systems, and it is reasonable to think that when this
drug is withdrawn multiple neuromodulatory systems may have been altered.
The first report linking lithium to goitre (Schou eta\, 1968) mentioned that two or
three months after discontinuation of lithium the goitres decreased in size and
disappeared completely. Since then several studies employing the design of
before vs on lithium have been published to evaluate the thyroid effects of
lithium therapy (Emerson et al, 1973; McLarty et al, 1975). This design has the
disadvantage to confuse effects of illness itself.
Discontinuation trials, however, are reported less often in the literature.
One example is the study of Spaulding et al {1972) who administered lithium for
5 days to euthyroid and thyrotoxic patients followed by a discontinuation period
of 5 days. In affective disorders, however, only uncontrolled trials have been
reported (Schou, 1968; Sedvall, 1968; Noyes et al, 1971). Consequently, the
hormonal changes affecting the pituitary-thyroid and pituitary-adrenal axes in
bipolar patients after lithium discontinuation which were reported in these
earlier studies, need confirmation using stronger designs. These hormonal
changes might be associated with the withdrawal syndrome previously
described (Mander and Loudon, 1988). In other words, changes in thyroid
hormones and Cortisol may be relevant in explaining the increased relapse rate
after the discontinuation of lithium. The examination of this relationship defined
the objective of the present study.
TABLE6.2
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The objective of this study is to investigate the neuroendocrine changes
involving thyroxine (T4), thyroid stimulating hormone (TSH) and Cortisol before
and after lithium discontinuation in bipolar patients and to test whether they are
related to the withdrawal syndrome observed in these patients.
6.2. METHODS
6.2.1. SUBJECTS
Fourteen bipolar patients (nine females, five males) were diagnosed by
DSM-III (APA, 1980) and identified through the lithium registry of the Royal
Edinburgh Hospital (R.E.H.). Permission of supervising consultants was
sought. All data regarding intake of lithium in Edinburgh are recorded by the
R.E.H. lithium registry. Standardization of lithium serum level estimations is
high because only one laboratory is involved. The inclusion criteria required
that patients should be clinically euthymic on lithium prophylaxis for at least
eighteen months, euthyroid at study entry and not taking any other psychotropic
drugs. Patients were carefully examined and those with physical illnesses,
family history of thyroid disease and physical complications of lithium treatment
were excluded. They were also excluded if they scored more than 2 on a 23
item questionnaire about depression and mania. Written informed consent was
obtained from all patients after full explanation of the nature of the study. Table
6.4 describes the demographic and clinical characteristics of the sample
studied. They were mostly middle aged and had been on prophylactic lithium
on average for almost a decade.
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6.2.2. STUDY DESIGN
The study consisted of three phases, each lasting four weeks. During
the first phase, patients were established on lithium carbonate (Camcolit® , 400-
2000 mg) and baseline clinical ratings were obtained. Patients were seen
weekly for the whole period of the study . During the second and third phase, a
randomised double-blind procedure was followed: subjects were separated in
two groups, the first received lithium for 4 weeks followed by placebo for 4
weeks, the second the reverse. At study entry, patients underwent physical
examination and laboratory thyroid-adrenal function assessment, which
included determination of serum levels of T4 ,TSH and Cortisol. The same
process was repeated after one month of lithium discontinuation. Patients were
seen every week for clinical assessment and a family member was contacted if
they were unable to attend. Blood was taken between 9 and 12 a.m. at the end
of each phase of the study or at the discontinuation of the trial, for example
following relapse.
Patients were classified as relapsed if: a) DSM-III criteria for mania were
fulfilled; b) they scored an increase over 5 from baseline on a symptom check
list; and c) they scored over 20 on the Manic Modified Rating Scale (Blackburn
et al, 1977), applied on days 1 and 30 of the trial. Subjects who withdrew from
the trial who did not meet all three criteria were considered to have remained
well (full details are given in Mander and Loudon (1988).
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6.2.3. HORMONES ANALYSIS
Within 2 hours of collection, all the blood samples were centrifuged and
the plasma was stored at -40° centigrade prior to the analysis. A high sensitive
time-resolved fluoroimmunometric assay was used to measure TSH (DELFIA®),
with coefficients of variation (CoVs) at 4.9 and 21.6 mll/l were 3.4 and 4.0%
respectively. DELFIA (Dissociation-enhanced lantanide fluoroimmunoassay -
DELFIAR, Pharmacia, Milton Keynes, U.K) is a solid phase, two-site
immunofluorometric assay (IFMA) which employs two monoclonal antibodies
directed against different antigenic determinants of the TSH molecule (Paterson
et at, 1985). One antibody is bound to a solid matrix while the other is
radiolabeled. Simultaneous binding of both antibodies to TSH results in the
formation of a radiolabeled insoluble "sandwich", the concentration of which is
directly proportional to the quantity of TSH present in the sample (Seth et al,
1984). The procedure of the Delfia measurement is described in detail by
Kalhola et al (1985). T4 was analysed using the same technique, that is
competitive time resolved fluoroimmunoassay (DELFIA), with coefficients of
variation (CoVs) at 27, 107, and 155 nmol/l of 7.6, 3.6 and 3.5% respectively.
Total Cortisol concentrations were determined by radioimmunoasay
using a modification of the method of Seth and Brown (1978) and an antiserum
(Scottish Antibody Production Unit) raised in sheep cortisol-3-O-
carboxymethyloxime-bovine serum albumin. The cross-reaction of this
antiserum as characterized by the Scottish Antibody Production Unit was:
Cortisol 100%, corticosteroid 0.18%, cortisone 0.07%, 21-deoxycortisone
0.30%, 11-desoxicorticosterone 0.03%, 11-deoxycortisol 0.58%, 17 alpha
hydroxyprogesterone 2.1%, dexamethasone 0.33%. Antisheep-goat serum
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(Scottish Antibody Production Unit) at a final tube dilution of 1/83 was used as
the second antibody. The sensitivity of the assay for Cortisol (90% B/Bo) was
11.6 nmol/l (0.42 ug/100ml). The intra-assay coefficient of variation were
2.2%(low pool, 153 nmol/l; 5.54 ug/100 ml), 2.8% (middle pool, 311 nmol/l;
11.3 ug/100 ml), 3.2% (high pool, 560 nmol/l; 20.3 ug/100 ml). The low,
medium and high pools had corresponding interassay coefficient of variation
(CoVs) of 4.6, 3.0 and 6.3%.
6.2.4. STATISTICAL ANALYSIS OF THE DATA
Data were analyzed using SPSS programs. Demographic data were
compared by means of chi square. A Paired t test was used to compare of
neuroendocrine function of patients on and off lithium. Correlations between
changes in thyroid and Cortisol indexes after lithium discontinuation with
demographic and clinical variables were determined by Pearson product
moment correlations. Because of their skewed distribution TSH levels were
normalized by log transformation for calculation of statistical differences. A Two
tailed significance test was adopted.
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6.3. RESULTS
6.3.1. VARIATIONS OF TSH LEVELS
A significant reduction (t= 2.94, p < 0.01) in plasma level of TSH from
2.0± 0.1 to 1.2 ± 0.9 mll/l was observed after lithium discontinuation (Figure
6.1). Patients with higher TSH levels during lithium therapy also had higher
baseline TSH concentrations after lithium withdrawal. Only one patient
showed a TSH level during lithium prophylaxis above 4.0 mll/l, a criteria
adopted by Bocchetta et al (1991) to define subclinical hypothyroidism. Thus,
despite significant variations in TSH levels, all measurements can be classified
as within the normal range (Figure 6.1). No association could be demonstrated
between TSH levels after lithium discontinuation and lithium levels, duration of
treatment, age, sex and Cortisol concentrations. TSH was negatively
associated with T4 levels (r= -0.73, p < 0.01).
6.3.2. VARIATIONS OF T4 LEVELS
Figure 6.2 describes the effects of lithium withdrawal on serum levels of
T4. After one month of discontinuation, there was a significant increase (t= -4.4,
p<0.001) in serum T4 concentrations from 92.1 ± 16.3 to 112.9 ± 31.1 nmol/l.
The increase in T4 was observed systematically in all but one patient. The
pattern of increase was similar to the decrease in TSH, i.e. those patients with
higher T4 concentrations during lithium therapy also had higher T4 levels after
lithium discontinuation. The measurements made while patients were on
lithium and after lithium discontinuation were all within the normal range.
Despite the significant variations in T4 levels, patients could not be described
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as being hypothyroid according to the criteria of Evered et al (1973) during
lithium treatment. T4 concentrations were not associated with lithium levels,
duration of treatment, Cortisol concentrations and sex, but were correlated with
age (r= -0.67, p < 0.01) and TSH concentrations after lithium withdrawal
(r= -0.73, p < 0.01). There was no difference in the pattern of thyroid function
after the discontinuation between patients who had been on lithium for more
than 100 months and those who had been on lithium for less time.
6.3.3. VARIA TIONS OF CORTISOL CONCENTRATIONS
Figure 6.3 shows the effects of lithium discontinuation on plasma
concentrations of Cortisol. A non-significant reduction (t= 0.92, p= 0.3) in
Cortisol level was found after lithium withdrawal. No association could be
demonstrated between Cortisol levels and lithium dosage, duration of treatment,
age, sex, T4 and TSH concentrations.
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TABLE 6.4
Demographic and clinical characteristics of patients discontinuing lithium.
Values are mean ± standard deviation.
Age at trial (years) 52.7 (16.4)
Sex (M,F) 5, 9
Illness duration (years) 9.8 (4.7)
Episode frequency (per year) 0.2 (0.2)
Duration of lithium therapy (years) 9.7 (4.9)
Last lithium level before
discontinuation (nmol/l) 0.72 (0.1)
TSH (mll/l)
Figure 6.1. Plasma TSH levels in bipolar patients before




Figure 6.2. Plasma T4 levels in bipolar patients before




Fig 6.3. Plasma Cortisol levels in bipolar patients on/off lithium.
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6.3.4. RELAPSE VS REMAINED WELL GROUPS
Table 6.5 shows the hormonal measurements of seven patients who had
relapses shortly after placebo substitution (13-19 days) and who then had their
lithium immediately restarted, compared with seven other patients who
remained well after lithium discontinuation. As no significant differences were
observed in TSH, T4 and Cortisol between these two sub-groups, patients
relapsing after lithium discontinuation could not be differentiated from those
remaining well on the basis of these measures. Relapse was not associated
with any variable (lithium dosage, duration of treatment, age and sex).
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TABLE 6.5
Plasma T4, TSH and Cortisol concentrations (mean ± s.d.) in relapsed and remained well
groups of bipolar patients before and after lithium discontinuation.
HORMONE BEFORE DISCONTINUATION AFTER DISCONTINUATION
RELAPSED WELL RELAPSED WELL
T4 (nmol/l) 84 (9) 100 (19) 102 (19) 123 (39)
TSH (mU/l) 1.9 (0.3) 2.1 (1.6) 1.4 (0.9) 0.9 (0.9)
CORTISOL (nmol/l) 315 (176) 240 (40) 222 (70) 261 (80)
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6.4. DISCUSSION
6.4.1. HOW WAS TSH ALTERED BYDISCONTINUATION OF LITHIUM?
The present study confirms the findings of previous studies which found a
decrease in thyroid function during lithium therapy characterized by an increase
in TSH plasma levels (Lazarus and Bennie, 1972; Emerson et al, 1973;
Lazarus et al, 1981; Smigan et al, 1984) and refutes others which proposed
that lithium inhibits the TSH release mechanism (Ruzsas et al, 1980) and those
which found serum TSH concentration significantly lower in lithium treated
animals (Bagchi et al, 1982). Thyroid stimulating hormone levels have also
been found to be significantly decreased in patients who had a dosage
reduction of lithium (Coppen et al, 1983). Significant decrease in TSH levels
were also observed by Klein et al (1981). The decrease in plasma TSH levels
observed after lithium withdrawal was statistically significant, however, the
mean TSH levels before and after lithium discontinuation were within the
normal range. It is interesting to note that mean TSH was in the top range of
normal values. These findings would suggest that these patients had enough
thyroid reserve to cope with prolonged lithium therapy. A positive association
between TSH levels and duration of lithium therapy has been found (Child et al,
1976). This study, however, did not find any significant correlations between
TSH values after lithium withdrawal and clinical and demographic variables.
Since lithium is concentrated in the hypothalamus and the pituitary, it is
difficult to be sure if these findings are the result of a primary antithyroid action
of lithium or whether they reflect direct action of lithium in the hypothalamus or
pituitary or both (Lazarus, 1986). The increase in TSH concentration after
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initiation of lithium therapy and its decrease after lithium discontinuation as
demonstrated in this study indicates that the cause of hypothyroidism is further
down the pituitary-thyroid axis, i.e. it suggests that the thyroid gland may not be
able to produce and/or release the normal amounts of hormone or conversely
that the peripheral degradation is altered (Smigan et al, 1984). Additional
evidence for the thyroid being the prime target of lithium is provided by St
Germain (1988) who claimed that alterations in TSH secretion in euthyroid
individuals treated with lithium may result primarily from the direct effects of this
agent on the thyroid.
6.4.2. HOW WAS T4 ALTERED BY LITHIUM THERAPY?
The present study is in agreement with those which found a decrease in
thyroid function during lithium therapy characterized by a reduction in T4
(Sedvall et al, 1968; Halmi and Noyes, 1972; Amdisen and Andersen, 1982).
Consequently it is at odds with Goodnick (1985) who found no significant
changes in thyroid function after three weeks of lithium discontinuation and also
with Maarbjerg et al (1987) who found an increase in T4 with prolonged lithium
therapy. The increase in serum T4 levels observed after lithium withdrawal
was statistically significant, however, the mean T4 levels before and after lithium
discontinuation were within the normal range. It is interesting to note that the
mean T4 concentration was in the lower segment of the normal range. It has
been recognized that small variations in basal thyroid function, even with the
normal range may be of potential importance (Bauer and Whybrow, 1988).
Lazarus and Bennie (1972) reported a positive association between
duration of lithium therapy and thyroid status. Transbol et al (1978) found an
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association between laboratory signs of hypothyroidism and females patients
over the age of 40. This study did not find any significant association between
T4 levels after lithium discontinuation and clinical or demographic variables.
The only exception was a negative correlation found between changes in T4
values and age.
These findings would suggest that these patients had enough thyroid
reserve to cope with prolonged lithium therapy. The suppressive effect of
lithium on the thyroid is similar, but hardly identical, to the suppressive effect of
high iodine concentrations (Wolff, 1979), and that, as with iodine, most subjects
compensate ("escape") sufficiently the lithium induced thyroid inhibition (Fyro et
al, 1973; Amdisen and Andersen, 1982). They also lend support to the
suggestion that patients who have low thyroid reserve (high TSH
concentrations off lithium) are those who may develop clinical hypothyroidism
or sustained abnormal thyroid function tests with prophylactic lithium (Shopsin,
1970; Berens and Wolff, 1975; Bagchi et al, 1982).
Which affective disorders patients are susceptible to develop
hypothyroidism in affective disorder patients and how the high prevalence of
hypothyroidism function tests can accord with the relatively low clinical
occurrence of hypothyroidism are still unresolved questions. Positive findings
have been associated with certain patient characteristics or study design.
Some investigators found females over 40 years old to be more susceptible to
alterations in thyroid function induced by lithium (Transbol et al, 1978).
Differences in sex ratio in different studies have been suggested as a possible
cause for the conflicting results regarding the effects of lithium on thyroid
metabolism (Emerson et al, 1973). Hypothyroidism affects females more
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frequently than males; a female/male ratio of 5:1 has been reported in 39
individual case reports (Lazarus, 1986). Duration of lithium prophylaxis and
temporal adaptive mechanisms may account for some of this discrepancy.
Some patients may lack the ability to escape after a certain time on lithium
(Emerson et al, 1973; Fyro et al, 1973). This hypothesis was not confirmed by
Smigan et al (1984) who did not find an increase of hypothyroidism with
increasing duration of treatment. The presence of thyroid antibodies is also
proposed as a predisposing factor (Lazarus et al, 1981; see also section
4.4.14). To date, no clear evidence is available to answer these questions
satisfactorily.
It is still not clear exactly how lithium alters thyroid physiology and
different mechanisms have been proposed to explain the effects of lithium on
the thyroid gland. The first is inhibition of secretion or action of thyroid
stimulating hormone (TSH). Secondly, inhibition of iodine concentrating
mechanism has been proposed (Lazarus and Bennie, 1972). Lithium reduces
the radioactive iodine uptake in the rat thyroid in vivo and in vitro. These high
uptakes reflect an increased iodine retention within the thyroid gland. It is
considered that the overall effect of lithium on depression of iodine coupling
reactions is not great, at least in relation to other aspects on thyroid metabolism,
e.g. secretion of hormone (Berens and Wolff, 1975). The third hypothesis is
inhibition of hormone synthesis (Wolff, 1979). Fourthly, inhibition of hormone
release from the gland has been proposed (Bhattacharya and Wolff, 1976).
Finally, inhibition of peripheral degradation of thyroxine or diversion of the
peripheral monodeiodination of T4 to rT3, an inactive metabolite, instead of T3
which is 4 to 5 times as active as T4 has been proposed (Lazarus et al, 1981;
for reviews see Cooper and Simpson, 1974; Jefferson,1990). The inhibition of
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secretion of hormone release is considered to be the main effect, at least from a
functional point of view (Sedvall et al, 1968; Lazarus, 1986).
The mechanism of the lithium induced impairment of thyroid function has
also been ascribed to autoimmune thyroiditis (Emerson et al, 1973) but
antithyroid antibodies titers were not measured in this study. At present, the
role of thyroid antibodies in lithium induced hypothyroidism remains
controversial. The incidence of the antibodies in lithium treated groups has
been found to be similar to untreated groups (Lindstedt et al, 1977). Further
studies did not confirm a strong relationship between the levels of thyroid
antibodies and the hypothyroidal effect of lithium therapy (Ghose et al, 1977;
Deniker etal, 1978; Smigan et al, 1984). Other studies suggested that lithium
does not induce antithyroid autoimmune disease but it may have an immuno¬
modulatory effect on existing autoimmune disease (Hassman and MacGregor,
1988).
Because of its hypothyroid effect lithium was suggested as a possible
therapeutic agent in the treatment of thyrotoxicosis (Temple et al, 1972;
Lazarus et al, 1974). For early treatment, lithium can be used alone or in
conjunction with antithyroid drugs but it does not have much advantage over
iodine (Lazarus, 1986). Lithium should not be used for long-term therapy of
thyrotoxic patients, however, unless it is combined with thionamide medication,
because an "escape phenomenon" (re-emergence of symptoms after 2 weeks
of lithium therapy) has been described due to iodine pooling (Bakker, 1982).
Hyperthyroidism following lithium withdrawal or dosage reduction has been
reported in patients with pre-existing Graves' disease (Wilson and Jefferson,
1985).
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Although this study did not find severe alterations in thyroid status in
patients on lithium, hypothyroidism must be regarded as a serious complication
when compared with other side-effects of lithium. The calculated incidence for
goitre development was 4% per year per 100 patients on continuous lithium
(Kushner and Wartofsky, 1988) and a reduction in thyroid function is reported to
be in the range of 4 to 30% (Hullin, 1978). Furthermore, hypothyroidism in
lithium patients may be misinterpreted as depression making diagnosis difficult
(Lindstedt et al, 1977; Turnbridge, 1979). Due to the possible harmful effects
of lithium on the thyroid, it has been proposed that thyroid function tests should
be performed periodically. Different schedules of checks have been proposed
for patients on lithium prophylaxis, such as every 2 to 3 months (Kushner and
Wartofsky, 1988), or every year (Maarbjerg et al, 1987).
6.4.3. HOW WAS CORTISOL ALTERED BY THE DISCONTINUATION OF
LITHIUM?
During lithium prophylaxis, Cortisol levels are frequently reduced (Meltzer
et al, 1984; Smigan and Perris, 1984; Muehlbauer and Mueller-
Oerlinghausen, 1985), consequently after lithium discontinuation they were
expected to rise. But, in fact, Cortisol concentrations showed a small fall; the
reduction, however, was not significant. This finding is in agreement with
Noyes efa/(1971) who found a reduction of the excretion of 17-OHCS in the
first 24 hours after lithium discontinuation which was reversed upon
reintroduction of lithium. Cortisol directly suppress TSH release from the
pituitary (Morley, 1981). In this study, however, no correlation between the
Cortisol levels and plasma concentrations of TSH and T4 were found.
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6.4.4. CAN HORMONAL CHANGES EXPLAIN EARLY RELAPSE?
In a longitudinal study, Kirkegaard et al {1975) found that a reduction in
T4 levels and an increase in TSH response was associated with no relapse in
ten patients who had been on therapy for a mean of 12 months, but in seven
patients who relapsed in the first 3 months of therapy these parameters were
not significantly modified. The changes induced by lithium in the hormonal
status of affective disorders patients suggested a possible association between
hormonal changes and the occurrence of early relapse after the discontinuation
of lithium. In this trial, patients were observed for only one month after lithium
discontinuation due to ethical requirements. A longer period, e.g. 3 months,
would be desirable to ruled out completely any association between relapse
and hormonal status. The small number of the sample also makes a reliable
interpretation of the results difficult, but considering the accepted normal levels
of hormonal measurements, there is no strong evidence for a hormonal
influence in the seven relapses observed within one month of lithium
discontinuation. Thus, the possibility of a withdrawal syndrome in bipolar
illness being induced by changes in the hormonal concentrations of TSH, T4
and Cortisol was not confirmed.
6.4.5. ARE LITHIUM RESPONSE AND ENDOCRINE EFFECTS RELATED?
It is widely accepted that increased thyroid function facilitates treatment
response in depression, e.g. the potentiation of tricyclic therapy by T3. Lithium
therapy, however, is associated with decreased thyroid hormone levels. To
solve this apparent contradiction, it was proposed that the relative decrease in
173
thyroid indices rather than the absolute hormone concentrations achieved with
treatment is the important factor associated with treatment response (Joffe et al,
1984). This study gives indirect support to this hypothesis.
It has been postulated that in peripheral tissues, such as liver and kidney,
nearly all nuclear T3 is derived directly from plasma T3 (Silva et al, 1978). On
the other hand, animal studies have shown that in the cerebral cortex of the rat
approximately 80% of T3 is produced locally (Crantz et al, 1982). Although
these studies were performed in rats, the physiochemical properties of their
thyroid hormones and nuclear T3 receptors are remarkably similar to those in
human tissue (Oppenheimer, 1979). Administration of T3 raises plasma T3 but
by negative feedback regulation, suppresses T4 production and consequently
by decreasing plasma T4 induce relative hypofunction in the brain (Joffe et al,
1984). Therefore, the effects of T3 supplementation appear consistent with the
findings of lithium prophylaxis, where reduction in plasma T4 are greater than
decreases in plasma T3 (Dunner and Fieve, 1978).
A number of possible interactions between lithium, affective disorders
and the endocrine system have been proposed (Johnson, 1988): a) the
endocrine effects may be totally unrelated to the mechanism underlying
recovery from affective disorder; b) lithium may influence endocrine functions
by exactly the same mechanism as that involved in the clinical efficacy; c) the
endocrine changes may be related to changes taking place in the central
nervous system in complex interactive ways; d) endocrine functions may be
more closely bound up with the mechanisms and etiology of
psychopathological states than has been acknowledged previously. At the
moment, it is still unclear how this relationship occurs.
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6.4.6. ARE CHANGES IN THYROID FUNCTION SPECIFIC TO LITHIUM?
The antithyroid effects observed with prophylactic lithium occurs with
other psychiatric treatments. Long-term imipramine has produced loss of
weight of thyroid gland in animals (Prange and Lipton, 1962) and in men
(Baumgartner et at, 1988). Reichlin et al (1959) found increased thyroxine
turnover during the last ten days of combined chlorpromazine-sleep therapy.
Diphenylhidantoin was found to have a significant depressant effect on
thyroidal hormones, but phenobarbitone had no significant effect (Liewendahl
et al, 1978; Yeo et al, 1978). Carbamazepine decreased peripheral hormone
levels while increasing thyrotropin levels (Roy-Byrne et al, 1984).
Electroconvulsive therapy has also been shown to decrease thyroid function
tests (Kirkegaard and Faber, 1981). As was seen with lithium, the hormonal
changes in the majority of patients using these drugs are within the normal
range. It remains to be elucidated whether the changes in thyroid function
induced by these different drugs share a common mechanism or are the result
of the illness itself.
6.4.7. HOW IS HYPOTHYROIDISM CLASSIFIED?
Evered et al (1973) and Wenzel et al {1974) proposed definitions of
thyroidal hypothyroidism from subclinical (grade 3) to overt (grade 1)
considering the TSH response to TRH stimulation, basal TSH level and T4 and
T3 concentrations. In grade 1, the only altered parameter is the TSH response
to TRH stimulation which is increased. In grade 2, both the TSH response and
the basal TSH level are increased. In grade 3, all three are disturbed, there is
175
an increase in TSH response and basal TSH, and the concentrations of T4 and
T3 are reduced.
Inherent to the definition of hypothyroidism is the adoption of a specific
laboratory criteria to determine the normal range of hormone concentration.
Alexander et al (1962) defined the limits of the normal range as the best
separation determined by inspection of the figures obtained from normal
individuals and those found in patients with diseases associated with
abnormally low or high values. The finding that thyroid function test in affective
disorders falls within the normal limits is not new. Boumann et al (1950)
reported that the results of the serum bound iodine test of 6 manics and 16
depressives were within the normal range but significantly different from those
of normal controls. The interpretation of the "normal" range in measurements of
peripheral TSH and T4 is difficult due to different definitions of normal values.
The normal range of TSH has been defined as: less than 10 mll/L (Levy et al,
1981), less than 3 mU/L (Larsen, 1982), less than 6 mU/L (Morley and Schafer,
1982), 3.5 ±2.0 mU/L (Wartofsky and Burman, 1982), 0.5-7.0 mU/L (Orsulak et
al, 1985), 0.16 - 5.9 mU/L (Kirkegaard et al, 1990). The range of the normal
limits of T4 has also been defined differently: 110 ± 23.1 nmol/L (Turnbridge et
al, 1977), 72-156 nmol/L (Kirkegaard et al, 1990), 140 nmol/L (Joyce, 1991).
Clearly the results obtained in this study are within the accepted normal range
and they do not indicate any abnormality in their laboratory tests of these
patients.
Subtle changes in thyroid economy may be associated with profound
changes in behaviour, yet not change significantly hormonal levels measured in
the periphery or be reflected only by changes within the "normal range", which
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may be defined too broadly. Thus, the disturbances in the thyroid may be best
understood as existing on a continuum and the traditional designation of hypo-,
hyper, and euthyroid state exists as arbitrary, non physiological, and not directly
relevant to a specific symptom or metabolic requirements of a target tissue
(Reus, 1988). Rates of changes in hormonal levels may be more important
than the levels themselves (Prange et al, 1977). According to this approach,
different definitions of normal values in measurement of TSH have been
proposed for patients on lithium (0-11 mll/L) versus patients not on lithium (0-8
mU/L; Lindstedt et al, 1973).
The TSH response to TRH stimulation was not performed in these
patients. This test would give a more comprehensive picture of the HPT axis
after lithium withdrawal. The TSH response, however, seems to change with
symptomatology in some depressed patients, i.e. there is a normalization of the
TSH blunting with clinical improvement (Kaplan and Sadock, 1989). As all
subjects were required to be euthymic at study entry the use of this test is limited
for this sample. In addition, the relevance of TSH response in manic relapse
has not been fully investigated (Kaplan and Sadock, 1989), and also small
changes in T4 concentrations have been reported to magnify TSH response
considerably (Vagenakis et al, 1974).
In terms of TSH and T4 concentrations, none of the patients during the
two phases of this study could be categorized as abnormal using these
classification. The changes that occurred in the HPT axis were relative rather
than absolute. If these relative hormonal alterations have any role in the
relationship between thyroid function in affective disorder patients and lithium
discontinuation, this could not be detected.
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6.4.8. ARE HORMONAL CHANGES INDUCED BY LITHIUM REVERSIBLE?
Two cases of permanent hypothyroidism after lithium discontinuation
have been reported (Perrild et al, 1978), however other studies have failed to
confirm this irreversibility of lithium effects on HPT axis (Schou 1968; Sedvall et
al, 1968; Shopsin, 1970; Lindstedt et al, 1973 ). Lithium withdrawal appears
to have reversed the alterations in T4, TSH and Cortisol levels which were
induced by its long-term treatment. This is in accordance with previous studies
(Schou 1968; Sedvall et al, 1968; Shopsin, 1970; Lindstedt et al, 1973). The
plasma levels of TSH and Cortisol after chronic lithium treatment were found to
be lower than after acute treatment (Nelson et al, 1988; Christie et al, 1989).
Additional evidence of the reversibility of the effects of lithium on the thyroid
gland is provided by two studies: first, Spaulding et al (1972) who observed
that the slope of the protein bound 125|/1311 returned to normal after the five day
discontinuation period; and second, Bakker (1982) who demonstrated that
basal TSH and TSH response to TRH were reversible in 8 euthyroid patients
who had their lithium stopped. Laboratory studies also confirm the reversibility
of lithium effects. Tsuchiya et al (1990) reported that in porcine thyroid cells
when lithium was removed from the medium, iodine uptake in the cells treated
with lithium chloride (LiCI) returned to the levels in the cells treated with lithium
TSH alone and cell viability measured by trypan blue was not changed by LiCI
treatment.
CHAPTER 7
THE ROLE OF DIETARY INOSITOL ON THE THYROIDAL AND
OTHER SIDE-EFFECTS OF LITHIUM
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7.1. INTRODUCTION
Lithium-induced hypothyroidism and other adverse effects may
jeopardize long-term treatment as a result of discontinuation of the therapy. In
order to prevent the side-effects of lithium in patients for whom long-term lithium
usage is recommended, a different strategy was followed - the addition of
inositol to the diet without discontinuation of lithium. The mechanism of action
of lithium remains poorly understood (Wood and Goodwin, 1987), although, a
second messenger system based on phosphoinositides (PI) located in the cell
membrane has been proposed as the primary target for lithium (Berridge et al,
1982, 1989). Supplementation of the diet with inositol, which does not cross
the blood brain barrier, might reverse the actions of lithium in target organs or
tissues. If the effects of the addition of inositol to the diet was to mimick the
peripheral effects of lithium discontinuation, two important conclusions could be
drawn: first, the involvement of PI cycle in the action of lithium in men would be
confirmed; secondly, a potentially important therapy to prevent the peripheral
side effects of lithium would be available. The aim of this study was to examine
the influence of inositol on thyroid function in patients receiving lithium.
In addition to the thyroid side effects, patients receiving prophylactic
lithium may present with other adverse effects, such as dry mouth, nausea,
nocturia, thirst and tremor. Reported incidences of patients showing these side
effects have varied from 66% (Johnston et al, 1979) to 90% (Vestergaard et al,
1988). In some cases, these side effects are responsible for the
discontinuation of lithium (Bech et al, 1976). Thus, the effects of inositol on
these adverse effects were also evaluated in this study.
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7.1.1. INOSITOL
In 1812, Vasquelin published the first account of a lipid which contained
phosphorus (Hawthorne and Pickard, 1979). Inositol was first reported as a
lipid constituent by Anderson and Roberts in 1930 (Hawthorne, 1982). In 1942,
Folch and Woolwey described a brain phospholipid containing inositol. Folch
subsequently introduced the term phosphoinositide (Hawthorne, 1982). In
1953, the exocrine pancreas was the first tissue in which phospholipid
metabolism was found to be stimulated by agonists, in this case acetylcholine
(Hokin and Hokin, 1953).
There are nine hexahydroxycyclohexanes, and they were originally
described collectively as 'inositols'. To avoid confusion of the generic term with
the only inositol which is found in the naturally occurring phosphoinositides, the
myo-prefix was added (myo-inositol) and the various isomers have been termed
cyclitols (Hawthorne, 1982; Agronoff, 1987). In animal cells, there are three
myo-inositol containing phosphatides: phosphatidylinositol myo-inositol (PI),
phosphatidylinositol 4-monophosphate (PIP), and phosphatidylinositol 4,5-bis-
phosphate (PIP2)- /Wyo-inositol is a cyclic hexitol with molecular weight of 180
daltons which characterizes the class of phosphoinositides. Phosphoinositides
constitute 2 to 8% of the lipid cell in eukariotic cells; PI accounting for 80 to 90%
of the total inositol lipids while polyphosphoinositides (PIP and PIP2) represent
10 to 20% (Hokin, 1985).
In 1971, Allison and Stewart were the first to report that the acute
administration of lithium resulted in a 30% decrease in the level of myo-inositol.
This decrease of myo-inositol was possible through the inhibition of the enzyme
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myo-inositol-1-phosphatase, which was first studied in yeast by Chen and
Charalampous (1966). In 1974, Naccarato et al showed that lithium completely
inhibits myo-inositol -1- phosphatase of the rat mammary gland. The first
demonstration of phosphatidylinositol metabolism in pituitary cells was made by
Hokin et al (1958).
Receptor stimulation triggers the cleavage of phosphatidylinositol 4,5-
bis-phosphate by phospholipase C giving rise to diacylglycerol and inositol
1,4,5-triphosphate, which are the second messengers for a series of
intracellular processes. Diacylglycerol activates protein kinase C by enhancing
its affinity for calcium which stimulates protein phosphorylation (Nishizuka,
1984) and inositol releases calcium from intracellular stores (Michell, 1975;
Downes and Michell, 1982; Berridge, 1984). Phosphatase enzymes
sequentially remove phosphate groups from inositol triphosphate, giving rise to
free inositol which is then converted to phosphatidylinositol bisphosphate to
reinitiate the phosphatidylinositol cycle (for a detailed review of inositol
metabolism see Michell, 1975; Downes and Michell, 1982; Hokin, 1985;
Berridge, 1987).
The formation of inositol in the thyroid has not not been systematically
studied. Most studies have used cells of the central nervous system to study
the metabolism of inositol, and four possible routes of formation of intracellular
inositol have been described in central nervous system (see Table 7.1). First,
by hydrolysis of phosphatidylinositol (Berridge et al, 1989). Secondly, by
synthesis de novo from glucose-6-phospate (Eisenberg, 1967). In rabbit brain
about 1% of the free myo-inositol was synthesized in vivo from glucose during a
period of 3 hours (Spector and Lorenzo, 1975) but, even if glucose uptake is
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enhanced, it did not cause further appreciable increases in the concentration of
phosphatidylinositol (Scott et al, 1966). The metabolic pathway of inositol from
glucose-6-phosphate involves in the final step the transformation of inositol-1-
phosphate to myo-inositol by the same enzyme myo-inositol-1-phosphatase
that is blocked by lithium (Berridge et al, 1989). Thirdly, by epimerization of
inositol to scyllo- and neo-inositol (Hipps et al, 1977; Sherman et al, 1978;
Wong et al, 1987). In several brain regions, the 'in vivo' concentration of myo¬
inositol is 20 times higher than of scyllo-inositol (Sherman et al, 1968) and the
concentration of scyllo-inositol is 20 times higher than of neo-inositol (Sherman
et al, 1971). Consequently, epimerization represents a minor pathway as a
source of inositol. Finally, transport from blood to the brain cells via the blood
brain barrier. Uptake of myo-inositol into the brain is highly controlled (Spector
and Lorenzo, 1975) and only 3% of plasma inositol is taken into the brain
(Margolis et al, 1977; Lewin et al, 1976; Barkai, 1981).
In the CNS, inositol is mainly synthesized from glucose via myo-inositol-
1-phosphate or by the hydrolysis of phosphatidylinositol (Margolis et al, 1971;
Spector and Lorenzo, 1975), while in the peripheral nervous system myo¬
inositol is taken up exogenously (Greene et al, 1982). The importance of
phosphoinositide hydrolysis in the CNS is highlighted by the differences in D-
and L- enantiomer accumulation. Sherman et al (1981) demonstrated that the
myo-inositol which accumulates in the brain of lithium treated animals is
predominantly the D-enantiomer, and therefore the one which is derived from
hydrolysis of phosphatidylinositol, as opposed to being derived from the de
novo synthesis pathway which gives rise to the L-enantiomer (see Figure 7.1.).
It remains unknown which pathway is the most important for the formation of the
intracellular pool of inositol in the thyroid.
FIGURE 7.1
Summary of inositol cycle. The sources of inositol (uptake, recycling and
synthesis) are illustrated. Abbreviations are as follows: Ptdlns -
phosphatidylinositol. Ptdlns4P - phosphatidylinositol-4-phosphate. Ptdlns
(4,5)P2 - phosphatidylinositol-4,5-bisphosphate. DG - diacylglygerol . PA -
phosphaditic acid. CDP-PA - cytidine diphosphate diacylglycerol. D-lns4P ,
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7.1.2. THE EFFECTS OF LITHIUM ON c-AMP AND INOSITOL
METABOLISM
Traditionally research in psychopharmacology has focused on individual
neurotransmitters. Lithium research has not been an exception to this pattern.
The mechanism of action of lithium has been studied in terms of modification of
noradrenergic, dopaminergic, and serotoninergic functions. Efforts using this
approach have been fruitless, however. More recent research has focused on
second messenger systems, adenylate cyclase activity and phosphatidylinositol
metabolism (Wood and Goodwin, 1987; Baraban et al, 1989). Therefore, the
mood stabilizing actions of lithium might be effective not because of the
alterations induced in noradrenergic or serotoninergic metabolism per se, but
because lithium alters the postsynaptic signal generated in response to such
endogenous neurotransmitters (Risby et al, 1991). This approach has been
more promising. Two hypotheses have been formulated: the adenyl cyclase
and the inositol hypotheses.
The adenyl cyclase hypothesis, as proposed by Sutherland and
Robinson (1966) suggests that c-AMP is a universal intracellular second
messenger or mediator for the action of most mammalian hormones. Lithium
inhibits adenyl cyclase (Dousa, 1970; Ebstein et al, 1976; Newman et al,
1983). Moreover, agents that stimulate cAMP accumulation inhibit agonist-
stimulated accumulation of inositol phosphates (Campbell et al, 1990; Hall et
al, 1989). Lately, a specific mechanism for "cross-talk" between cAMP and
phosphoinositide has been proposed with still poorly defined functions
(Baraban et al, 1989). Because stimulation of the alpha 1 adrenoreceptor
inhibits inositol phospholipid breakdown (Kendall et al, 1985), it has been
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argued that in reducing noradrenaline stimulated cAMP production (Ebstein et
al, 1980) lithium could be acting through its inhibition of alpha 1
adrenoreceptors rather than beta adrenoreceptor (Godfrey et at, 1989).
The inositol hypothesis of the mechanism of action of lithium may be
summarized as follows: lithium inhibition of inositol-1 -phosphatase depletes
inositol and reduces phosphatidylinositol turnover, and thus dampens cellular
responses to neurotransmitters (Berridge et at, 1989). Transmitters affected
would include all those known to act via the phosphatidylinositol cycle,
including norepinephrine, serotonin, acetylcholine, histamine, and several
peptides. As a result cells overstimulated by processes postulated as causal in
mania or depression would be brought to a more normal functional level
(Menkes et al, 1986). There is some experimental evidence for the inositol
hypothesis. At therapeutic concentrations, lithium inhibits the activity of the
enzyme inositol-1-phosphatase (Hallcher and Sherman, 1980). Lithium
inhibition of inositol 1-phosphatase is noncompetitive (Berridge et al, 1989)
suggesting that the more active the cell, the more it might be affected (Cornish-
Bowden, 1986). Long-term lithium therapy decreases rat brain inositol levels
and increases inositol-1-phosphate content (Allison et al, 1971, 1976).
Since lithium affects both adenylate cyclase and phosphoinositide,
alternative hypotheses involving these two systems have been put forward in
order to explain the effects of lithium. The first hypothesis concerns the
guanine nucleotide-binding proteins (GTP proteins), which transduce signals
from receptors to second messenger systems (for a review of GTP proteins see
Gilman, 1987). Lithium within the therapeutic range inhibits adrenergic and
cholinergic increase in GTP binding proteins in rat cortex by interfering with Gs
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and Gp (Avissar et al, 1988). A second hypothesis relating affective disorders
and the effects of lithium involving the second messenger systems was
formulated by Wachtel (1989). It proposes that affective illnesses arise from the
imbalance of the two major intraneuronal signal amplification systems -
adenylcyclase (AC) and phospholipase (PLC). Depression would result from a
hypofunction of adenyl cyclase and hyperfunction of the phospholipase system,
and mania would result from opposite effects. The therapeutic effect of lithium
would be due to the dampening of an over-active AC system in mania and to
the dampening of the PLC system in depression (Wachtel, 1989).
7.1.3. LITHIUM, INOSITOL, c-AMP AND THE THYROID
The interaction of cyclic-AMP, phosphoinositol, thyroid stimulating
hormone (TSH) and lithium in the thyroid is complex. TSH exerts two primary
effects on the thyroid: the stimulation of adenylate cyclase and the enhanced
turnover of phosphatidylinositol (Gerard et al, 1982). TSH stimulates the
incorporation of 32P into phospholipids, especially phosphoinositol (Freinkel,
1957; Scott et al, 1966; Schneider, 1972). In the absence of TSH,
monophosphatidylinositol which contains only 10% of the lipid 31P accounted
for about half of the lipid 32P while phosphaditylcholine which contains half of
the lipid 31P accounted for about a third of the lipid 32P. In the presence of
TSH, a greater proportion of the incorporated radioactivity was diverted to
monophosphatidylinositol (Scott et al, 1966). This enhanced incorporation 32P
into phospholipids is independent of adenylcyclase since (i) dibutyryl cyclic
AMP is unable to mimic this effect (Gerard et al, 1982), (ii) it occurs at
concentrations of TSH which are too low to stimulate adenylate cyclase activity
(Burke, 1970-a), (iii) it is not affected by drugs such as theophyline and
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prostaglandin E2 which are known to increase the level of cyclic AMP in thyroid
tissue.(Burke, 1969, 1970-b; Zor et al, 1969). Cyclic-AMP has also been
found, however, to induce independently an increase in 32P incorporation into
phospholipids (Burke, 1969). TSH also enhances the incorporation of inositol
14C into thyroid lipids (Freinkel, 1960; Jungalwala et al, 1971).
TSH increases the rate of formation of cyclic AMP by activation of
adenylcyclase both in homogenates (Pastan and Katzen, 1967) and slices of
bovine thyroid (Gilman and Rail, 1966), but treatment of thyroid membranes with
phosphatidylinositol depresses the stimulation of adenylate cyclase by TSH
and also inhibits TSH binding to plasma thyroid membranes (Omodeo-Sale et
al, 1978; Aloj et al, 1979).
The role of lithium in the function of the thyroid needs further clarification.
Lithium inhibits TSH stimulation of adenyl cyclase in the thyroid, and this action
has been implicated in the reduction of 1311 accumulation in that organ (Wolff et
al, 1970). Lithium inhibition of thyroid stimulating hormone sensitive to
adenylate cyclase may be related to the hypothyroidism induced by the drug
(Burke, 1970-a; Wolff et al, 1970). The effects of lithium on the
phosphatidylinositol metabolism of the thyroid have not been systematically
studied. Due to their easy availability, some studies have examined the effects
of lithium on the phosphatidylinositol metabolism of the rat's pituitary tumour
cells (GH3). In those cells, thyroid releasing hormone (TRH) and lithium
stimulated the hydrolysis of phosphatidylinositol (Drummond and Raeburn,
1984).
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Additional evidence for a role of phosphatidylinositol in thyroid function
comes from the differences in the way that cyclic AMP and inositol respond to
acute and chronic TSH stimulation. It has been suggested that TSH causes a
coordinated increase in the formation of phospholipids and RNA and that
dibutyryl cyclic AMP mimics the more rapid effects of TSH on transport and
metabolic functions but does not influence the slower responses to the hormone
(Kerkof and Tata, 1969). Thus, it may be hypothesized that cyclic AMP is more
involved in the acute stage of TSH stimulation while phosphaditylinositol may
have more influence on chronic TSH effects, such as those blocked by
prophylactic lithium. Furthermore, because it does not enter the brain to any
great extent, inositol is unlikely to interfere with the therapeutic effects of lithium.
It may reduce some of its adverse effects, however. Of these, those on the
thyroid are most worrying and necessitate expensive and frequent monitoring.
7.1.4. AIM
The objective of this study was to evaluate the effects of adding inositol to
the diet of clinically stable bipolar patients on prophylactic lithium upon
thyrosine (T4) and thyroid stimulating hormone (TSH) concentrations and on
other peripheral side-effects of lithium and to compare with those found of a




Eleven bipolar patients (8 males, 3 females) diagnosed according to
DSM-III criteria (APA, 1980) were compared with nine normal controls (6 males,
3 females) before and after adding inositol to their diet. Patients were recruited
from the Lithium Register of the Royal Edinburgh Hospital or were referred by
supervising consultants while normal controls were recruited from the University
staff and community. To be eligible for this study the following criteria were
applied:
a) patients should be stable on lithium for at least one year.
b) on entering the study, both patients and controls should be euthymic and
euthyroid.
c) controls should not have any previous or family history of psychotic illness.
Any subject who had a known physical illness or a family history of
thyroid disease was excluded from the trial. Four patients were on lithium only
while the other seven were on lithium plus imipramine (1), amitriptyline (1),
phenelzine (1), chlorpromazine (2), temazepan (1), ortemazepan and
clonazepan (1). No subject was taking any medication during the trial. Written
informed consent was obtained from all subjects after being given a full
explanation of the nature of the study.
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7.2.2. STUDY DESIGN
This was a pilot study involving a single-blind design. On the first and
last two days of the trial sucrose was administered to the subjects while in the
intervening sessions inositol was administered. Inositol was started at a doses
of 2 g/day and it was increased by 2 g on every second day, so that after one
week subjects were taking 8 g/day. Plasma samples, taken before and seven
days after adding inositol to the diet, were analysed for free thyroxine and
thyroid stimulating hormone. Subjects were weighed prior to the addition of
inositol.
5.2.3. RATING SCALES
Symptom severity and mood were assessed by the Beck Depression
Inventory (BDI; Beck et al, 1961), Personal Feeling Scale (PFS; Wessman and
Ricks, 1966) and Visual Analogue Mood Scale (Zeally and Aitken, 1969).
The BDI is a 21-item scale containing descriptive symptoms which were
found to discriminate depressed from non depressed psychiatric patients.
These symptoms refer to characteristic clinical aspects of depression, for
example pessimism, social withdrawal suicidal wishes. For each symptom,
there are four or five statements in the first person ranging from a mild or neutral
statement up to one indicating a particularly severe degree of that particular
symptom. Each statement is assigned a score of 0, 1, 2, or 3 to indicate the
degree of severity of the symptom. The total score obtained on the BDI is the
sum of the individual scores for each item. The maximum score on the BDI is
63. This inventory was found to have good internal reliability and was
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validated in clinical settings. Beck et al (1961) reported correlations of BDI
scores with physicians' ratings of 0.65 to 0.67 and reliability was found to range
from 0.86 to 0.93. A correlation of 0.82 between the BDI and the Hamilton
Rating Scale for Depression - HRSD (Hamilton, 1960) has been reported by
Williams et al (1972). These correlations were highest near recovery and
lowest at the acute stage of illness (Paykel et al, 1973). Possible explanations
for this finding are the distorting effects of illness on self perception, lack of
insight and response sets.
The aim of the PFS was to provide subjects with a comprehensive and
exact vocabulary of affect and feeling that would be suitable for repeated self
reports (Wessman and Ricks, 1966). It consists of a list of sixteen descriptive
scales. Each scale has 10 statements ranging from extreme feelings at one
end of the continuum, through more neutral feelings, to extreme contrasting
feelings at the opposite end. In each scale, the subject is asked to choose the
statement that best describe his or her mood at that time.
The Visual Analogue Mood Scale is a self recorded scale and contains
the following topics - how well, how depressed and how elated subjects feel.
These variables are recorded by marking a point on a 100 mm line to indicate
how intense the feeling was (0=minimum, 100=maximum). Lines are scored
using a millimetre rule and the mean mood and the standard deviation are
calculated. The Visual Analog Mood Scale has been shown to be reliable,
valid and clinically useful as a repeated measurement of mood (Aitken, 1969;
Folstein and Luria, 1973).
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Frequent side-effects of lithium therapy (dry mouth, nausea, nocturia,
thirsty, tremor) were estimated by a completion of a side-effects check-list using
the following scale: not at all (0), mild (1), moderate (2) and severe (3) based
on how disabling the patient perceived the side effect to be.
5.2.4. PROCEDURE
All the scales were administered on the third and tenth days of the trial.
All subjects were tested in the morning, between 9 and 11 AM after an overnight
fast. Access to these data to the subjects was not permitted during the trial
period.
7.2.5. HORMONE ANALYSIS
All blood samples were centrifuged within 2 hours of collection and the
plasma was stored at -40° centigrade prior to the hormonal analysis. Both TSH
and T4 were analysed using a high sensitivity time-resolved
fluoroimmunometric assay (DELFIA®). The coefficients of variation (CoVs) for
TSFI at 4.9 and 21.6 mU/l were 3.4 and 4.0% respectively and for T4 were at 27,
107, and 155 nmol/l of 7.6, 3.6 and 3.5% respectively. DELFIA (Dissociation-
Enhanced Lantanide FluorolmmunoAssay - DELFIA®, Pharmacia, Milton
Keynes, U.K) is a solid phase, two-site immnunofluorometric assay (IFMA)
which employs two monoclonal antibodies directed against different antigenic
determinants of the TSH molecule (Paterson et al, 1985). One antibody is
bound to a solid matrix while the other is radiolabeled. Simultaneous binding
of both antibodies to TSH or T4 results in the formation of a radiolabeled
insoluble "sandwich", the concentration of which is directly proportional to the
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quantity of TSH or T4 present in the sample (Seth et al, 1984). For a detailed
description of the procedure of the Delfia measurement see Kalhola et al (1985)
and Methods of the previous chapter.
7.2.6. STATISTICAL ANALYSES OF THE DA TA
Data were analyzed using SPSS programs. The groups were
compared on the basis of sex by means of chi square and on the basis of age
and weight by t tests. A multivariate analysis of variance (MANOVA) was
performed to analyse data regarding hormonal levels, rating scales and side
effects before and after the addition of inositol. This statistical method allows
the comparison of the control and patient groups on all outcomes
simultaneously. TSH levels were normalized by log transformation for analysis
purposes. A two tailed level of significance was used throughout the study.
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7.3. RESULTS
7.3.1. DEMOGRAPHIC AND CLINICAL VARIABLES
Table 7.1 describes the demographic and clinical characteristics of the
sample studied. No significant differences were observed for any demographic
variable between the patient and control groups. The only clinical variable
showing a significant difference between the patient and control groups was
weight (t=2.4, p<0.02), with patients being heavier than controls. Weight gain
has been associated with chronic administration of lithium in 20 to 60% of
patients (Vendsborg et al, 1976; Vestergaard etat, 1988), and is also seen with
antidepressants (Fernstom and Kupfer, 1988) and neuroleptics (Amdisen,
1964). As all patients were taking one or more of these drugs they were
expected to be heavier.
7.3.2. TSHAND T4 MEASUREMENTS
Table 7.2 shows the means (S.D.) of the T4 and TSH levels found in the
patient and control group before and during inositol administration. In terms of
thyroidal side-effects, adding inositol to the diet would be expected, according
to the hypothesis outlined above, to have a similar effect as stopping lithium.
The findings after one week of inositol, however, did not support this hypothesis.
There were no significant differences in hormonal concentration between
subjects (F=0.74, df=18, p=0.4) nor in the interaction of hormone measurement
by time (F=0.78, df= 18,1, p=0.38) nor in the interaction of group by hormone
measurement by time (F=0.02, df= 18,1, p=0.88). Figures 7.2-A and 7.2-C
show T4 and TSH levels in both groups before the supplementation with
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inositol. Figures 7.2-B and 7.2-D display T4 and TSH concentrations,
respectively, in both groups after the addition of inositol. On entering the study,
all subjects had T4 and TSH levels within the normal range and this continued
after one week of inositol.
7.3.3. RATING SCALES AND SIDE EFFECTS CHECK-LIST SCORES
Table 7.2 shows the means (S.D.) of the scores obtained in the rating
scales and side effects check-list by the patient and control groups before and
during inositol administration. In terms of rating scales, there was no significant
difference between subjects (F=0.06, df=17, p=0.81), but a trend was observed
to indicate that the performance of the patient and control group differed on
different scales (F=2.5, df= 4, p=0.09).
In terms of side effects, some subjects showed more side effects than
others (F= 5.12, df=17, p=0.03), but there was no significant difference in the
interaction group by side effect (F= 1.08, df= 4, p=0.37). The interactions of
group by side effect by time and of side effect by time were both non significant
(F=1.01, df=4, p=0.42 and F=1.33, df=4, p=0.3)
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TABLE 7.1
Demographic and clinical variables of the patient and control groups to whom inositol
was administered for one week. All values are mean ± S.D.
VARIABLE PATIENT CONTROL
Age at trial (years) 55.0 (18.4) 51.3 (18.3)
Sex (M:F) 3:8 3:6
Weight (kilos) 80.9 (10.7) 68.5 (12.0)
Illness duration (years) 9.8 (5.8) -
Episode frequency (per year) 0.4 (0.3) -
Duration of lithium therapy (years) 8.6 (5.7) -
Last lithium level before adding
inositol (nmol/l) 0.66 (0.19) -
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TABLE 7.2
Plasma T4 and TSH concentrations, scores obtained with self-rating scales and check-list of the most
frequent side effects in the patient and ccontrol group before and during administration of inositol. All
values are mean ± SD.
PATIENTS CONTROLS
Before On Before On
Inositol Inositol Inositol Inositol
Hormone
T4 (nmol/l) 91 (25) 89 (26) 83 (18) 81 (18)
TSH (mU/L) 3.0 (1.7) 2.7 (1.1) 2.0 (1.1) 1.9 (0.9)
Rating Scale
Beck 8.1 (7.5) 7.0 (7.7) 2.2 (2.4) 1.5 (2.1)
PFS 10.8 (1.8) 11.7 (2.2) 12.6 (1.4) 13.4 (1.8)
VAS Depressed 22 (20) 18 (18) 7 (6) 7 (5)
VAS Elated 65 (23) 73 (25) 48 (31) 73 (25)
VAS Well 77 (15) 81 (18) 91 (9) 87 (13)
Side Effect
Dry mouth 0.9 (0.8) 0.7 (0.9) 0.1 (0.3) 0.2 (0.7)
Nausea 0.1 (0.4) 0.1 (0.4) 0.1 (0.3) 0
Nocturia 1.2. (0.7) 0.9 (0.9) 0.7 (0.9) 0.6 (0.7)
Thirst 0.9 (0.8) 0.7 (1.0) 0.2 (0.4) 0.1 (0.3)
Tremor 0.7 (1.0) 0.7 (1.0) 0 0
Beck - Beck Depression inventory
PFS - Personal Feeling Scale
VAS - Visual Analogue Scale
VAS was measured by lines of 100 mm where 0=minimum and 100=maximum.
Side effectswere rated from 0 (no symptom) to 3 (severe symptom).
FIGURE 7.2
Serum T4 concentrations in bipolar patients and normal controls before (7.2-
A) and after adding inositol to the diet (7.2-B). This figure also shows TSH
levels in the same group of subjects before (7.2-C) and during the
administration of inositol (7.2-D). Mean ± S.E. are illustrated through
horizontal lines.
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7.4.1. HAS INOSITOL ANY ROLE IN REDUCING THYROIDAL SIDE
EFFECTS?
The results obtained from the addition of inositol to the diet of bipolar
patients with the aim of reducing the side-effects of lithium were disappointing.
The findings of this study do not support the view that dietary inositol can
change, in any significant way, TSH and T4 concentrations. A high level of free
myo-inositol may be essential to allow resynthesis to balance receptor
mediated degradation (Berridge, 1984). The addition of inositol aimed to
provide extra amounts of the substance to the thyroid and it was expected that
changes would occur in T4 and TSH levels similar to those found with the
withdrawal of lithium (increase in plasma thyroxine and decrease in TSH, for
details see previous Chapter). However, the addition of inositol has failed to
alter significantly the thyroidal status of either patients or controls. A more
pronounced effect of inositol might have been observed if subjects had a
marked reduction in thyroid function. As this was a pilot study, however, it was
ethically advisable to evaluate the effects of dietary inositol, if any, in an
euthyroid population.
Dietary inositol, given at a dose of one gram a day for two weeks,
improved diabetic neuropathy in seven patients (Salway et al, 1978). Inositol
increased the amplitude of evoked action potentials of the median, sural and
politeal nerves by an average of 76%, 160% and 40% respectively but there
was no significant change in the conduction velocities (Salway et al, 1978).
This was the main guide to what dose of inositol to employ.
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There is ample evidence that several of the biological effects of lithium
can be reversed by the addition of myo-inositol (Zawalich et al, 1989; Kofman
and Belmaker, 1990; Zhu and Fu, 1990). Downes and Stone (1986) observed
that the enhancement of CMP-phosphatidase levels by carbachol in the
presence of lithium could be reverses by adding back myo-inositol. The
teratogenic effects of lithium on developing Xenopus laevis embryos can be
completely blocked by replenishment of inositol (Taylor, 1988; Busa and
Gimlich, 1989). The ability of lithium to attenuate muscarinic agonist-induced
desentization in rat hippocampal slices was reversed by the addition of 1 mM
myo-inositol (Pontzer and Crews, 1990). However, not all studies support the
view that the addition of inositol reversed the effects of lithium. Kendall and
Nahorski (1987) found that buffering the cellular inositol pool by in vitro
preincubation with 2.5 mM myo-inositol did not prevent the inositol depletion by
lithium. However, the effects of lithium in the intact brain may be different.
Taken together, these findings would suggest that the in vivo effects of lithium
may involve more complex mechanisms than the simple depletion of cellular
inositol. The incorporation of many labelled precursors, including inositol, in
vitro into phosphatidylinositol of thyroid tissue is enhanced by the addition of
thyrotropin (Jungalwala et al, 1971). During lithium prophylaxis a sustained
elevation of thyrotropin is observed. The necessary level of thyrotropin in vivo
to influence inositol incorporation, however, may be above the normal range of
TSH found in long-term lithium treated patients or controls in euthyroid state.
The concomitant administration of other drugs may have altered the
human thyroid metabolism. Only four out of the eleven patients were on lithium
alone, the other seven were on lithium plus a variety of other drugs (see
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Methods). These drugs have not been clearly associated with the
hypothalamic pituitary thyroid axis (McLarty et aI, 1978; Prange, 1985) nor has
any statistically significant difference in thyroidal status between patients on
lithium only and lithium plus other psychotropic drugs been found (Lazarus et
al, 1981).
To date, there is no good evidence to support the importance of the
transport of inositol from blood to the thyroid for hormonal secretion. It appears
that in the thyroid gland, the newly synthesised phosphatidylinositol stimulated
by TSH is synthesised de novo rather than utilizing released diacylglycerol
because the total incorporation of glycerol is unchanged. However, the
proportion of glycerol going to phosphatidylinositol rises at the expense of other
phosphoinositides, so no conclusive interpretation can be drawn from these
findings (Michell, 1975).
In summary, organs that are known to have a synthetic capacity, such as
the thyroid, are often also known to be capable of inositol transport, thus the
degree of dependence on one means of inositol supply or another is often
unclear (Wong et al, 1987). Cells or tissues sensitive to lithium are those that,
for one reason or another, are unable to buffer internal inositol stores by uptake
of external inositol (Berridge et al, 1989). An unresolved issue is which
mechanism does the thyroid gland mainly depend on.
7.4.2. CAN INOSITOL ALTER SCORES ON RATING SCALES?
The finding that euthymic patients show a trend to score more poorly than
controls in the BDI and PFS may be due to illness factors, since patients tend to
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perceive themselves in a more pessimistic way and describe a poorer mental
state (Paykel et al, 1973).
Another aspect that deserves comment refers to the use of self rating
scales in this study. One criticism, at least, can be made about self rating
scales, that is, they must have enough insight and be willing to give correct
answers. Despite their deficiencies, self rating scales are widely used in
psychiatric assessment, because they are economical in terms of research time
and can be used repeatedly (Hamilton, 1987).
7.4.3. HAS INOSITOL ANY ROLE IN THE TREATMENTOF OTHER SIDE
EFFECTS OF LITHIUM?
Discontinuation of lithium therapy can be necessitated by the presence of
other side effects (Van Putten, 1975; Jamison et al, 1979). The effects of
inositol supplementation was also evaluated in relation to the most frequent
complaints - dry mouth, nausea, nocturia, thirst and tremor (Bone et al, 1980;
Vestergaard, 1983). In the patient group, dietary inositol failed to reduce the
intensity of any of these side effects .
Inositol did not seem to alter the subjective sensation of thirst and
nocturia in patients receiving long-term lithium therapy. Thirst is a common
adverse effect of lithium. King et al (1985) found that 67% of patients complain
of thirst despite the low levels of lithium on which they had been maintained, but
reported incidences rates have varied from 35 to 70% (Vestergaard, 1983).
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During lithium therapy, gastrointestinal symptoms, such as nausea,
coincide with the absorptive rise of serum lithium concentration (Schou et al,
1970). The incidence of nausea in long-term lithium therapy is estimated to be
about 10-30% (Bech et al, 1976; Campbell et al, 1991), but nausea has been
reported to be more frequent in non euthymic patients (Bone et al, 1980). Dry
mouth is present in 10 - 25% of patients receiving long-term lithium therapy
(Christodoulou et al, 1977; Ghose, 1977). Both symptoms were unaltered by
the administration of inositol.
Tremor is one of the most frequent side effects, with reported frequencies
varying from 33 to 65% (Vestergaard, 1983). Inositol did not significantly alter
this adverse effect in the patient group. Three aspects of lithium therapy have
been associated with tremor:
1) Lithium levels - tremor has been found in 45% of the patients with levels of
0.85 mmol/l, and in only 15% of patients with levels of 0.68 mmol/l (Vestergaard
et al, 1988). Our patient group had mean lithium concentrations of 0.66 mmol/l
which can be considered in the lower range, and consequently it could be
classified in the low incidence group.
2) Duration of lithium therapy - a reduction in the frequency of tremor has been
observed with prolonged lithium treatment (Schou et al, 1970), but this finding
has been disputed (Volk and Muller-Oerlinghausen, 1986). Tremor was not
reported by significant numbers in the patient group, however.
3) Simultaneous intake of lithium and other medications - it has also been
associated with tremor. It has been reported that tremor is more frequent in
patients taking lithium and antidepressants simultaneously (Schou, 1983). The
addition of inositol does not seem to influence tremor in patients taking lithium
alone or with antidepressants, but the small numbers of patients taking either
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lithium (4) or both medications (3) in this study does not allow further
conclusions to be drawn.
7.4.4. WERE SIDE EFFECTS ADEQUA TEL Y ASSESSED?
The conversion of adjectives which describe severity into a set of
numbers in arithmetical progression is a procedure which may be unacceptable
to statistical purists (Hamilton, 1987). It not only implies that the intervals
between one grade and the next are equal but they are also equal to the
interval between absent (counting as 0) and mild (counting as 1). However,
these procedures have been shown to be reliable (Hamilton, 1987). To assess
side effects, two methods have been used: observer scales and self rating
scales. In this study, side effects were not estimated by objective means; for
instance, the subjective complain of thirst was not confirmed by water intake
and nocturia was not confirmed by a 24-hour urine volume. One of the
limitations of subjective rating scales is that an assumption is made that different
patients will rate a symptom in a similar way. There has been agreement
between scores obtained by observer rating scales and self rating scales, at
least in depression (Williams et al, 1972). Thus, as a first step in the
assessment on the effects of dietary inositol, these self-rating scale
questionnaires seemed appropriate.
7.4.5. WAS ONE WEEKOF INOSITOL LONG ENOUGH FOR ITS EFFECTS
TO BE SEEN?
Patients were evaluated after only one week of inositol administration.
This period may be too short to observe any significant changes in the thyroidal
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and other side effects of lithium therapy. Addition of inositol for longer periods
might be necessary to observe any inositol action on the side-effects of lithium.
7.4.6. WERE THE INOSITOL DOSES SUFFICIENT?
The doses of inositol might have not been high enough to induce
alterations in the thyroid status or to affect the adverse effects of chronic lithium
administration. Based on the present knowledge, the doses of inositol used
should have been sufficient, since the normal dietary intake is only 300-900
mg/day in man (Clements et al, 1973). While the extent to which dietary inositol
is absorbed is still uncertain, it is apparent that large inositol loads result in
significant elevations of plasma inositol which persist for several hours in man
(Clements et al, 1973).
Good results have also been obtained in the treatment of diabetic
neuropathy with one gram of inositol for a fortnight (Salway et al, 1978). In
diabetics rats, the effects of inositol are contradictory; 1% inositol improved
motor conduction, but this improvement was abolished and experimental
neuropathy was exacerbated by a diet containing high concentration of inositol
(Salway et al, 1978). Consequently, there was a paradox whereby low
concentrations of inositol were associated with impaired nerve conduction and
high levels of inositol were harmful. The implication for this study is that the
dose, instead of being low, might have been too high.
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CHAPTER 8
LITHIUM AUGMENTATION IN ANTIDEPRESSANT RESISTANT
PATIENTS: A QUANTITATIVE ANALYSIS
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8.1. - INTRODUCTION
The concept that pharmacotherapy is an effective treatment for major
depression dates back from 1960's (Kraines, 1967). Some patients, however,
fail to respond to standard antidepressant treatment. Treatment resistant
depression (TRD), as this phenomenon is known, is a common and well-known
clinical problem (Nierenberg and White, 1990). While between 70% and 80%
of depressed patients respond within 3 weeks to a tricyclic antidepressant and a
further proportion may respond within another 3 to 4 weeks to a second-line
antidepressant (Klein et al, 1980; Nolen et al, 1988), between 10% to 30% of
patients with a major depressive illness do not respond to antidepressants
given at an adequate dose and for an adequate period of time (Keller et al,
1984; Nolen et al, 1988). For those patients who fail to respond to standard
antidepressant treatment, different strategies have been proposed: a)
optimization of the current regimen; b) substitution of a different treatment for
the current drug; c) combination of two different treatments, each having
different mechanisms of action; and d) augmentation of the therapeutic effects
of the current drug by a second drug (for comprehensive reviews see Extein,
1989; Goodwin, 1990). Augmentation differs from combination because it is
based on the assumption that the second drug will interact in a specific way with
the first drug to magnify the first drug effects. Unlike combination there is no
assumption that the second drug will have any independent therapeutic effect
(Extein, 1989). Therefore the interaction is greater than the sum of its parts
(potentiation) rather than equal to the independent effects of each drug
(additive).
208
Pharmacological augmentation of the effects of either re-uptake inhibitors
or MAOIs is an attractive second-line approach to the management of treatment-
resistant depressed patients. To achieve it, a variety of agents have been
proposed including L-tryptophan (Pare, 1963), stimulants (Wharton et al, 1971),
triiodothyronine (Goodwin et al, 1982) and reserpine (Price et al, 1987).
Positive results, however, have been most extensively reported with lithium
(Price, 1989).
8.1.1 LITHIUM AUGMENTATION
Himmelhoch et al (1972), were the first to describe the benefits of adding
lithium and antidepressants in the treatment of refractory depression.
Tranylcypromine was added to 21 tricyclic (TCA) unresponsive depressives. A
modest response was observed with the use of lithium alone, but when mono
amine oxidase inhibitor (MAOI) was added a fuller response evolved.
Lingjaerde (1973) showed, in a placebo controlled trial, that lithium enhanced
the antidepressant effects of TCA in depressive patients (resistant or not). Van
Putten and Sanders (1975) found that lithium improved the psychiatric status of
35 resistant cases. Neubauer and Bermingham (1976) obtained good results
in 20 endogenous depressives when lithium was given either alone or in
combination with TCA.
The first trial of lithium augmentation in resistant patients which attracted
real interest was published by de Montigny et al (1981). This trial was not the
first to report the augmenting effect of lithium but it highlighted the rapidity of its
action. It had widespread impact and certainly helped to established lithium as
the most studied potentiating agent in tricyclic antidepressant (TCA) resistant
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depression (Schou, 1990). In their study, Montigny et al reported that, of 35
unipolar depressives treated for three weeks with a TCA, all eight initial non
responders showed a dramatic improvement within 48 hours of the addition of
lithium. Six of the eight patients maintained this improvement even though
lithium had been discontinued. The importance of this trial warrants further
discussion. Firstly, the improvement with the addition of lithium may also have
reflected a delayed effect of TCA since 3 weeks is not sufficient time for the TCA
treatment to achieve its full therapeutic effect. A placebo effect was discounted
since the patients felt hopeless that another treatment would be of any help.
Secondly, the lithium and antidepressant interaction was considered to be
synergistic rather than an independent effect of lithium acting as an effective
antidepressant. This conclusion was unwarranted since the patients had not
been treated with lithium alone. This initial report was later confirmed by
another study (de Montigny et al, 1983). In this second study, 39 unipolar
depressed patients, unresponsive to TCA, had an average symptom reduction
of 62 %. The authors speculated that the mechanism of TCA effects might
involve enhancement by lithium of the serotonergic transmission (see Section
8.4.2). Initially, the justification for lithium augmentation was an empirical one,
but improved understanding of the mechanism of action of antidepressants
gave a better rationale for its use (de Montigny and Aghajanian, 1978).
There have now been 49 case reports and open studies (as listed in
Schou, 1990; Thase et al, 1989; Dinan and Barry, 1989) with some 387
patients being given lithium in addition to a tricyclic or MAOI. No less than 243
(62.7%) responded, to a greater or lesser extent, to the addition of lithium, often
within 48 hours as de Montigny et al (1981) had claimed. However, these
findings are derived from studies that are methodologically weak. While they
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may have been clinically convincing, they cannot be taken as conclusive
without controlled evaluation of lithium augmentation.
8.1.2. REVIEWS ON THE AUGMENTATION OF LITHIUM
The initial enthusiasm for lithium augmentation has been tempered by
the small number of controlled studies. To date there have only been seven
double-blind, placebo controlled trials of lithium augmentation in patients
resistant to a standard course of an antidepressant. Although traditional
qualitative reviews of the literature (Schopf, 1989; Schou,1990) have
supported the benefits of this approach, they also highlight the difficulty of
drawing firm conclusions based on the results of several small studies, none of
which is conclusive in itself and some of which are actually negative. These
reviews also concluded that the controlled studies carried out so far have
produced contradictory findings and call for further research in the area. Since
the efficacy of this approach to treatment-resistant depression is of considerable
clinical importance, and trials of an adequate size are difficult to perform, there
is a need to extract as much quantitative information from the existing data as is
possible. As described (Chapter 5), quantitative analysis can combine the
results of different trials of similar methodology to improve the quantitative basis
of our understanding of a given treatment effect, and it shifts the focus to effect
size rather than significance levels in evaluating therapeutic efficacy.
8.1.3. AIM
The objective of this study was to review the controlled trials of lithium




The importance of meta-analysis as a valid method to review and
integrate findings of different studies has been described in detail in Section
5.2.1.
8.2.1.1. Data Collection
An attempt was made to gather data from all controlled trials of lithium
augmentation in treatment resistant depression. The relevant references were
obtained using a computer-aided search and an informal search through Index
Medicus, recent journal reviews and published studies. Direct contact with
authors was made when details of interest were not available from the
published data (see Sections 5.2.1.1 and 5.4.6 for a comprehensive description
and discussion of these methods).
8.2.1.2. Inclusion Criteria
Only controlled studies were analysed and consequently, trials included
in the review were required to have random assignment of subjects to lithium or
placebo and double-blind evaluation. In addition, all studies included in this
analysis defined treatment resistant patients as those not responding to a
minimum of 150 mg /day of a tricyclic antidepressant (or an equivalent
antidepressant) given for 3 weeks or more. Patients were required to have a
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minimum lithium level of 0.4 mmol/L at the time of assessment of treatment
response (Blierand de Montigny, 1985; but see Section 8.4.9.6.). In spite of
the small number of subjects, a study by Kantor et ai {1986) was included in
order to analyse the maximum number of patients.
8.2.1.3. Exclusion Criteria
Two controlled studies were excluded. The first was by de Montigny et
ai (1983) due to its use of a lithium rather than placebo control group, and the
second was by de Cournoyer et ai (1984) which did not lend itself to this type of
analysis on account of its cross-over design and lack of sufficient raw data to
allow inclusion of the results of the first phase of the trial. In the study by Stein
and Bernadt (1988) the lithium levels in the double blind placebo-controlled
phase were < 0.4 mmol/l. It was worth analysing, however, because of the
relatively large number of patients studied. Effect sizes were, therefore,
calculated with and without this study.




Table 8.1 gives details of patient entry criteria and lithium duration,
lithium dose and serum lithium levels of the controlled trials analysed in this
meta-analysis. Either lithium or placebo was added to an antidepressant in all
studies. Most studies reported on unipolar patients, except for Schopf et al
(1989) where a third of patients were bipolar. All patients met either DSM III or
research diagnostic criteria (RDC) for major depressive disorder/episode.
There was a wide range of Hamilton Rating Scale for Depression (HRSD)
scores suggesting that the studies included patients with a wide spectrum of
illness severity. Whilst most patients had been on antidepressants for three
weeks or more, illness duration at the time of study entry is often unclear, with
the exception of the Zusky et al (1988) and Schopf et al (1989) trials which gave
a mean duration of six months. In Table 8.1 "Duration" refers to the period
during which the trial was double-blind and placebo controlled. This period
was different in most cases from the full duration of the trial which was 24 days
in Heninger et al {1983), 21 days in Zusky et al {1988) and 14 days in Schopf et
al (1989).
Table 8.2 shows the findings of these studies. Schopf et al (1989) and
Stein and Bernadt (1988) defined 'responders' as patients with a >50% drop in
HRSD and Kantor et al (1986) used a >40% drop in HRSD. Heninger et al
(1983) used a decrease of 2 or more points on the Short Clinical Rating Scale
(SCRS; a 15 point nurse rated 'psychopathology' scale) as their measure of
response, while Zusky et al (1986) defined 'responders' as those with a HRSD
score of 7 or less. Only half the studies were said to be 'significant' (p < 0.05)
but all the studies (except Stein and Bernadt,1988) showed a positive treatment
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effect as indicated by negative (0-E) values. Indeed, when pooled significance
intervals were considered, these results were unlikely to have occurred by
chance (p < 0.001).
Figure 8.1 illustrates both individual and pooled effect sizes and
confidence intervals. The pooled odds ratio is 0.14 with a 95% confidence
interval ranging from 0.05 to 0.44. The pooled (O-E) value is -6.5 which means
that 13 out of 34 patients or nearly 40% were 'responders' when treated with
lithium.
The chi square of heterogeneity was 2.5 (NS), indicating that the studies
did not significantly differ in the results obtained. When the study of Stein and
Bernadt (1988) was included, the chi square of heterogeneity was 8.5 giving a p
value of 0.005, thereby highlighting its methodological differences from the rest
of the studies. The pooled odds ratio increased to 0.29 with inclusion of this
study while the 95% confidence intervals became 0.12 - 0.73 which was a
significant increase in width, as would be expected.
The number of unpublished studies reporting negative results necessary
to reverse the conclusion that lithium is effective in augmentating the
antidepressant response in TRD would be 13 studies. If the study of Stein and
Bernadt (1988) is included, this would be reduced to 9 studies.
The power of the three studies which did not find significant differences
between lithium and placebo groups was calculated. The statistical power of
the studies of Kantor et al {1986), Zusky et a! (1988) and Stein and Bernadt
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(1988) were 0.17, 0.30 and 0.23, respectively. Thus, the possibility of missing a
true difference in these studies was at least 70% (in Zusky et al, 1988).
An updated version of the study by Stein and Bernadt (1992), using de
Montigny criteria of improvement, found a greater number of patients
responding when a higher dose of lithium was administered, demonstrated by
the fact that 15/34 (44%) patients responded to lithium 750 mg as compared to
6/34 (18%) who responded to lithium 250 mg. The mean lithium levels in the
250 mg group was 0.25 nmol/l and in the 750 mg group was 0.70 nmol/l. Their
conclusion was that lithium 750 mg is significantly better than lithium 250 mg
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The odds ratio with the 95% confidence intervals for individual and pooled data
from lithium augmentation studies. The left side (< 1.0) favours a positive effect
of lithium augmentation and the right side (>1.0) favours no effect. Some
studies have 95% confidence intervals which extended beyond 4.0 and are not
drawn in full (Kantor et al (1986) from 0.004 to 11.6; Zusky et al (1988) from
0.07 to 4.51; Stein and Bernadt (1988) from 0.22 to 15.8). 'Pooled' refers to











8.4.1. IS LITHIUM EFFECTIVE IN POTENTIATING ANTIDEPRESSANT
RESPONSE?
These findings suggest that lithium augmentation is effective in treatment
resistant depression. The pooled effect size is large and Figure 6.1 illustrates
the difference in emphasis between a statistical analysis based on significance
levels and one based on effect sizes. Thus, 'negative' studies (Kantor et al,
1986, Zusky et al, 1988, and Stein and Bernadt, 1988) are not statistically
significant but equally are not necessarily negative (in terms of effect size) as
would be reported in traditional reviews (Schopf, 1989 and Schou, 1990). As
highlighted in Chapter 5 the difference is not trivial because it leads to opposite
conclusions; that lithium is ineffective (because 'not significant'), or that it may
be effective (as shown by a favourable effect size) but the confidence interval is
too great to allow certainty. The uncertainty is also highlighted by the results
obtained in the analysis of heterogeneity between studies. No heterogeneity in
the studies' results was observed when four studies were combined (x2=2.5,
NS). However, when the study by Stein and Bernadt (1988) was included in
the analysis, the chi square of heterogeneity was significant (x2=8.5, NS). This
is a quantitative way of identifying aberrant studies.
The findings reported here are in agreement with previous narrative
reviews (Schopf, 1989; Schou,1990) which found a positive effect of lithium in
the potentiation of the antidepressant response in TRD patients. In summary,
this meta-analysis supports the practice of lithium augmentation in TRD. The
odds of remaining ill are reduced by 56% to 95% with lithium augmentation.
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There remains considerable uncertainty over the duration of treatment
necessary to promote and sustain the treatment response.
8.4.2. WHAT IS THE MECHANISM OFACTION OF LITHIUM AUGMENTATION
The exact mechanism of lithium's augmentation remains unclear. De
Montigny et al (1983) have suggested that lithium augmentation may result from
the cumulative enhancement of serotonergic transmission mediated by post
synaptic actions of tricyclic and presynaptic actions of lithium. Long-term
administration of tricyclics drugs induces a sensitization of postsynaptic
serotonin receptors in rat forebrain regions (de Montigny and Aghajanian,
1978).
Short-term administration of lithium seems to enhance serotonergic
transmission via a mechanism which is different from that in the tricyclics.
Several studies suggest that acute treatment with lithium causes a presynaptic
increase of the serotonergic function (Blier and de Montigny, 1985; Wood and
Goodwin, 1987) due to an increase in tryptophan uptake and its conversion to
serotonin (Knapp and Mandell, 1973). Moreover, long-term treatment
increases 5-HT release (Treiser et al, 1981). Lithium could enhance the
presynaptic sensitized 5-HT neurons by tricyclics. Since lithium addition failed
to modify TCA drug plasma levels it is unlikely that the improvement was due to
a pharmacokinetic interaction (de Montigny et al, 1983). Thus, it was
suggested that the rapid responses observed in depressive resistant patients
after receiving lithium was due to a dual effect enhancing serotonergic
transmission: a) sensitization of postsynaptic serotonin receptors with prior
tricyclic administration and b) subsequent presynaptic enhancement with short-
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term lithium administration (de Montigny et al, 1983). Lithium has been shown
to enhance post-synaptic behavioral responses (Goodwin et al, 1986).
Patients with affective disorders showed a different 5-HT homoeostatic
response to lithium treatment compared with healthy volunteers (Price et al,
1989). The prolactin response of the 5-HT function was increased by short
term lithium treatment in both groups whereas depressive patients on long-term
lithium treatment showed no difference (Glue et al, 1986; Price et al, 1989). A
more recent study, however, has shown that the addition of lithium to patients
taking tricyclics resulted in an increase in the prolactin response to L-tryptophan
after both four days and four weeks of treatment (Cowen et al, 1991). In
addition, several strategies to decrease brain 5-HT produced relapses in
depressed patients who improved with antidepressants (Treiser and Cascio,
1981). The reduction of plasma tryptophan in a diet free of the amino acid
precursor of serotonin (Delgado et al, 1990), and the administration of
parachlorophenylaline, which decreases 5-HT synthesis by inhibiting the
activity of tryptophan hydroxylase (Shopsin et al, 1976), resulted in a rapid
recurrence of depressive symptoms. Thus, a sustained serotonin function
seems to be essential for a continued antidepressant effect (Ontiveros et al,
1991). However, the antidepressant induced serotonin receptor sensitization
itself remains subject for continuing debate. No consistent alterations of
serotonin turnover following long-term antidepressant administration either in
animals or in depressed subjects was found (Charney et al, 1981).
Lithium also affects other neurotransmitter functions which may be
involved in the lithium augmentation process. According to another
neurotransmitter theory the therapeutic effect of antidepressants is linked to the
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down-regulation of beta-ad renoceptors in the brain (Banerjee and Kung, 1977).
Almost all TCA and MAOI have this action (Sulser, 1987). Long term lithium
treatment also reduces the functional activity of beta adrenergic transmission by
inhibiting the noradrenergic stimulated formation of cAMP at the site of adenyl
cyclase (Ebstein et al, 1980). It has been reported that the down regulation of
the density and agonist affinity of the cortical beta adrenoreceptors depends on
5-HT function (Sulser, 1987). Thus, the addition of lithium to restore deficient 5-
HT neurotransmission might indirectly lead to beta adrenoreceptor
subsensitivity (Sulser, 1987).
Finally, according to the cholinergic-adrenergic hypothesis of affective
disorders (Janowski et al, 1972) which proposed that a relative cholinergic
hyperactivity is present in depression, lithium might contribute to the
normalization of mood by a balancing effect on the two neuro systems. Lithium
at therapeutic concentrations has been shown to block cholinergic activation
(Worley et al, 1988).
It is generally accepted that alterations in a single neurotransmitter
cannot account for the therapeutic mechanisms of all antidepressants (Van
Praag et al, 1987; Lopez-lbor, 1988). In addition to the 5-HT/NE hypothesis it
also has been suggested that antidepressants properties may depend on the
effects of the second messengers involving G proteins and phosphoinositides
(Heninger and Charney, 1987). Thus, the exact mechanism of lithium's
potentiating action has not been established with certainty. However, from the
available evidence, lithium augmentation seems to be clearly implicated in
altering serotonergic mechanisms (Heninger et al, 1983).
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8.4.3. HOWSOON IS A RESPONSE OBTAINED AFTER THE ADDITION OF
LITHIUM?
Some of the uncontrolled studies confirmed de Montigny's initial claim of
a dramatic improvement within two days after the introduction of inositol (Joyce
et al, 1983; Louie and Meltzer, 1984; Nelson and Byck, 1982), while other
uncontrolled studies reported a more gradual response, that is, 1 to 6 weeks
(Birkheimer et al, 1983; Roy and Pickar, 1985; Schrader and Levin, 1985;
Price et al, 1986; Thase et al, 1989). It is questionable whether a response to
lithium augmentation given for only 48 hours can be regarded as fully
meaningful. The rationale for the original design of the de Montigny et al
(1981) trial was based on the hypothesis that chronic administration of tricyclic
antidepressants leads to increased sensitivity of forebrain neurons to 5-HT and
that the acute administration of lithium releases 5-HT onto these receptors to
form the basis of antidepressant efficacy. This acute presynaptic enhancement
of transmitter release has been shown to occur at lithium concentrations >0.4
mmol/1 (Blier and de Montigny, 1985). Some authors do report a therapeutic
effect after 48 hours of lithium augmentation at appropriate concentrations (de
Montigny et al, 1983; Cournoyer etal, 1984; Schopf et al, 1989) but others
report little or no effect until one week after commencement of lithium (Heninger
et al, 1983). Schopf et al (1989) report an increase in the proportion of
responders from about 20% responding at 48 hours, to 40% responding within
two weeks. But higher rates of response have also been reported. Ontiveros
et al (1991) have shown that in 30 melancholic patients resistant to desipramine
57% improved with the addition of lithium.
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The rapid effect of lithium augmentation is evidence against an
independent "antidepressant effect" of lithium since in most studies several
weeks are required before any improvement in depression can be detected (de
Montigny et al, 1983).
8.4.4. WHO RESPONDS TO LITHIUM AUGMENTATION?
Specificity of lithium augmentation for bipolar depression has been
claimed (Nelson and Mazure, 1986). However, good results have been found
in some uncontrolled studies which included only bipolar patients (Roy and
Pickar, 1985) as well as other uncontrolled studies which included only unipolar
patients (Nelson and Byck, 1982; Birkhimer et al, 1983; Thase et al, 1989).
Schopf et al (1989) included bipolar patients who, when depressed,
appear to show a response to lithium alone. This could have increased the
chance of a spurious positive response to lithium augmentation, but the ratio of
responders to non-responders in the unipolar and bipolar groups is similar at
one week, so that the response to lithium does not appear to have been biased
by the inclusion of bipolar patients. This similarity of response to lithium
augmentation in unipolar and bipolar patients has also been reported by Price
et al (1986).
The clinical pattern of improvement seems to have an 'all or none'
feature. In studies done by de Montigny and associates most patients fell either
into the 'no change' or 'marked improvement' groups with few showing mild or
moderate improvement (de Montigny et al, 1988). This finding, however, has
been disputed by Price et al (1986) who found that the clinical response to
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lithium augmentation occurs along a clinical spectrum rather than in a simple all
or none fashion.
8.4.5. IS LITHIUM POTENTIATION SPECIFIC TO TRICYCLICS?
One of the most interesting aspects of lithium addition in resistant
depression is that it can potentiate not only TCA but a large number of other
antidepressants treatments (de Montigny et al, 1988). Patients resistant to
MAO inhibitors, tetracyclics, serotonin re-uptake blockers, and other
antidepressants improved with the addition of lithium (de Montigny et al, 1988).
The hypothesis that the rapid clinical response after the addition of lithium with
tricyclic treatment resistant depression is based on the interaction of lithium
induced presynaptic serotonergic enhancement with postsynaptic sensitization
(de Montigny et al, 1983). Antidepressants that either inhibit monoamine
oxidase, e.g. phenelzine, or selectively block serotonin re-uptake, such as
indalpine, do not cause postsynaptic sensitization to serotonin. However, since
these drugs desensitize inhibitory presynaptic serotonin autoreceptors, the net
effect is to enhance serotonin neurotransmission (Price et al, 1986). Thus,
lithium should enhance the efficacy of these drugs by a different mechanism
from that of tricyclics.
8.4.6. SHOULD LITHIUM AUGMENTATION ALWAYS BE TRIED IN
TREATMENT RESISTANT DEPRESSION?
Different strategies to deal with treatment resistant depression have been
proposed (Extein, 1989; Goodwin, 1990). There is no consensus, however,
concerning which strategy should be adopted in treatment resistant depression
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or what order these strategies should be presented. A first approach to
treatment resistant depression (TRD) may be the optimization of the treatment
through a therapeutic trial in which the doses and duration of treatment are
adequately monitored. This strategy is more conservative and helps to
establish whether a patient who is considered resistant to therapy is in fact not
adequately treated. A common step if optimization is not successful is
substitution (Extein, 1989). Adding another drug to the therapeutic regimen
(combination or augmentation) seems to be a logical step when substitution
does not work (Goodwin, 1990). Among the possible alternatives of
augmentation, lithium is probably the most common. There is, however, little
research done on which strategy is preferable for specific diagnostic groups.
Thus, the available data do not permit the categorical recommendation of when
lithium should be tried in TRD.
8.4.7. METHODOLOGICAL CONSIDERATIONS ABOUT REFRACTORY
DEPRESSION
8.4.7.1. What is an Adequate Definition of Refractory Depression?
The question poses a major methodological problem in studying
refractory depression. This problem was addressed at the World Psychiatric
Association symposium on therapy resistant depression in 1974. A distinction
was made between absolute and relative treatment resistance. Absolute was
defined as failure to respond to 150 mg/day of imipramine or the equivalent
after 4 to 6 weeks and relative was defined as the failure to respond to less than
150 mg/day. The implication of this definition was that relative treatment
resistance was due to under treatment of depression. The distinction between
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absolute and relative treatment resistance appears to be crucial for both
methodological and clinical reasons. The evidence from several studies points
to under treatment as the crucial variable conferring refractoriness to depressed
patients (Schou and Weeke, 1988; Goodwin and Jamison, 1990).
In 1984, Goodman and Charney proposed another definition for
refractory depression, being an episode of major depression, not secondary to
a medical or drug induced condition, which fails to respond or sustain a
response, to an adequate trial of an antidepressant drug of established efficacy
for 4 weeks at a dosage considered therapeutic. However, a number of points
are to be considered in any definition of TRD: a) how severe must the
depression be after an adequate trial of treatment to be considered as
resistant? and b) what constitutes adequate treatment for each antidepressant?
(Nierenberg, 1990).
The most widely used definition of full antidepressant response in the
psychiatric literature is a decrease greater then 50% in the Hamilton Rating
Score for Depression (Endicott et al, 1981). The problem with this definition is
that patients with very high scores will still be depressed even after a decrease
of 50% in their HRSD scores. An alternative is to set an upper limit on the
Hamilton score , e.g. a maximum score of seven on the 17-item version to be
considered improved (Endicott et al, 1981). Another approach is to report both
the proportion of patients who have a 50% decrease in their Hamilton scores
and the proportion of patients whose Hamilton scores are below the upper limit
as suggested by Zimmerman et al (1985).
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Different definitions of adequate treatment have been proposed (Keller et
al, 1986-a; Goethe et al, 1988; Sackheim et al, 1990). These criteria integrate
antidepressant dose, duration and blood levels. Surveys have demonstrated
that antidepressants are often used in sub therapeutic doses (Quitkin, 1985).
There is some suggestive evidence that patients should be treated with
adequate doses of antidepressants, e.g. 300 mg of imipramine or the equivalent
for tricyclic antidepressants, before concluding that the medication is ineffective
(Guscott and Grof, 1991). However, there is always the problem of side effects
induced by high doses of antidepressants which may prevent the tolerance of
these doses in patients.
Inadequate length of treatment emerges as a major factor along with
under dosing in the treatment of depression. Some patients show signs of
improvement as early as 3 to 10 days after initiation of the treatment (DiMascio
et al, 1979), but others begin show improvement after two or three weeks of
therapy. Taking this fact into consideration, most authors recommend at least 4
weeks of treatment as a minimum therapeutic trial (Keller et al, 1986-a; Goethe
et al, 1988; Sackheim et al, 1990).
Tricyclic antidepressant serum monitoring is indicated in patients who fail
to respond to treatment despite adequate doses (Hollister, 1979). However,
there is no evidence to demonstrate that the use of serum monitoring in routine
clinical practice improves outcome (Guscott and Grof, 1991).
There is some evidence that refractory depression is more frequently
associated with variables involving the diagnostic (primary vs secondary
depression) and treatment (e.g., adequate doses and duration) processes
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rather than the patient. Although, there is also ample evidence that some
patients are more treatment resistant than others, the degree of the resistance
(absolute or relative) is often unclear (Guscott and Grof, 1991).
8.4.7.2. Was the Diagnosis Correct?
When confronted by a patient defined as having treatment refractory
depression, the possibility of misdiagnosis should be considered. The
possibility that there is a primary non affective disorder coexisting with a
depressive syndrome should also be considered (Guscott and Grof, 1991).
The studies included in this meta-analysis apparently used standard
classificatory systems (DSM III and RDC) to diagnose depressed patients .
8.4.7.3. Were Patients Compliant with Treatment?
Noncompliance may be an important factor in patients defined as
refractory (Guscott and Grof, 1991). It is important to distinguish a non
compliant patient from a treatment resistant one (see Section 4.4.2. for a
detailed discussion of the clinical implications of compliance). In outpatients,
the problem of non compliance is especially highlighted (Nierenberg and White,
1990).
8.4.7.4. Were Side Effects Important?
The common occurrence of side effects when high doses of TCA are
used is a considerable obstacle to the attainment of adequate therapeutic
dosage (Schatzberg et al, 1983).
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8.4.7.5. How was Outcome Measured?
Some studies have made a distinction between improvement of
symptoms and psychosocial functioning. It was claimed that antidepressants
have more effects on specific symptoms but psychotherapy has more effects on
of psychosocial functioning (Klerman et al, 1974; Weissman et al, 1981).
Rating scales have been the standard means of assessing improvement (for a
detailed discussion on clinical improvement (see section 5.4.10).
8.4.7.6. Is There a Coexisting Medical or Psychiatric Disorder?
Refractoriness to antidepressant treatment was found to to be associated
with chronic medical problems and ongoing alcohol abuse (Akiskal, 1982;
MacEwan and Remick, 1988). Therefore, it is essential to exclude these
variables as possible causes of the refractoriness of depression.
8.4.8. LIMITA TIONS OF THE LITHIUM AUGMENTA TION STUDIES
The interpretation of these trials is confounded by some methodological
issues which need to be be taken into consideration regarding the role of




The limitation of small numbers in all the studies is only partly overcome
by their combination to give a grand total of 99 patients in all (if Stein's study is
included). Since probably up to 30% of patients treated with a tricyclic
antidepressant do not respond, this remains a relatively disappointing total.
Kantor et al (1986) suffered a large number of drop-outs (six patients) and due
to the resulting small numbers (4 on lithium, 3 on placebo), this study taken on
its own, was entirely inconclusive.
8.4.8.2. Definition
Most studies included in this meta-analysis used the de Montigny et al
(1981) definition of treatment resistant depression (>150 mg/day of a tricyclic
antidepressant given for 2/3 weeks leading to a Hamilton score decrease of
less than 40% from the pretreatment value). Many clinicians would favour the
World Psychiatric Association definition (1974) which requires that a patient be
treated for between four and six weeks with a tricyclic antidepressant at a dose
greater or equal to 150 mgs/day, in order to be defined as treatment resistant.
Nevertheless, it is doubtful that many clinicians would in practice wait more than
4 weeks before changing to another treatment if no response was seen.
8.4.8.3. Duration
Most trials had a duration of prior antidepressant treatment of three
weeks. A three week antidepressant trial has been considered to be too short
for the antidepressant drug to show its effect fully (see Section 8.4.9.1). The
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lithium augmentation period was in some studies, e.g. Kantor et al (1986), too
short (48 hours). This short period allowed the detection of only those patients
who had a fast response to lithium augmentation. As response to lithium
augmentation is variable a three week trial has been proposed as an adequate
period to assess full benefit (Price etal, 1986).
8.4.8.4. Different Populations
There is the possibility that different populations of depressed patients
might have been studied. A prolonged mean illness duration in some studies
(Zusky et al, 1988; Schopf et al, 1989) may mean that different studies have
included different patient populations.
A second aspect for consideration is the inclusion of bipolar and unipolar
depressives. It has been reported that lithium augmentation is more effective in
bipolar depression than in unipolar depression (Nelson and Mazure, 1986). All
trials included only unipolar patients, with the exception of the study by Schopf
et al (1989) in which one third of the sample was bipolar. Therefore, it is
premature to comment on this aspect until further controlled studies are carried
out.
A third point refers to the inclusion of patients with double depression
(patients who do not have clear cut episodes of depression but are dysthymic
continually). If patients had double depression (Keller et al, 1982; Klein etal,
1988) it was not stated in any of these studies.
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8.4.8.5. Design
Most of the trials used the same design as de Montigny et al (1981), that
is adding lithium to an antidepressant trial of only a few weeks' duration. This
has been claimed to be methodologically flawed because it leaves open the
possibility that improvement shortly after the introduction of lithium may reflect
delayed effects of pre-existing antidepressant treatment (Nierenberg and White,
1990). The allocation of patients was non randomized in the studies of
Heninger et al {1983) and in Stein and Bernadt (1988).
8.4.8.6. Doses and Serum Levels
In most of the studies, lithium doses and serum levels were within the
accepted therapeutic range with the exceptions of that of Stein and Bernadt
(1988) in which serum levels were well below the therapeutic limits (mean level
of 0.23 mmol/l), and that of Zusky et al (1988) in which low lithium doses and
low steady state plasma concentrations (0.10 -0.80 mmol/l) were observed.
However, de Montigny et al (1981) reported that low plasma levels of lithium
(0.4 mmol/l) were sufficient to induce potentiation of TCA drugs. Other studies
have reported good results in antidepressant augmentation with plasma lithium
concentrations even lower, 0.1 to 0.2 mmol/l (Kushnir, 1986; Madakasira,
1986). The available evidence, however, does not favour a 'low dose strategy'.
8.4.8.7. Severity of Depression
While illness severity is said not to influence response to lithium
augmentation (de Montigny et al, 1983; Schopf etal, 1989) the majority of the
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patients included in this analysis were moderately depressed (total mean
Hamilton score, 24.4). It cannot be assumed that the efficacy of lithium
augmentation would be as great in severely depressed patients and thus the
range of patients to which the favourable effect of lithium applies remains
uncertain.
8.4.8.8. Use of Other Drugs
Other problems with the Schopf et al (1989) study included the use of
small doses of neuroleptics in a number of patients, and less than adequate
doses of antidepressants in others (although tricyclic serum levels for these
patients were reported to be within the therapeutic range).
8.4.8.9. Outcome
A binary outcome scale, required for the Mantel-Haenszei method, may
appear too crude to assess an acute treatment such as lithium augmentation.
However, it appears to reflect clinical decision-making reasonably well. The
other advantage lies in the simplification of the raw data for direct analysis; this
minimises methodological bias but allows optimal use of the available data by
pooling all study results.
Individual studies contain other minor variations that may limit their
comparability. Heninger et al (1983) used a nurse rating scale, the SCRS, to
assess outcome thus making their results less comparable with those of other
studies. They reported, however, unambiguously the favourable clinical
outcome of the study.
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8.4.9. LIMITATIONS OF THIS META ANALYSIS
A detailed discussion of the limitations of meta-analysis is found in
Appendix 5.2. In this section, the drawbacks of quantitative analysis will be
related to the lithium augmentation trials. Firstly, meta-analysis is probably the
only way to get adequate numbers of patients to estimate an average effect size
in lithium augmentation trials. Secondly, the use of simple trials designs
should help the interpretation and pooling of data. Thirdly, the need for
randomization in future trials must be emphasized. Finally, big numbers of
patients can help to stratify patients and therefore provide a more specific
interpretation of the data.
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CHAPTER 9
CONCLUSIONS AND FUTURE RESEARCH
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Study 1 - LITHIUM PROPHYLAXIS AND DISCONTINUA TION IN UNIPOLAR
DEPRESSION: EFFICACY, WITHDRAWAL SYNDROMEAND
SEASONAL PATTERN OF READMISSION
The main practical conclusions of this study are firstly that patients who are
doing well on lithium should be encouraged to persevere with it and secondly that
the presence of a withdrawal syndrome after lithium discontinuation in unipolar
depressed patients is not supported. Additionally, there is no evidence that
readmission to a hospital in unipolar depressed patients on and off lithium is
increased in autumn-winter or spring-autumn. This study provides further
confirmation that lithium is of prophylactic benefit in unipolar depressive illness and
it should strengthen the intention to treat recurrent depressive illness with lithium in
our everyday clinical practice.
FUTURE RESEARCH
There are a number of other questions related to the use of lithium in
unipolar depression that still need to have an adequate answer. These include:
In 1975, Schou and Thomsen stated that there was no agreement on how
long lithium prophylaxis should be continued and no established criteria existed for
discontinuing lithium treatment on the basis of their treatment response. Sixteen
years later these points have not yet been satisfactorily answered and further
research is needed. Similarly, there are no clear guidelines on when lithium
prophylaxis should start.
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What are the predictors of recurrence and discontinuation? Preventive
treatment should continue for those patients who have a high risk of recurrence but
up to the moment no specific risk variable, such as biologic markers or personality
traits, has been identified that would predict which patients require longer courses
of maintenance treatment, nor any variable has been associated with
discontinuation of lithium therapy. Similarly, the characterization of patients who
fail to comply with lithium needs to be better investigated.
Does one relapse mean that lithium should be stopped? This question is
still unanswered.
Is lithium less effective when it is introduced for the second time? The late
non-response to lithium treatment may represent an important area of research
from both the biological and clinical viewpoint. It also highlights the fact that the
response or non-response of lithium may fluctuate instead of being a permanent
feature of the illness with some patients showing inconsistent responses to lithium
(Carroll, 1979). A similar point is argued by Maj et al (1989-b) who has indicated
that lithium in bipolar patients may be less effective if it is reintroduced after being
discontinued, and poses the question whether this pattern also holds in unipolar
depression.
The search for biological features associated with withdrawal syndrome is in
the early stages. At the moment, we can only speculate about the possible
mechanism of the withdrawal syndrome in bipolar patients discontinuing lithium.
This topic is dealt in the hormone discontinuation study in Chapter 6.
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The study of seasonality patterns in affective disorders needs to be
addressed considering the distinction between unipolar and bipolar affective
disorder and the effects of medication. Seasonality data from the southern
hemisphere and from regions near the equator are still missing. Both issues
should be subjects of future research.
Group therapy and social support in lithium maintenance therapy have been
associated with a positive effect on the posthospital course of bipolar patients
(Davenport et al, 1977; O'Connell et al, 1985). The effects of psychotherapy,
group therapy and social support on the adherence to lithium therapy and on the
outcome after lithium discontinuation in unipolar patients have not yet been fully
explored.
Personality disturbances were found in 48% of recurrent unipolar depressed
patients and they were able to distinguish with 65% accuracy patients who
responded normally and those who responded more slowly (Pilkonis and Frank,
1988). A poor response to antidepressants has been observed in patients with
abnormalities of personality (Bielski and Friedel, 1976; Shawcross and Tyrer,
1985). The assessment of the importance of personality variables in the outcome
of lithium prophylaxis and discontinuation is another area not yet fully investigated.
Relapse may be defined as a symptomatic exacerbation in a patient who
has responded to treatment but not yet fully remitted or an aggravation of symptoms
in a patient who has not been well for a sufficient length of time to be declared fully
recovered (Thase, 1990) while recurrence is the emergence of a new episode in a
patient who has fully recovered from a prior episode (Thase, 1990).
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Study 2 - LITHIUM TREATMENTAND PROPHYLAXIS IN UNIPOLAR
DEPRESSION: A META-ANALYSIS
The magnitude of the effect of lithium in controlled studies of prophylaxis
is fully compatible with the observations in uncontrolled studies which in the
past have received much criticism, for example, Baastrup and Schou (1967)
and Angst et al (1970). In all studies, treatment with lithium appears to improve
the rate of favourable outcome from 30 to 70%. To summarize, the existing
literature strongly supports the value of lithium in prophylaxis of recurrent
unipolar depressive illness. This effect size is clinically significant because
rates of recurrence in unipolar illness are high. However, no advantage can be
claimed for lithium over other antidepressants, particularly the older tricyclic
drugs, and the value of lithium alone in acute treatment of depression remains
uncertain. The uncertainty remains because remarkably few patients have
ever been randomized in trials of acute lithium treatment.
There is a need to put in perspective the evaluation of clinical trials and
their comparison with uncontrolled clinical studies and data from audit. The
techniques employed here offer considerable advantages and deserve to be
much better known. It is difficult, with hindsight, not to reach the conclusion that
lithium's value in the prophylaxis of depression was clinically apparent to the
workers who first used it. Their quantitative estimates of its value from
uncontrolled studies would appear not to have been exaggerated. An
argument about the quantities rather than the qualities exhibited by the
research might have been more fruitful at the time. There is certainly no reason
not to use quantitative methods to address such controversies now and in the
future.
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Meta-analyses will not necessarily give a different answer to a research
review, but it should provide a better quantified answer. By showing the results
of the studies and how the analysis was done, meta-analysis allows the reader
to draw his or her own conclusions about the validity of the conclusions.
FUTURE RESEARCH
It is recommended that acute depression should be separated in bipolar
and unipolar depression and the use of lithium be analyzed in each disorder.
The treatment of acute bipolar depression has been not properly explored . In
fact, there has been no placebo-controlled study of any other drug other than
lithium in bipolar depression during the past 20 years. A major problem is the
practice by the pharmaceutical industry of testing drugs for depression primarily
in unipolar patients (Prien and Potter, 1990). The effectiveness of lithium in
bipolar depression is less robust than for mania. A review by Fieve and
Peselow (1983) found that 65 to 85 patients could be classified as having
"partial improvement," but the clinical significance of this term was not clear.
Future studies should assess whether the combination lithium plus
antidepressants has unequivocal advantages over lithium alone. Forth coming
trials should include not only measures of recurrences rates but also include
evaluation on the severity and duration of the episodes.
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Study 3 - TSH, T4 AND CORTISOL AFTER LITHIUM DISCONTINUATION
IN BIPOLAR AFFECTIVE DISORDER
There was no significant difference in thyroid and Cortisol status of
bipolar patients who relapsed and those who continued well after lithium
withdrawal. Thus, the hormonal consequences of lithium discontinuation can
not explain clinical relapse.
FUTURE RESEARCH
The development of techniques for the in vivo measurement of central
nervous system thyroid hormone concentrations and effects is essential in order
to understand how peripheral hormone metabolism is related to CNS function.
The central effects of pharmacotherapeutic drugs, such as lithium, and
the modulation on these effects exerted by the thyroid status should be
investigated more extensively.
There is the need to study the thyroid status in unipolar and bipolar
patients who had never been on drugs. This population would permit the
separation of the effects of the illness on the thyroid function from those of the
medication.
The relationship between subtle thyroid hypofunction and affective
disorder should be examined in detail in order to assess its importance in the
outcome of affective illness.
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How peripheral hormone metabolism is associated with CNS
metabolism and the importance of the specific enzymes in this process are two
topics deserving further investigation.
The short period of observation does not permit comment on the
hormonal changes in the medium and long term after lithium discontinuation.
However, this is an important question that needs to be addressed
Study 4 - THE ROLE OF DIETARY INOSITOL ON THE THYROIDAL AND
OTHER SIDE-EFFECTS OF LITHIUM
The main conclusion of this study is that dietary inositol administered for
short periods of time in euthymic bipolar patients does not seem to affect thyroid
function nor other side effects of lithium therapy. Inositol does not seem to
mimic lithium discontinuation. To date, there is no evidence that inositol is
useful in the management of the adverse effects of of lithium.
FUTURE RESEARCH
The evidence available for phosphatidylinositol turnover has ben
provided mainly by laboratory and animal experiments. In humans
phosphatidylinositol cycle has been studied in red blood cells and platelets
(Downes and Mitchell, 1982). Enhanced phosphatidylinositol turnover,
however, has not been shown in human tissues or cells. Techniques of in vivo
31P nuclear magnetic resonance spectroscopy which enable the detection of
lithium induced increases inositol 1 phosphate (Renshaw et al, 1986) may
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allow, in the future, the assessment of differences in the phosphatidylinositol
cycle in humans (Agam and Livne, 1989).
The phosphatidylinositol metabolism in human thyroid needs to be
clarified and an accurate description of the role of phosphatidylinositol in
hormonal secretion must be made. The importance of non-PI mechanisms in
thyroid secretion need to be adequately established.
The effects induced by lithium on phosphatidylinositol breakdown in the
thyroid gland need to be assessed comprehensively.
Study 5 - LITHIUM AUGMENTA TION IN ANTIDEPRESSANT RESISTANT
PATIENTS: A QUANTITATIVE ANALYSIS
The findings suggest that lithium augmentation is effective. The pooled
effect size is large and the results illustrate the difference in emphasis between
a statistical analysis based on significance levels and one based on effect size.
Thus "negative" studies (Kantor et al, 1986; Zusky et al, 1988; Stein and
Bernadt, 1988), are not statistically discriminating but, equally, are not
necessarily "negative" (in terms of effect size) as would be reported in traditional
reviews (Schopf, 1989; Schou,1990). The difference is not a trivial one
because the analyses lead to opposite conclusions, that lithium is ineffective
(because "not significant") or that it may be effective (as shown by a significant
effect size) but that the confidence interval is too great to allow certainty. The
present review supports the practice of lithium augmentation in treatment
resistant patients. The odds of remaining ill are reduced by between 56% and
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95% with lithium augmentation. This appears to be a worthwhile benefit. The
present data does not offer clues as to who will respond and it is not known how
long to continue treatment for. Finally, it is not known what the long-term
prognosis of these patients is.
FUTURE RESEARCH
More research is needed on the importance of diagnostic and treatment
variables in the phenomenon of refractory depression (Keller et at, 1986-b).
There has been no consensus of which strategy to adopt to treat
refractory depression if optimization (increasing the dosage and duration) of the
current treatment fails. Three possibilities arise: substitution of a different
antidepressant, combination of two different treatments, or augmentation of the
initial or primary antidepressant by adding a second drug that enhanced the
antidepressant effect of the first drug (Nierenberg et at, 1990). If augmentation
is to be preferred, two related point need to be fully explored: firstly, to
determine which modality of augmentation should be prescribed - lithium,
triiodothyronine, L-tryptophan, stimulants or reserpine, and secondly, to assess
whether there is any difference in efficacy of different antidepressants after
lithium augmentation (Nierenberg et at, 1990).
Some studies have investigated the long term outcome of patients with
refractory depression, for example Nierenberg et al (1990) showed that there
was a good outcome in half of their sample within three years after lithium
augmentation, additional research on this topic is needed, however, in order to
clarify the roles of lithium and primary antidepressants in the maintenance
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treatment of acute responders of lithium augmentation and more specifically to
determine the duration of treatment with lithium necessary to promote and





The columns in the life able are calculated in the following way:
Column (A) presents the number of patients who were still well at the beginning
of the indicated three month interval.
Column (B) tabulates the number of patients who were last observed well in the
particular interval.
Column (C) shows the adjusted number of patients studied in the various
intervals. If N denotes the number of patients who began the interval well and
D the number last seen well during the interval, then only N-D were capable of
being observed during the full interval. D is counted as D/2 under the
assumption that they were last observed in the middle of the interval, therefore
column (C) equals to N - D/2.
Column (D) represents the number of patients who were readmitted during the
interval. If R denotes the number of patients being readmitted in the interval,
the number beginning the next interval well is N - (D+R).
Column (E) contains the interval-specific probability (p) of remaining well. It
represents the probability of a patient who was well at the start of the interval
will be well by the end of the interval..
Column (F) indicates the cumulative probability (P) of remaining well at he end
of an interval. It is calculation by the successive multiplication of each specific
interval probability of remaining well. The value of (P) in any interval is given
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by the product of the corresponding value of (p) and of all preceding values of
(P)-
Column (G) displays the 95% confidence interval associated with each
cumulative probability of remaining well
2) CALCULATION OF THE 95 % CONFIDENCE INTERVALS
The estimation of the 95% confidence limits is given by the cumulative
probability of the interval plus minus 1.96 (from the tables of the standard
normal distribution) multiplied by the standard error of the interval. Consider,
for example the estimation of the the interval 10-12 months of the discontinued
group after lithium withdrawal, its cumulative probability is equal to 0.66 and its
standard error is calculated as follows:
Var(P12) = (0.66)2 {(0.18/(39.5 x 0.82) + (0.13/(31.5 x 0.87) +
(0.08/26.5 x 0.92)}
Var(P12) = 0.076
thus the standard error is equal to 0.15 and the 95% CI = 0.66 ± 1.96 x 0.15, or
the interval from 0.51 to 0.81, assuming that all dropouts have failed.
3) COMPARISON OF TWO SURVIVAL CURVES
To compare two samples at all points simultaneously a chi-square
procedure due to Mantel (1966) is used. The result of this chi-square which
incorporates a correction for discontinuity is then referred to tables of chi-square
with one degree of freedom to test for the significance of the difference between
the two series of probabilities. Let Ni and N2 be the two adjusted number of
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patients, pi and P2 the conditional probability of remaining well and £ their
weighted average, i.e., p* = (Nixpi + N2xp2)/(Ni + N2). The following statistics
is used:
x2= III KNj_x NaVlNj. tMail*feuoaU - iffl2
X {[p*(1-p*)N,N2]/(NiN2-1))
APPENDIX4.2.1























































































































































































































































































































































































































































































































































































































































































































































































































Calculation of Effect Sizes in Controlled Studies
Odds ratio are estimated by dividing the observed minus expected (O-E)
number of failures in each group and by the variance.
failure success total
treated a b a+b
control c d c+d
total a+c b+d N
The expected number of failures in the treated group ( E ) is given by:
e = (a+c) x (a+b)
N
where (a+c) = number of patients failing (or not improving) in the treated
and control group.
(a+b) = number of patients in the treated group.
N = total number of patients in the trial.
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Then, (E) is contrasted with the observed number of failures in the treated
group (O). If treatment was wholly without effect, the quantity (O-E) would differ
only randomly from zero with variance (V) and standard error (VV) given by:
V = (a+cf x fb+dl x (c+dl x (a+b)
N2X (N-1)
For 'i' individual studies, the sum X(0-E)j would differ randomly from zero
(with variance equal to the sum of individual variances , X (Vj) if treatment were
without effect. X(0-E)j will be negative if treatment is effective.
The odds of failure of patients treated with lithium relative to the odds of
failure of patients receiving another treatment is given by exponential ((0-E)/V)
with 95 % confidence intervals ± exp. (1.96 /VV) (Yusuf et at, 1985). An odds
ratio equal to 1.0 means no treatment effect, below the unity favours the
treatment and greater than the unity favours the comparing treatment. An odds
ratio of 0.9, e.g. suggested a reduction of 10% in the odds of failure with lithium.
Each (0-E)/V and the X((Oj-Ej)/VXVj) is assumed to be normally distributed.
The calculation of the chi-square of heterogeneity is given by the
difference between the total chi-square and the chi-square of association with
N-1 degrees of freedom where N is the number of studies, or:
X((Oj-Ej)2/Vj) - (X (Oi - Ej))2/XVj in 'i' studies
Calculation of Effect Sizes in Uncontrolled Studies
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The procedure to calculate the effect sizes of uncontrolled studies involve
the combination of individual Z scores for each study from the one-tailed
significance equivalent to that declared in the study. These Z scoreswere
combined to derive an overall probability of effect (XZj)WN.where Zis the score
in standard deviation units corresponding to the level of significance (one
tailed) given in any study and N is the number of studies. Effect size in these
studies is calculated by transforming published statistics into a common
measure such as Pearson's r. From this an estimate of effect size can be made
by a transformation of r into Fisher Z (Zr). The mean for N studies, Z'r = (XZr)/N,
is transformed back to r to summarize the overall effect size. The studies were
also compared to ensure that the pattern of results appears homogeneous.
This was performed for both Z values (L(Z -Z')2) and effect size (X(Nj-3) (Zrj-
Z'r)2), both are distributed as chi-square with N-1 degrees of freedom, where N
is the number of studies.
Calculation of Fail Safe N
The Z values, previously calculated, can also be used to estimate a so-
called "fail safe N", or the number of unpublished statistically non-significant
studies that would invalidate the overall trend of the published findings (Cooper,




where n = number of studies required to reverse conclusion
k = number of studies
Z' = mean of z
Calculation of Statistical Power
Power was calculated according to the formula described by Cohen
(1977) for the estimation of effect size and power in contingency tables:
W=V{X(Proportion of the observed number of events in each cell - the
proportion of the expected number of events in that cell)2/ the proportion of the
expected number of events in that cell}. W varies from zero (when the paired
proportions in all cells are equal and hence there is no effect and the null
hypothesis is true) to one (when the difference in proportions is maximum).
The result was referred to Cohen (1977) with level of significance equals to 0.05
and one degree of freedom. When the number of the sample was below 25
subjects tables by Detsky et al {1985) were used.
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APPENDIX 5.2
WHATARE THE DIFFERENCES BETWEEN A META-ANALYSIS AND A
TRADITIONAL REVIEW?
Traditional reviews use the narrative or qualitative method. The
reviewer critically analyzes the selected studies, summarizes their results and
assesses the effectiveness of the treatment. The narrative review may be
biased in at least five ways: a) selective inclusion of studies, where some
studies may be excluded on "methodological" grounds, especially if they views
which are opposite to those of the reviewer; b) studies may also be excluded
because the theoretical constructs are considered irrelevant; c) crude and
misleading interpretation of study findings, frequently only reporting their
statistical significance; d) failure to examine possible relationships between the
characteristics of the studies and the study results; and e) no or very little report
about the methods of reviewing (Glass et al, 1981; Wolff, 1986). Inherent to
this approach is the process of inference, which is complicated when findings
do not agree. Typically, there are private rules for selecting and integrating
studies, and no systematic approach for resolving contradictory findings is
followed. Studies conflicting with the reviewer's point of view are discarded on
the basis of the characteristics of the sample or the research design (Kavale
and Glass, 1981). These methods of eliminating conflicting results are usually
subjective and ad hoc. Another negative aspect of the traditional review is that
there is no way of estimating the sampling variance across the studies (Abrami
et al, 1988). In conclusion, the standards of objectivity, verifiability and
replicability are often ignored (Kavale and Glass, 1981).
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A second method is the combination of the raw data of the original
studies - a secondary data analysis. In this case, the reviewer goes back to the
original raw data and combines them to determine the overall effect. The
advantage of this method is that it permits research questions to be pursued that
have not been previously addressed with a particular data source. There are
some problems with this method, however, firstly, raw data are often not
available; secondly, the methods used are often not identical; thirdly, it does
not account for unbalanced designs which could result in the Simpson's
paradox (Simpson, 1951; Glass et al, 1981).
The third method of summing studies is the quantitative methods. Ways
of integrating findings in a quantitative way have been proposed since the
1930's. Fisher (1932) and Pearson (1938) sought to combine probability
values from tests of significance, but it was in the agricultural field that the first
quantitative analyses were performed (by Yates and Cochran, 1938). By 1950,
social science researchers were trying to establish the combination of
probabilities as a useful tool (Mosteller and Bush, 1954). Several quantitative
methods for summarizing literature have been developed: combining
significance tests (Mosteller and Bush, 1954; Rosenthal, 1978), vote counting
(Light and Smith, 1971), cluster analysis (Light and Smith, 1971) and meta¬
analysis (Glass et al, 1981).
Combining significance tests is based on the probabilities associated
with the test statistics from each of the original studies. The problem with this
method is that sample size and the magnitude of the effect are not taken into
account and the results are therefore non interpretable (Hedges and Olkin,
1985).
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Vote counting is a very crude way of combining results by counting in
terms of statistical significance those studies which favour the control group,
those favouring the experimental group and those with non significant
outcomes. The category containing the largest number of studies is assumed
to represent the direction of the true relationship. This method has a number of
shortcomings: firstly, it does not take into account the strength of the
relationship nor the magnitude of the effect, i.e. all studies are given the same
importance although one may be just significant and the other highly significant;
secondly, it ignores sample sizes and since large samples produce more
statistically significant results it is biased against studies with small samples,
which usually show absence of significance due to inadequate sample size;
thirdly, there are no criteria for differentiating studies with good and poor
research design (Hedges and Oikin, 1980; Streiner, 1991). If all studies had
the same sample size and a unimodal distribution reflecting one population, the
reliability of this method would be greater. As these conditions are seldom met,
vote counting is not accepted as an accurate method of reviewing.
Paradoxically, the power of this procedure decreases as the number of studies
reviewed increases (Hedges and Olkin, 1980).
In cluster analysis, studies are clustered based on the question under
consideration. The original data used in the analysis must be obtained and if
no differences are identified among the clusters, or if there are they can be
statistically adjusted, they can be further combined and analysed. The
drawbacks in this approach are the difficulty in obtaining the original data and
the focus on variation between treatments, rather than on the variation of effect
sizes across studies (Pillemer and Light, 1980).
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Meta-analysis is the latest development of the quantification approach in
integrating studies. In medical reviews, the term overview has also been used
(Peto, 1987-a). There are three main objectives that any meta-analysis wishes
to satisfy: a) to eliminate bias in study selection; b) to make use of all
information; c) to detect statistical interaction (Kavale and Glass, 1981). During
the 1970's, meta-analysis flourished in social and educational sciences. In
medicine, the earliest meta-analysis was an article by Beecher (1955) on
placebo, but it was in the early 1980's that meta-analysis became a popular
instrument to review medical literature (Sacks et al, 1987). Comprehensive
textbooks have been published on the techniques and methodology of meta¬
analysis (Glass et al, 1981; Rosenthal, 1984; Hedges and Olkin, 1985; Wolf,
1986).
Glass (1976) coined the term meta-analysis to refer to statistical analysis
of a large collection of analysis results from individual studies with the purpose
of integrating their findings. The meta-analysis approach consists of: a)
defining the problem and the admissible studies; b) locating the studies; c)
classifying and coding the studies' characteristics; d) quantitatively measuring
the characteristics of the studies in a common scale; and e) aggregating the
study findings and relating those findings to the study characteristics. It is a
systematic, reproducible approach to the integration of studies. The main goal
of meta-analysis is to establish facts and relationships despite any biases that
may be present because of the methodology used in a study (Kavale and Glass,
1981).
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There are still some doubt about its usefulness. Some researchers
consider meta-analysis to be merely a statistical trick that produces
oversimplified generalizations out a complex of disparate results (Thompson
and Pocock, 1991). However, meta-analysis is not a fad. It has its roots in
central values of the scientific method: replicability, quantification, casual and
correlational analysis (Bangert-Drowns, 1986), and because of that it can
deliver generalizable answers to basic questions by integrating valuable
information that is scattered in individual studies. In addition, there are very
little fancy statistics at all in meta-analysis, but as with any scientific method
meta-analysis has advantages and disadvantages. The determination of the
external validity of a meta-analysis, i.e. how generalizable are its findings, is not
that simple. As Smith et al (1980) suggested this decision is a responsibility
shared by the researcher and the reader. The reader must bear in mind the
conditions in which the study took place and compare them with the real
situation.
What format for presenting review findings should be preferred is an
open and complicated question. In principle, there is no difference between a
traditional review and meta-analysis as long as they are conducted without
bias. There are situations when a narrative method may be preferable to a
meta-analysis, e.g. when effects sizes are diverse and small or the number of
methodologically adequate trials is small. If a meta-analysis is performed in
these conditions, its conclusions should be considered only as preliminary.
Traditional reviews have another advantage: they usually discuss in more
depth each study being reviewed, looking for patterns and inconsistencies
(Slavin, 1984). In other situations, e.g. when there is a large number of studies,
a meta-analysis may be the only possible approach (Cooper, 1979).
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Descriptive reviewers are more likely than statistical reviewers to find little or no
support for the alternative hypothesis, such as in the study by Cooper and
Rosenthal (1980) on sex differences in task performance, where traditional
reviewers neglected probabilities or were too conservative in combining them.
Statistical procedures can help to identify relationships that may not be large
enough to be detected through the traditional method (Light and Pillemer,
1984). If a decision is made in favour of using meta-analysis as a review
method, the next decision should concerns which techniques are to be used.
The answer to this question will depend on the topic being studied and on the
data available from the original studies. The techniques used have been
discussed above.
WHATARE THE MAIN ADVANTAGES OF META-ANALYSIS?
The principal advantages of meta-analysis are: firstly, meta-analysis
makes reviews more interpretable due to its procedures being precisely
described, objective and repeatable. Vague terms like 'no relationship', 'strong
relationship' and 'very significant' are replaced by numerical values. Further,
because meta-analytic procedures record the exact p level there is no need to
claim a 0.05 result as a significant result and a 0.06 as a non significant one
(Rosenthal, 1990).
Secondly, it obtains an estimate of the magnitude of the experimental
effects which is scale free, allowing the combination of results using different
scales of measurement. In addition, it has the ability to control the
contradictions in a group of studies (Pillemer and Light, 1980).
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Thirdly, meta-analysis can be used in the design of multi-centre trials
because the raw data may not be comparable for the purposes of compiling
data at the individual subject level.(Pillemer and Light 1980; Hedges and Olkin,
1985; Abrami etaI, 1988).
Fourthly, it increases power of the data synthesis due to the integration of
findings of small studies in a coherent way. In clinical psychiatry, the sample
size or time required to undertake a large randomized trial may be prohibitive,
and consequently, clinical decisions must be made based on findings of small
trials. If most effects are small to medium and sample sizes are moderate, a
predominance of studies with non significant results will be likely (Hedges and
Olkin, 1985). Meta-analytic techniques are used to combine the results of
similar trials in an effort to integrate their findings. In doing so it increases the
power due to an increase in sample size. Even studies with minor flaws can be
analyzed and the influence of the flaws can be determined and adjusted for, if
necessary (Jackson, 1980; Kraemerand Andrews, 1982).
The importance of meta-analysis was illustrated by Glass (1976) when
he pointed out that the results of dozens or even hundreds of studies can no
more be grasped in narrative reviews than one can grasp the results of dozens
or hundreds of test scores without the aid of techniques for organizing and
interpreting the data. Finally, meta-analysis provides ways of integrating
studies that can avoid the classic "more research is needed" statement so often
found in narrative reviews, meta-analysis provides ways of integrating studies
that may make this statement not compulsory (Pillemer and Light, 1980).
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WHATARE THE MAIN DISADVANTAGES OF META-ANALYSIS?
The introduction of meta-analysis is by no means widely spread and
accepted. There is strong opposition by some authors, such as Eysenck (1978)
who called meta-analysis "mega-silliness". The main objections to meta¬
analysis are:
1. Mixing apples and oranges - Grouping together different types of variables
(e.g., outcomes), such as Glass (1976) did when all kinds of psychotherapies
were analysed together, is one object of criticism. Combining the results of
different studies runs the risk of producing an amalgam that makes no
conceptual sense (Gallo, 1978). Glass's argument is that if we combine data
from people who are different, why not combine studies that are somewhat
different? Furthermore, Glass (1977) and Glass et al (1981) observe that such
aggregation is useful for the study of the "fruit" and the only studies that need to
be compared are different studies. As only one outcome was studied in this
meta-analysis, this problem was averted.
2. Garbage-in garbage-out - Some meta-analyses collect trials with huge
differences in research quality designs and include trials with poor research
design which invalidates the conclusions of the meta-analysis (Eysenck, 1978).
The critics of meta-analysis do have a point when they say that no meta¬
analysis is better than the studies that went into it (Slavin, 1984). The
defenders of meta-analysis argue that a priori decision to exclude studies
based on research quality is not acceptable due to possible bias in terms of the
reviewer's subjectivity in evaluating research design (Glass et al, 1981). To
avoid the controversy of mixing good and bad quality trials, this meta-analysis
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analyzed controlled and uncontrolled studies separately. This approach had
the objective of testing whether differences in quality are related to differences
in outcome. Nevertheless, the analyses of the controlled and uncontrolled
studies yielded similar results, showing in both cases a positive effect of lithium.
Similar results have also been reported by Glass et al {1981) who reviewed 12
meta-analyses and found a difference not bigger than 0.1 standard deviation in
effect size between high and low internal validity studies, and concluded that no
relationship could be postulated between effect size and research validity.
3. Non-independence - According to Landman and Dawes (1982) there are
five possible sources contributing to results being dependent: a) multiple
responses from the same subjects; b) measures taken at various points in time
from the same subjects; c) dependence of scores with a single outcome
measure (e.g., both a subtest and a global score containing the subtest are
treated as outcome measures); d) dependence on studies within a single
article (e.g., two different studies using at least some of the same subjects are
reported in the article); e) dependent samples across the studies (e.g., two
different studies using at least some of the same subjects are reported in
different articles). Several methods have been suggested to eliminate these
sources of dependency. One is to use only one dependent variable from each
study (Cooper, 1979). Another procedure is to use an average effect size from
each study (Kulik et al, 1979). At the moment, there is no consensus as to how
this problem should be handled (Wachter, 1988) mainly because the
conceptual and statistical implications of this problem have not yet been worked
out (Rosenthal, 1984). The first three problems are particularly common in
psychological trials where the same subjects are observed on a series of
outcome measures, or repeatedly on the same outcome. But they are non-
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existent in this review. The fifth source of dependency was eliminated through
the exclusion criteria. Non-independence may also occur, however, when
different subjects from different cells of a between group factorial design
provides the study outcomes, as is the cause in the fourth source of
dependency. In fact, this has ocurred in some of the trials, e.g. in Prien et al
(1984), where lithium was compared to placebo, antidepressants and the
combination of lithium plus antidepressants. An alternative frequent solution to
the problem has been to treat each finding as independent (Smith et al, 1980;
Abrami et al, 1988). In this meta-analysis, this latter position was adopted.
4. Inflated Ns - The calculation of effect size for every dependent variable
inflates the number of effect sizes. This problem did not exist in this meta¬
analysis due to the fact that only one outcome being studied.
5. Objectiveness - A weakness associated with meta-analysis design is that
there is no control, except through the selection of papers, over which
treatments have been applied or how subjects are assigned to them (Louis et
al, 1985). The objectiveness of meta-analysis is questioned by Searles (1985)
who found opposite conclusions in two meta-analyses of agoraphobia.
Searles concluded that the results of meta-analysis are highly dependent upon
"how the pie is sliced, and who is doing the slicing". It must be remembered
that meta-analysis is not a "cookbook" procedure and the assumptions
underlying the meta-analysis must be made explicit, otherwise misleading
results may occur (Cook and Leviton, 1980; Kavale and Glass, 1981). To
avoid any bias in interpretation of a meta-analysis it has been urged
(McConaghy, 1990) that all meta-analysis should include the list of the studies
included, and the means and standard deviations of the treated and control
270
group before and following treatment. To comply with these guidelines, all
information concerning the numbers improving and not improving in the lithium
and comparison groups was given (see Tables).
6. Statistical technique vs. human thought and planning - Strube and
Hartmann (1982) have pointed out the danger of the results of the review being
limited to the description of statistical techniques. Nevertheless, there should
be no contradiction between the meta-analysis and interpretation of the data.
As Cooper and Rosenthal (1980) stated, the interpretation of the results of a
review using the meta-analysis method is aided, not determined, by meta-
analytic findings.
7. Sample bias - Contrary to the characteristics of good quality research, the
sample of studies on which the meta-analysis is based is not random, and is
consequently biased (Strube and Hartmann, 1982). This bias becomes
apparent when it is observed that most meta-analyses is based on published
studies (see the file drawer problem, Section 5.4.8). Glass (1977) argues that
research design should not be confounded with research integration. Each of
the two has a logic of its own, and therefore some concepts appropriate to
primary research are not adequate for reviews.
8. Repeated bias - if several studies are done by one group of investigators or
on one group of participants, this could lead to repeated bias. To avoid this
problem, this meta-analysis included only the latest version of any study which
used the same group of subjects in more than one publication.
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Many of these criticisms extend to traditional reviews. Studies of poor
quality may be included, a sampling bias may be observed, and the mixing of
studies with different types of patients, where the outcome is measured by
different techniques, are all examples of limitations inherent to any review. The
only difference is in dealing with these problems. In traditional reviews there is
no clear justification, while in meta-analysis reasons must be explicitly stated as
to why such a direction was taken as this is a more structure kind of review.
Another criticism of meta-analysis relates to its use in non medical
experiemental designs where its use may be trivial. It does not carry the same
force for clinical trials where the principles of design are now universally
acepted, outcome may deadd or alive and numbers are the main limiting
factoirs in small studies.
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APPENDIX 6.1
Effect sizes were calculated using Cohen's d formula (Rosenthal, 1984):
(i) d = (M1-M2)/ S pooled
where Mi and M2 are the means of the two groups to be compared and o
pooled is the pooled population standard deviation.
(ii) S pooled = V{[(n-,-1 )si2 + (n2-1 )s22]/[n1 + n2]}
where ni and n2 are the number of subjects in the two groups and S12 and s22
are the variances of their failure measures.
Cohen's d is a slightly biased estimate of effect size (Wolf, 1986).
Hedges and Olkin (1985) developed a weighted unbiased estimator of mean
effect size (dw) which was used:
(i i i) dw = Xwd/Xw
where w is the reciprocal of the estimated variance of d in each of the studies in
the meta-analysis.
(iv) w = 2(ni + n2)/ (8 +d2)
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The homogneity of effect sizes can be tested to determine whether
studies are sufficiently heterogenous to require an analysis of possible
moderating variables.
(v) X2= X [w (d-dw)2]
where dw and w are defined as in (iii) and (iv).
The 95% confidence interval was calculated according to Hedges and
Olkin (1985):
Effect size (dw) ± 1-96 V(1/w)
The number of additional studies necessary to reverse the conclusions of
the meta-analysis was calculated according to the formula:
(v i) NfS = N(dav ■ dc)/dc
where NfS is the fail safe N, dav is the average effect size and dc is the criterion
selected to be assumed by dav when some knowable number of hypothetical
studies were added to the meta-analysis. The chosen value of dc was 0.2,
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